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ABSTRACT 
 
The control of contagious bovine pleuropneumonia (CBPP) has been identified as a 
priority by the Organisation of African Union/Inter-African Bureau of Animal Resources.  
This project aimed to address some of the issues associated with the diagnosis and 
control of CBPP infections in cattle. Experimental studies tested current and novel 
vaccines which were used to provide more information about the importance of humoral 
immune response to CBPP and assess current and new diagnostic tests. Differences 
between infections caused by planktonic and biofilm grown isolates were also studied to 
assess if biofilm grown cells remain infective or are more virulent. 
 Two novel vaccine formulations, one consisting of five purified proteins and one using 
tween 20 washed cells, both formulations were combined with a commercial adjuvant 
designed to help stimulate the potentially prectective Th2 response.  These novel 
vaccines efficacy was compared with the current T1/44 vaccine given subcutaneously 
as recommended, or intranasally to determine if that inoculation route stimulates a 
protective mucosal immune response.  Six weeks after vaccination, the cattle were “in-
contact” challenged using experimentally infected cattle.  
A total of 45 cattle of Sanga and Africaner breeds were randomly selected from a CBPP 
free area and ear tagged for identification. Five cattle per vaccine (T1/44 sub-
cutaneously, T1/44 intranasally, Purified Protein and Tween 20) were vaccinated six 
weeks prior to placing them with 5 non-infected control cattle and 10 cattle 
endobronchially intubated with a local Mmm field strain 40F05. After 122 days the cattle 
were sacrificed and gross pathology compared at post mortem.  
iv 
The T1/44 vaccinated cattle had some small CBPP lesions but much less than the two 
novel vaccines. Both the Purified Protein and Tween 20 vaccines elicited low protection 
and in some cattle they appeared to have exacerbated the disease as their pathological 
lesions were comparable to the non-infected in-contact CBPP challenged control cattle.  
At the same time a study was carried out to determine if a biofilm prepared isolate would 
be more pathogenic than one grown conventionally. Five cattle were endobronchially 
intubated with Mmm biofilm and housed together with 5 non-treated control cattle for the 
same duration as mentioned above. The biofilm intubated group appeared less 
pathogenic than the comparative planktonic intubated group although some of the 
biofilm in-contact group succumbed to CBPP. 
Serological results obtained during the experiment were evaluated in four different tests, 
Lateral Flow Device (LFD), Competitive Enzyme Linked Immunosorbent Essay 
(cELISA), Lipoprotein Q Enzyme Linked Immunosorbent Essay (LPPQ ELISA) and 
Latex agglutination test (LAT). The results demonstrated that LFD is a promising field 
test at a cut-off point of 30%, but current serological tests are ineffective at detecting all 
stages of CBPP infection.  
Furthermore, serological results were used to establish the importance of humoral 
immune response in protection. A high response to IgA (Immunoglobulin subclass A) in 
an indirect ELISA was observed in sera from chronically infected animals. This suggests 
that a high IgA immune response is an indication of disease progression. Additionally, 
proteins with a molecular mass of 110, 95 and 48 kDa may be important part of the 
protevtive immune response since these proteins were present in T1/44 sub-
cutaneously vaccinated cattle that had less CBPP lesions than the other groups.  
v 
Further work is required to improve serological detection of CBPP and to develop more 
effective vaccines to help control the disease. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
 
 
1 INTRODUCTION 
 
1.1 Classification and general characterization of Mycoplasmas 
 
The class Mollicutes includes eight known genera of bacteria (Table 1.1), namely, 
Entomoplasma, Mesoplasma, Spiroplasma, Acholeplasma, Asteroleplasma, 
Anaeroplasma, Ureaplasma and Mycoplasma (Razin et al., 1998; Messick, 2004). 
Mycoplasmas are self-replicating prokaryotic microorganisms distinguished from other 
bacteria by their unique properties: a total lack of a cell wall, their small size, and minute 
genome (Razin et al., 1998). In addition to their simple structure, mycoplasmas have a 
double stranded circular DNA chromosome ranging between 580 and 2,220 kilobase 
(kb) with a guanine plus cytosine content that varies between 23 and 40 mol% (Nicholas 
et al., 1995) (Table 1.2). The absence of a cell wall makes the treatment of mycoplasma 
diseases difficult, therefore, rendering them to be refractory to some commonly used 
antibiotics, such as penicillin (Ayling, 2002).  
Mycoplasmas are thought to have evolved from Gram-positive bacteria and through 
evolution; they have mainly retained the chromosomes that are essential for life (Ayling, 
2002). This resulted in them having a small genome which lacks the ability to synthesize 
amino acids, nucleic acid precursors and lipids (Ayling, 2002). Therefore, these 
organisms lead a parasitic mode of life for their survival (Pilo et al., 2005). 
Mycoplasma mycoides subsp. mycoides (Mmm) is a member of the Mycoplasma 
mycoides cluster that is associated with diseases of ruminants (Thiaucourt et al., 2005; 
17 
Egwu et al., 1996). The cluster previously consisted of six species that share 
biochemical, immunological and genetic characteristics (Anon, 2001). However, Manso-
Silvan et al., (2009) revised the cluster and suggested that M. mycoides subsp. 
mycoides large-colony (MmmLC) and M. mycoides subsp. capri be classified as the 
same sub-species since they are only distinguished through serological tests. 
Furthermore, they suggested that Bovine Group 7 (BG7) be reclassified in its own group 
called M. leachii (Manso-Silvan et al., 2009). Currently, the Mycoplasma mycoides 
cluster is composed of five taxa with three subclusters which correspond to M. mycoides 
subspecies, M. capricolum subspecies and species M. leachii (Table 1.3). Of these 
mycoplasmas, Mmm and Mycoplasma capricolum subspecies capricolum (Mccp) are 
the most significant and they are the causative agent of contagious bovine 
pleuropneumonia (CBPP) and contagious caprine pleuropneumonia (CCPP) 
respectively (Kusiluka et al., 2000). With this taxonomic change Mmm no longer requires 
the “small colony” (SC) designation. These two taxa are restricted to Africa, Asia and the 
Middle East (Tardy et al., 2009). The species of the Mycoplasma mycoides cluster may 
cause respiratory, arthritis, genitourinary, or mammary disease with severity of the 
disease depending upon the virulence of the strain (Tardy et al., 2009). 
18 
Table 1.1. The major characteristics and taxonomy of the class Mollicutes 
Classification   Number of  Genome Mol%  Cholesterol  Distinctive                    Habitat 
    Recognized size (kb) G+C  requirement  properties  
    Species 
       
Order I: Mycoplasmatales    
Family I: Mycoplasmataceae 
 
  Genus I: Mycoplasma  129
b
  580-1,140 23-40  Yes          Optimum growth at 37
o
C     Humans, animals 
                  
  Genus III: Ureaplasma  6  760-1,170 27-30  Yes   Urea hydrolysis             Humans, animals 
  Genus IV: Eperythrozoon
d
 5  730-770
c 
?  ?   Parasitize RBC    Animals 
 
Order II: Entomoplasmatales 
Family I: Entomoplasmataceae 
 
   Genus I: Entomoplasma  5  790-1,140 27-29 Yes  Optimum growth at 30
 o
C Insects, plants 
   GenusII: Mesoplasma  12  870-1,100 27-30 No  Optimum growth at 30
 o
C Insects, plants 
 
Family II: Spiroplasmataceae 
    Genus: Spiroplasma  45
e
  770-2,220
 e
 24-31 Yes  Helical motile filaments  Insects, plants 
           Optimum growth at 30-37
 o
C  
Order III: Acholeplasmatales 
Family I Acholeplasmataceae 
    Genus I: Acholeplasma 13  1,500-1,650 26-36 No  Optimum growth at 30-37
 o
C Animals, also insects 
               plants for some species  
Order IV: Anaeroplasmatales 
Family I: Anaeroplasmataceae 
    Genus I: Anaeroplasma 4  1,500-1,600 29-34 Yes  Oxygen sensitive anaerobes Bovine, ovine rumen 
    Genus II: Asteroleplasma 1  1,500  40 No  Oxygen-sensitive anaerobes Bovine, ovine rumen 
 
Undefined taxonomic status 
Phytoplasma  ND
a
  640-1, 1185 23-29 not determined uncultured in vitro  Insects, plants   
a
Uncultured phytoplama in not taxonomically defined; two candidates phytoplasma species have been published (Davies et al., 1997; Zreik et al., 1995). A modified 
Table adapted from Razin et al. (1998); 
b
http://www.bacterio.cict.fr/m/mycoplasma.html ; 
c
Messick et al. (2000) 
d
http://www.bacterio.cict.fr/e/eperythrozoon.html; 
e
Williamson et al. (2011)  
?
not yet known  
19 
TABLE 1.2. Properties distinguishing Mollicutes from other eubacteria 
Property Mollicutes Other eubacteria 
Cell wall Absent Present 
Plasma Membrane Cholesterol present in most 
species 
Cholesterol absent 
Genome size 580-2,220 kb 1,050-10,000kb 
G+C genome content 23-40 mol% 25-75 mol% 
rRNA operons numbers 1 or 2a 1-10 
5S rRNA length 104-113 nucleotides Over 114 nucleotides 
tRNA genes numbers 30 (M. capricolum) 
33 (M. pneumoniae) 
84 (B. subtilis) 
86 (E. coli) 
UGA codon usage Tryptophan codon in 
Mycoplasma, Ureaplasma, 
Spiroplasma 
Mesoplasma 
Stop codon 
RNA polymerase Rifampin resistant Rifampin sensitive 
a
Three rRNA operons in Mesoplasma lactucaea 
Table adapted from Razin et al. (1998).  
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TABLE 1.3. Members of the Mycoplasma mycoides subspecies mycoidescluster 
Species           Disease    Main host (and others) 
M. mycoides subspecies mycoides SC  Pleuropneumonia (CBPP)     Cattle, (goats, sheep, yak,  
         reindeer, bison) 
 
M. mycoides subsp. capri           MAKePs*       Goat, (sheep)  
 
M. capricolum subsp. capricolum          MAKePs*    Goat, (sheep) 
 
M. capricolum subsp. capripneumoniae         Pleuropneumonia (CCPP)  Goat 
 
M. leachii (formely BG7)          Arthritis, mastitis,        Cattle 
               
Manso-Silvan et al., (2009)  
*MAKeps = mastitis, arthritis, keratitis, pneumonia and septicaemia syndrome 
 
1.2 Contagious Bovine Pleuropneumonia 
 
Contagious bovine pleuropneumonia (CBPP) is a bacterial disease caused by 
Mycoplasma mycoides subspecies mycoides (Mmm). It results in severe fibrinous 
exudative pleuropneumonia and mainly affects cattle. CBPP is an Office International 
des Epizooties (OIE) listed and notifiable disease. Endemic countries are restricted from 
international cattle trading (March, 2004; Dedieu et al., 2005a). Since the control of 
rinderpest, CBPP is the most significant disease of animal health in Africa; where it is 
still present (Niang et al., 2006a).  
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1.3 Causative agent of CBPP 
 
Mmm is one of the smallest prokaryotic bacteria with a genome of 1,211,703 bp 
(Westberg et al., 2004). It is fastidious but can be cultured in growth media described by 
Thiaucourt et al., (2005) or in an extremely productive medium, PRM, developed by Rice 
and Miles at King’s College, London (Nicholas et al., 2000) and named after the 
developers. It was not until the end of the 19th Century that the causative agent (Mmm) 
was isolated by Nocard and Roux, (1898). However, it was more than 50 years before 
the organism was named as Mycoplasma mycoides subspecies mycoides by Edward 
and Freundt (Edward and Freundt, 1956).  
 
1.4  Mode of transmission of Mycoplasma mycoides 
 
CBPP mainly affects cattle although some Buffalo (Bubalus bubalis) that were in 
proximity of the infected cattle in Italy were affected albeit to a lesser extent (Santini et 
al., 1992). The disease in Water buffalo, Yak, Reindeer and Bison has been reported 
(Provost et al., 1987) but the African buffalo (Syncerus caffer) seems to be resistant to 
CBPP (Windsor and Wood, 1998). Mmm has been isolated from goats and sheep 
(Brandão, 1995, cited by Nicholas, et al., 2008) and their role as reservoir of infection 
and in the epidemiology of the disease is not yet known.  
CBPP is transmitted by direct or very close contact between a coughing infected animal 
and susceptible animals (Masinga and Domenech, 1995; Windsor and Wood, 1998); 
indirect spread has also been verified (Windsor and Masinga, 1977). Mmm may be 
found in urine of infected animals, thus alerting a possibility that transmission can occur 
from urinary tract to nose (Thiaucourt et al., 2005). Similarly, Mmm was isolated from 
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semen of infected bull, suggesting that sexual contact and artificial insemination with 
infected semen may play a role in the spread of the disease (Thiaucourt et al., 2005). 
Cattle movement has been implicated to be the major source of spreading the disease 
(Masinga et al., 1996) and this remains a challenge for the control of CBPP in Africa 
(Thomson, 2005) where transhumance and nomadism are widely practiced.  
 
1.5  CBPP: Disease manifestation 
 
CBPP is a disease of the respiratory tract characterized by pneumonia and serofibrinous 
pleurisy (Masinga et al., 1996) with an incubation period of 9 to 28 weeks in naturally 
infected cattle (Dedieu et al., 2005a), however in most experimental cases, the disease 
manifests within 40 days of infection (Egwu et al., 1996). The clinical signs depending 
on the severity of the disease or the virulence factors of the infectious agent are: 1) 
Hyperacute form: the animal does not show obvious clinical signs as it dies quickly; 2) 
Acute form: the animal has fever followed by respiratory complications (painful 
breathing, coughing, standing with an extended head and neck, nasal discharge and 
foamy saliva). Abortions as well as diarrhea have been reported and 3) Sub-acute form: 
the animal has similar symptoms as the acute form but to a lesser degree and fever 
being irregular (Anon, 2002). This form occurs in about 40-50% of affected animals 
(Anon, 2002). The animals that survive the acute form of the disease may become 
chronic. The chronically infected animals are usually emaciated and may present no 
apparent respiratory signs (Thiaucourt et al., 2005). These chronic animals retain 
sequestra in their lungs in which the infection remains for more than 12 months and 
could be a major source of infection should the sequestra break (Thiaucourt et al., 
2005). CBPP affected calves may not present any signs of respiratory distress but 
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swollen joints are typical clinical signs (Anon, 2002). However, Trichard et al., 1989, 
revealed typical CBPP pneumonic lesions in 4-9 months old calves, during the 1982 
outbreaks in Namibia. 
 
1.6 Geographical distribution of CBPP  
 
A previous review indicates that CBPP existed in the ancient world (Provost et al., 
1987). Although, it was difficult then to be certain of the history of CBPP prior to the 
eighteenth century (Salmon, 1896), Dupuy et al (2012) with the Bayesian evolutionary 
analysis estimated that CBPP may have emerged around 1700 AD in Europe. However, 
cattle movement due to Napoleonic military campaigns in the 19th Century has spread 
the disease rapidly throughout Europe. Other continents were at risk, and consequently, 
infection was observed beyond the European borders in the mid-1850s (Egwu et al., 
1996; Dupuy et al., 2012). Egwu et al (1996) narrated the history of CBPP infections 
over the world. Even though CBPP may have been present in Britain during the 17th and 
18th centuries, Britain was re-infected in 1839 from Holland through Island (cited in 
Nicholas et al., 2008). Since there were no serious control measures in Britain, 1500 
and 3000 outbreaks were reported in 1870 and 1875 respectively. However, with 
payment of full compensation to owners for slaughtered animals, the number of 
oubreaks dropped down to about 2000 in 1890 (cited in Nicholas et al., 2008).  CBPP 
was officially eradicated from Brittain in 1898 (Fisher, 2003). The disease was 
eradicated in many countries during the 20th Century by a combination of measures 
mentioned in 1.9 (Dedieu et al., 2005a). The United States of America eradicated CBPP 
in 1892 after the Bureau of Animal Industry to fight the disease was set up by the 
Federal Government in 1887 (Amanfu 2009). CBPP persisted in Germany until 1923 
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and Poland up to 1936. By 1972, CBPP was eliminated from Australia (Anon, 2002). 
Sporadic outbreaks occurred on the French/Spanish border in 1956 and in Portugal in 
1967. Subsequently, CBPP outbreaks were officially recognized in the eastern Pyrenees 
on both the French/Spanish border in 1980’s. France eradicated the disease in 1984 
and remained free ever since. A sudden reappearance of the disease between 1983 
and 1990 was observed in southern Europe: Spain, Portugal and Italy (Scacchia el al., 
2007). It was effectively controlled and since 1999, no CBPP outbreaks have been 
reported in Europe (Nicholas et al., 2000).  
Besides reported cases of the disease in India, Bangladesh, Myanmar and the Middle 
East (Anon, 2002), the intensity of it in Asia and the Middle East remains unclear 
(Thiaucourt et al., 2005). A detailed history of CBPP in China was not known until 
recently. The pathogen seems to have entered the country in 1919 and through a 
massive increase in cattle production in 1949, the disease spread to many regions in the 
country. As a result, China has initiated the production of vaccine from a virulent isolate 
(Ben-1) that was attenuated in rabbits and for a larger production, Tiben sheep were 
used (Xin et al., 2012). About 74.5 million cattle in the affected regions were vaccinated 
with Ben-1 vaccine that has a high protection rate and duration of immunity of 28 
months. CBPP has not been seen in China since 1989 (Xin et al., 2012).  
The status of CBPP in Africa differs greatly with that in Europe. The OIE, 2005 reports 
highlighted at least 26 countries in West, Central, East and Southern Africa that were 
infected. A total of 1289 deaths of cattle from 272 outbreaks with 7510 cases were 
reported from sub-Saharan countries in 2003 (Thomson 2005; Amanfu, 2009). The 
Central African Republic reported a recurrence of CBPP with 102 cases and 100 deaths 
(Anon, 2005 & 2007a). However, this number may have increased to at least 30 
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countries in Sub Sahara (Nicholas et al., 2009). Jores et al. (2013) reported 28 countries 
in Sub Sahara to be infected with CBPP. 
The introduction of CBPP into Africa was either via South Africa in 1854 by a bull 
originating from Holland or through Ethiopia and Sudan by infected Indian cattle 
belonging to the British Expeditionary Force in the late 19th Century (Egwu et al., 1996). 
Subsequent to its introduction most of African countries were infected by CBPP (Egwu 
et al., 1996). Within two years of CBPP introduction into South Africa in 1954 it had 
killed more than 100,000 head of cattle (Schneider et al., 1994a; Trichard et al., 1989). 
Through movement control, slaughtering and vaccination, CBPP was eradicated and 
South Africa has remained free of the disease since 1921 (Schneider et al., 1994a; 
Trichard et al., 1989). Zimbabwe was infected in 1861 and the disease was eradicated 
by 1904 (Thiaucourt et al., 2005; Thomson, 2005). The disease entered Angola in 1888 
and it has been endemic since 1914 (Thiaucourt et al., 2005; Thomson, 2005). Zambia 
had managed to control the disease in 1946 after it was infected by Angola in 1915. 
However, outbreaks occurred in several years with a recent one reported in 2004 
(Kabilika et al., 2007). 
The incidence of CBPP decreased in the 1970s, when research in some African 
countries (Kenya, Chad and Nigeria) was internationally sustained via “Joint Project 16”. 
However, in the late 1980s and early 1990s, possibly in the wake of the cessation of the 
combination vaccine and the interest of veterinary authorities moving to other concerns, 
the disease came back in the two fronts, the east and the south (Amanfu, 2009). 
According to Amanfu (2009) the outbreaks resulted in the reappearance of the disease 
in the endemic areas and the re-infection of the free countries. The re-infections in 
Tanzania: 1990, 1991 and 1995; Democratic Republic of Congo: 1991; Rwanda: 1994; 
Botswana: 1995; Northwestern-Zambia: 1997-present and Burundi: 1997 are due to 
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uncontrolled movement of cattle from infected areas, which may have happened 
because of the breakdown in the surveillance system, emergency preparedness and 
prompt reaction to the outbreaks (Amanfu, 2009).  
The 1995 re-introduction of CBPP into Botswana (Amanfu et al., 1998) after a period of 
over 50 years of freedom demonstrated that countries that are next to infected countries 
are constantly at risk. Botswana eradicated the disease by slaughter and compensation 
in 1996 and is currently free of CBPP. A recent increase in numbers of outbreaks was 
observed in West, East and Central Africa. Since the last occurrence of CBPP in Egypt 
in 1991, the countries in Northern Africa are free of the disease (Thiaucourt et al., 2005; 
Thomson, 2005).  
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Fig.1.1. Occurrence of CBPP in Africa: 2006-2008 (Hamsten, 2009) 
 
The history of CBPP in Namibia is traced back to 1856 when the disease was 
introduced through Cape Province by infected oxen (Schneider et al., 1994a). Through 
animal quarantine measures adopted then, the disease was confined to a localized 
outbreak at Warmbad in the south, and subsequently eradicated (Hübschle et al., 2003). 
However, it was re-introduced in 1859 by cattle coming either from Botswana or the 
Cape Province and spread throughout the country. As a result, a large number of cattle 
died and 1860 was called the year of “Otjipunga” (lung) by the Herero people (Schneider 
et al., 1994a).  
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CBPP was eradicated in 1919 from central commercial farming areas of Namibia by 
control measures outlined in 1.9.1 and 1.9.2 (Schneider et al., 1994a, Trichard et al., 
1989). Despite being eradicated from these areas, CBPP remains endemic today in the 
northern communal areas (Hübschle et al., 2004; Schneider, 1994b) where half of the 
Namibian population resides and it is separated from the rest of the country by a Trans 
Veterinary Cordon Fence (TVCF). Animals in this area are quarantined for 21 days 
before they are slaughtered at local abattoirs in that area (Anon, 1956), creating a 
discrepancy in marketing prices between farmers in quarantine zones and that outside 
quarantine (Windsor and Wood, 1998). 
The CBPP situation in northern communal areas has improved since 1997 after the 
implementation of yearly T1/44 vaccination. However, a threat from unvaccinated 
Angolan cattle to resident cattle remains a challenge due to animal movement to Angola 
in search of grazing as well as from Angola into Namibia for marketing (Anon, 2003).  
In August 2003, after a respite of over 60 years, Linyanti constituency in the Caprivi 
region, northeast of Namibia experienced a CBPP outbreak (Fig 1.2). The infection is 
believed to have originated from a neighbouring country. By December 2003, a total of 
206 cattle died of the disease. By the end of the outbreak in early 2005, nearly 380 
cattle at three crush pens in the Linyanti constituency succumbed to CBPP. In order to 
halt the spread of the disease, a total of 37,181 cattle were vaccinated with 96% 
coverage. Table 1.4 below depicts the trend of the disease between 2005 and 2015. The 
measures applied to control CBPP in Europe and elsewhere cannot be emulated in 
many African countries because of inadequate financial resources and transhumance 
way of living. Therefore, CBPP remains endemic in many African countries (Anon, 
2002). 
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In view of the disease situation in Africa and the paucity of data from Asia and the 
Middle East as well as the high demand in international trade of live cattle, a re-
introduction of the disease to free countries is probable (Heller et al., 2007). Hence, a 
concerted effort from infected countries together with international communities is vital in 
the fight against CBPP. 
 
 
Fig.1.2. The map of Namibia. This shows the Linyanti village in the Maunga constituency (red star) in the 
Zambezi region (formerly Caprivi) where CBPP outbreaks occurred in 2003 (Anon, 2003). 
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Table1.4. The trend of CBPP infection in the Northern Communal Areas between 2005 and 2015 (Anon, 
2016) 
  2005 2006 2007 2008 2009 2010 
 
 
2011 
 
 
2012 
 
 
2013 
 
 
2014 
 
 
2015 
No of 
Outbreaks  19 6 5 1 6 12 
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1 
No. of 
Clinical 
Cases  150 26 10 3 30 28 
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3 
No. of 
Deaths  39 22 3 0 2 12 
 
 
 
 
9 
 
 
 
 
14 
 
 
 
 
23 
 
 
 
 
2 
 
 
 
 
0 
 
1.7 The economic impact of CBPP 
 
CBPP poses a major threat to cattle farming worldwide and especially in Africa (Dedieu 
et al., 2005a; Nicholas et al., 2000). In 1995 the OIE, reported that CBPP was causing 
heavy losses in cattle and had a more economic impact than any other cattle disease in 
Africa (Egwu et al., 1996). 
The economic as well as the social cost accrued from this devastating disease in the 
world is significant (March, 2004). High mortality rate, stamping-out, vaccinations, loss of 
weight and reduced working ability among others are factors associated with economic 
and social cost. (March, 2004). In Africa, losses accrued from CBPP are estimated to be 
in the region of US$2 billion per annum (Waite and March, 2001; March et al., 2000). 
The economic loss accrued by Britain in 1860, when 187,000 cattle died of CBPP was 
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estimated at £2 million per annum (Egwu et al., 1996). In Italy during the 1990 to 1993 
outbreaks, more than 24,000 cattle were slaughtered in three infected areas (Regalla et 
al., 1996). The Botswana veterinary authority in 1996 slaughtered 320,000 head of cattle 
at an estimated cost of US$100 million, with indirect cost in over US$400 million during 
the outbreak (Geering et al., 1999; Windsor and Wood, 1998). Tambi et al. (2006) 
investigated the cost accrued from controlling CBPP in twelve sub-Saharan African 
countries and arrived at an estimate cost of 30 million euros (2.5 million euros per 
country) per annum due to morbidity and mortality while the total ecomonic cost (direct 
and indirect production losses as well as disease control costs) was estimated at 44.8 
million euros. However, an investment of 14.7 million euros to control CBPP would 
prevent a loss of 30 million euros (Tambi et al., 2006).  The CBPP outbreaks in China 
between 1949 and 1989 have resulted in the death of 178,570 cattle at an estimated 
loss of 356 million RMB (Xin et al., 2012).  
CBPP restricts cattle production and has grave implications for food security and 
people’s livelihoods in Africa (Amanfu, 2009). The eradication of the disease in 
Botswana has resulted in the increase of malnutrition in children due to the massive 
slaughter of cattle; therefore, fewer animals were available for food (Boonstra et al., 
2001). 
 
1.8 Diagnosis of CBPP 
 
The diagnosis of CBPP is based on clinical signs, necropsy findings augmented by 
serological, molecular and cultural tests (Thiaucourt et al., 2005).  
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1.8.1 Clinical diagnosis of CBPP 
 
CBPP may be diagnosed through clinical symptoms during acute stage. Usually, the 
animal is depressed, has modest fever and lacks desire to eat. These clinical signs are 
succeeded by coughing and heavy painful breathing due to pleuropneumonia, which 
progresses as the intensity of the disease advances. The infection in calves tends to be 
restricted to arthritis with swelling of the joints (Anon, 2002), although it was reported 
differently by Trichard et al. (1989) (section 1.5). 
 
1.8.2 Necropsy findings 
 
The pathological lesions of CBPP are typically unilateral and restricted to the thoracic 
cavity and lungs (Egwu et al., 1996). During the acute stage, the gross pathological 
lesions are characterized by fibrinous deposits on the parietal and visceral surface of the 
lungs (Provost et al., 1987). The different stages of the disease among other factors are 
observed through, red, gray and yellow hepatisation of the lung lobules. Furthermore, 
marble appearance of the lung which sometimes accompanied by adhesion of the 
parietal and visceral surface is evident. A sequestrum surrounded by fibrous capsules is 
obvious of chronic stage of CBPP. The thoracic cavity of diseased animal may contain 
litres of pleural fluid (Egwu et al., 1996). Figures 1.3 and 1.4 represent typical CBPP 
lesions seen at post mortem. 
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Fig. 1.3. CBPP lesions in animal experimentally infected with Mmm. 
 
 
Fig.1.4. Sectioning of the lung revealing CBPP lesions in animal experimentally infected with 
Mmm by contact (images derived from the current study).
Fibrin in visceral pleura 
 
Sequestra, indicating 
the chronic stage of 
the disease 
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1.8.3 Laboratory diagnosis of CBPP 
 
The laboratory techniques involved in the diagnosis of CBPP are outlined in OIE 
manual (Anon, 2008) and are described in chapter 2 of this thesis. The presence of 
the disease can be confirmed by: 
1) The detection of the causative agent through either culture, or polymerase 
chain reaction (PCR).  
2) Detection of serum antibodies through different serological tests such as: 
Complement Fixation Test (CFT), Competitive enzyme-linked 
immunosorbent assay (cELISA) and Immunoblotting (IBT).  
Mmm is also detected by immunohistochemistry in tissues fixed in 10% formalin 
(Bashiruddin et al., 1999). Many different tests such as ELISAs using recombinant 
antigens (Thiaucourt at al., 2005) and rapid diagnostic test using polysaccharide- 
sensitized latex beads have been developed (March et al., 2003; Ayling, 2002).  
In Namibia CBPP is diagnosed through clinical signs and necropsy findings in the 
field and at abattoirs. The laboratory diagnosis comprised of determination of 
causative agent through culture, PCR and antibody detection by CFT and cELISA. 
 
1.9 Control of CBPP 
 
CBPP is controlled through various control measures such as; vaccinations, strict 
cattle movement control and stamping-out policy. The implementation of these 
measures varies according to the epidemiological situations, animal husbandry and 
the effectiveness of the veterinary service in a particular country (Thiaucourt et al., 
2005). 
 
 
35 
1.9.1  CBPP vaccinations 
 
CBPP in endemically infected areas is mainly controlled by vaccinations (Thiaucourt 
et al., 1998). The control of CBPP using vaccination in Europe dated back to 1852 
with a possibility of being tried earlier than that in Africa. In an early attempt to build 
immunity in susceptible animals a piece of lung or pleural fluids from infected animal 
were inoculated at the tip of the tail and on the bridge of the nose of animals in 
Europe and Africa respectively (Thiaucourt et al., 2003; Blancou, 1996). Although, 
immunity was conferred, a high mortality was observed. As a result, attenuated 
vaccines were formulated and used in Australia and Africa in the 1950s. These 
include KH3J, T1/44 and its streptomycin resistant derivative, T1/SR (Thiaucourt et 
al., 2003).  
These vaccines have been passaged several times in broth culture or embryonated 
egg to reduce the pathogenicity and are affected by factors such as a drop in titer, 
viability, media, storage and transport (March, 2004; Thiaucourt et al., 2000). In 
addition, observations from the field together with experimental studies have 
highlighted the low efficacy of the current vaccines which results in not effectively 
protecting cattle from outbreaks of disease (Waite et al., 2001; Rweyemamu et al., 
1995; Thiaucourt et al., 2000) and reversion to virulence among others (Thiaucourt et 
al., 2000; Mbulu, et al., 2004; Totte et al., 2008). The T1/44, the OIE recommended 
vaccine for use in endemic areas of Africa, confers immunity up to one year 
(Thomson, 2005; Rweyemamu et al., 1995), therefore, requiring yearly vaccination, 
which is a burden to poorly financed veterinary services (Musisi et al., 2003). 
Thomson (2005) estimated a five-year economic cost accrued from CBPP 
vaccination in nine endemically infected countries in Africa (Table 1.5). 
A streptomycin resistant derivative, T1/SR vaccine that was used during the 1990s 
CBPP outbreaks frustrated both the farmers and livestock experts in Botswana 
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during the 1995 outbreaks because it failed to stop the spread of the infection; hence, 
its use was discouraged (Tulasne et al., 1996).  
Therefore, the development of an improved vaccine with long lasting immunity is a 
prerequisite for the eradication of CBPP in Africa. Many attempts to formulate an 
inactivated vaccine have proved futile. The lipoprotein Q (LppQ) immunostimulating 
complex (ISCOM) vaccine that has explored the role of a Th1 response in the 
pathogenesis of Mmm and in protection and a whole cell mycoplasma vaccine 
inactivated with saponin exacerbated the disease as the vaccinated animals were 
affected to the same extent or even more than the in-contact control animals 
(Nicholas et al., 2004). The more recently held experiment with purified subunit 
vaccine consisting of five recombinant putative variable surface proteins of Mmm did 
not confer protection and the animals were similarly affected as the in-contact non-
immunized animals (Hamsten et al., 2010). 
Therefore, no breakthrough has been seen in the development of a better protective 
vaccine for CBPP. 
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Table1.5. Annual cost of CBPP vaccination in nine endemically infected 
countries (1998-2003)1 
 
 
 
Country 
Average no. of 
cattle 
vaccinated 
annually 
(million) 
 
Range 
(million) 
 
Cattle population 
estimate for 20002 
(approx. average 
annual vaccine 
coverage) 
Estimated 
annual 
expenditure in 
US$ million 
(range) 
Angola 0.83 0.53-0.91 4.15   (20) 0.42 (0.27-0.46) 
Burkina Faso 1.53 1.34-2.14 5.10   (30) 0.77 (0.76-1.07) 
Cameroon 2.88 1.80-3.70 5.95   (48) 1.44 (0.91-1.85) 
Ethiopia 0.30 0.06-0.41 35.50 (0.8) 0.15 (0.03-0.21) 
Ghana 0.14 0.05-0.34 1.34   (10) 0.29 (0.03-0.17) 
Kenya 1.18 0.26-1.96 11.50  (10) 0.59 (1.30-1.71) 
Mali 3.02 2.59-3.41 7.30    (41) 1.51 (1.30-1.71) 
Nigeria 1.43 0.19-3.20 15.20  (9.4) 0.72 (0.09-1.60) 
Tanzania 1.77 0.07-5.10 17.70  (10) 0.89 (0.03-2.60) 
 
1 
Based on average cost of US$ 0.50 per dose 
Table adapted from Thomson (2005) 
 
1.9.2 Strict cattle movement control 
 
Implementation of strict animal movement is the ideal method of reducing the spread 
of CBPP and this coupled with other control measures mentioned earlier proved to 
be a success in eradication of CBPP (Anon, 2002). However, in Africa where 
pastoralism and transhumance are widely practiced, the method is far from being 
successful. Furthermore, porous borders, financial constraint and political instabilities 
faced by some African Governments results in veterinary authorities not being able to 
impose regulatory measures pertaining to animal control (Thomson, 2005).  
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1.9.3 Eradication strategies for CBPP 
 
As demonstrated in Europe and USA in the 1860s, the control of CBPP is better 
achieved by slaughtering the whole herd population when it is found in a disease-free 
country or area. CBPP was eradicated from Europe through culling combined with 
quarantine and strict cattle movement (Sylla et al., 1995). In 1995, Botswana 
successfully eradicated the disease through culling and cattle owners were 
compensated (Amanfu et al., 1998).  
 
1.9.4 Factors hindering the control of CBPP 
 
The long disease incubation period, cattle movement due to various factors such as 
differences in availability of pasture and water as a result of drought are a major 
obstacle to the control of CBPP (Masinga et al., 1995; Windsor and Wood, 1998). In 
addition, the short lasting immunity conferred by currently used CBPP vaccines; 
result in the failure to control the disease (Masinga and Domenech, 1995). The 
detection of affected animals in CBPP endemic countries might be hampered by the 
illegal or misuse of antibiotics which reduces the clinical signs (Musisi et al., 2003). 
Although, the use of antibiotics has been officially discouraged on the grounds that 
they may mask disease symptoms and create carriers (Provost et al., 1987), it is still 
widely used in Africa (Thiaucourt et al., 2003; Ayling et al., 2000). In the absence of a 
better vaccine, antibiotics continue to be employed as an applicable control-measure 
by farmers to reduce CBPP mortality (Lesnoff et al., 2004). An Office International 
des Epizooties (OIE) meeting held in Rome in 2006 under the theme “CBPP control: 
Antibiotics to the rescue?” was mainly to assess the efficacy of antibiotics in treating 
CBPP infected animals. Various experimental studies were carried out in vitro and in 
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vivo. An in vitro study (Ayling et al., 2000), investigated the effectiveness of five 
antimicrobials against CBPP in an attempt to assist the Veterinary authorities. The 
study suggested that tilmicosin and danofloxacin are useful in the control of CBPP. 
Hence, an experimental study using danofloxacin in treating CBPP in naturally 
infected cattle in 2004 outbreak in Caprivi Region of Namibia proved that antibiotics 
could reduce the spread of the disease to healthy animals (Hübschle et al., 2006). 
The use of Long Acting (LA) oxytetracycline in the treatment of CBPP infected 
animals had a positive effect as 12 out of 14 animals recovered although complete 
elimination of the mycoplasma was not achieved. Furthermore, the treatment 
stopped the spread of the pathogen to healthy in-contact animals (Niang et al., 
2006a). This might pave a way to treating CBBP infected animals in endemic areas 
whilst waiting for a more efficacious vaccine candidate. The lack of sensitivity and 
specificity of the tests applied in Sub-Saharan Africa is also a limitation to effectively 
control the infection (Naseem et al., 2010). To this end, the only practical means to 
contain CBPP in Africa is therefore by prophylactic methods (Lesnoff et al., 2004). 
However, Aligaz and Munganga (2019) suggested three possibilities of controlling 
the disease by (1) treating 85.7% of infectious cattle with antibiotics, without 
vaccinating healthy cattle, (2) vaccinating 80% of susceptible cattle within a period of 
49 days, without treating the infectious cattle and (3) assuming that 50% of 
susceptible cattle are vaccinated within 73 days and 50% of infectious are treated 
with antibiotics. The option of using the combination of vaccination with antibiotics is 
the one likely to be successful (Aligaz and Munganga, 2019). However, for this option 
to be a success, vaccines and antibiotics should be readily available to farmers of 
which cattle are at risk of exposure to infection. One of many problems associated 
with failure to control CBPP in sub-Saharan Africa is a failure to deliver control 
services to farmers whose cattle are at high risk of exposure to infection (Onono et 
al., 2017). In order to assist public sectors to deliver control services (vaccinating and 
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antibiotics treatment), a contractual agreement between public and private sectors 
should be adopted (Onono et al., 2017). 
 
1.10 Future prospects for the control of CBPP 
 
The requirements set out by OIE to be adopted by countries that wish to acquire a 
disease free status, such as slaughtering of infected as well as in-contact herds 
(Anon, 2002) may not be fiscally realistic for some of the African governments, which 
are already burdened by wars and famine (Lesnoff et al., 2004; Windsor, 2000). 
Therefore, the control of CBPP in endemically affected areas requires a mass 
vaccination for not less than five years augmented by strict cattle movement control 
where it is possible (Masinga and Domenech, 1995). Based on the economic 
implications of the disease in the world, and the threat for re-introduction into 
countries that are free of the disease (Lorenzon et al., 2003), a concerted effort, 
involving regional and international coordination in controlling international cattle 
movement as well as harmonizing control strategies is needed for the intended 
eradication to be a success (Masinga et al., 1995; Sylla et al., 1995). In addition, 
veterinarians and community health workers should be trained in detecting clinical 
symptoms in the cattle as early as possible (Heller et al., 2007; Sylla et al., 1995). 
For CBPP to be eradicated a joint effort should work towards the understanding of 
pathogenesis of Mmm as well as research to formulate a better vaccine. The Pan 
African Rinderpest Campaign (PARC) has financially invested in CBPP vaccine 
research aimed at ISCOM with a hope to come up with improved vaccines. Until 
then, continuous vaccinations should remain the method of choice to contain CBPP 
in Africa (Thiaucourt et al., 2003). Abusugra et al. (1997) envisaged the future 
eradication of CBPP to be through the development and use of an improved vaccine. 
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In an attempt to set up control measures for CBPP, the Southern African Developing 
Communities (SADC) Member States convened at a workshop in Dar Es Salaam, 
Tanzania in September 2007 and decided that considering the porous borders, 
CBPP will be better managed when countries develop robust early warning systems, 
harmonized surveillance and disease control strategies. The trading of livestock and 
livestock products should be encouraged to follow a formal regime either within the 
country or in the region. There must be mutual agreements that the activities taken to 
control the disease in all Member States are similar and equally effective (Anon, 
2007b). These resolutions look promising on papers; however, their implementation 
is likely to prove more difficult. 
The measures that have to be implemented to control CBPP are not feasible in many 
countries in Africa. Therefore, the only option is the use of T1/44 live attenuated 
vaccine, even though it has some limitations mentioned in 1.9.1. The efforts to 
formulate new vaccines have so far not given desirable outcomes. Therefore, it is 
against this background, that an understanding of the humoral immune responses of 
the host, in relation to pathogenicity or protection may pave the way towards the 
formulation of better vaccines against CBPP. Only after successful intervention 
through prophylactic measures, the disease that has affected the continent for more 
than 150 years will be finally eliminated.  
 
1.11 Pathogenicity of CBPP 
 
The close interaction between the mycoplasma and the host cells is complex 
(Howard and Taylor, 1985). However, the ability of an infectious organism to attach 
to particular host receptors is important for establishing colonization (Howard and 
Taylor, 1985) and may lead to the development and severity of the disease as well 
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as the spread of the infection in the body (Razin et al., 1998). Mycoplasmas elicit 
specific and non-specific immune responses upon entering the host immune system 
(Razin et al., 1998; Howard and Taylor 1985). The specific immune response 
involves the host defense mechanisms to produce different antibodies, stimulation of 
cell-mediated immunity, and opsonisation and phagocytosis of organisms (Razin et 
al., 1998). 
The pathogenicity of Mmm is not fully understood; however, Mmm being a mucosal 
disease enters the host via the respiratory route and attaches itself to the epithelial 
cells (Thiaucourt et al., 2005). It colonizes the mucous membrane and this may 
subsequently lead to its pathogenicity (Thiaucourt et al., 2005). The membrane 
lipoproteins (LppA, LppB, LppC, and LppQ) are alleged to be involved in the 
virulence of Mmm (Hamsten et al., 2008). Persson et al. (2002) described the role of 
variable surface proteins (Vmm) of mycoplasmas in augmenting colonization and 
adapting to host cells at different stages during infection leading to it to evade the 
host immune system. Dedieu et al. (2005b) investigated the virulence factors leading 
to apoptotic cell death and demonstrated that Mmm secretes toxic components in 
vitro which cause cell death. This might suggest that when Mmm invades the immune 
system it causes apoptotic cell death to the major cells of the immune system, the 
CD4 T-cells. The CD4 T-cells are essential for the host defense mechanism at the 
onset of infection (Dedieu et al., 2005b). The hydrogen peroxide (H2O2) formed by L-
alpha-glycerophosphate oxidase (GlpO), that is secreted by Mmm plays a role in the 
oxidation of glycerol and it is responsible for cell death (Pilo et al., 2005, 2007; 
Dedieu et al., 2005b). The H2O2 has been demonstrated as one differentiating factor 
between European and African strains. The African strain is more virulent possibly 
due to the production of H2O2 (Houshaymi et al., 1997).  
In addition to the virulence factors of Mmm, the capsular galactan attaches to lung 
tissue and trigger the formation of self-antibody to pneumogalactan which is 
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associated with autoimmune reaction and may induce pathological lesions seen in 
the lung of CBPP affected animal (Anon, 2001). It is however, unclear how 
pathological lesions observed in diseased animals are produced (Thiaucourt et al., 
2005; Anon, 2001). 
In addition, although mycoplasmas have a very limited genome, little is known about 
their methods of persistence in the host (McAuliffe et al., 2006). Mycoplasma species 
vary in their abilities to produce prolific biofilm. Biofilms are bacteria that attached to a 
substratum or each other and surrounded by an extracellular polysaccharide matrix. 
Bacteria are believed to persist in the host by a formation of an adherent biofilm 
(McAuliffe et al., 2006). Biofilms are stubornly resistance to host defences and stress 
than planktonic cells. Furthermore, biofilms are resistant to antibiotics, antibodies as 
well as phagocytes and may cause host damage as phogotytosis is not taking place 
and the released phagocytic enzymes damage surrounding tissues and exacerbate 
infection (McAuliffe et al., 2006). 
Although previous studies have shown that cattle recovered from CBPP are normally 
immune or resistant to re-infection (Dedieu et al., 2006; Lanzavecchia and Sallustro, 
2005; London et al., 1999; Windsor and Masinga, 1977; Gourlay, 1975), the immune 
response that is essential for protection is unknown. It has been demonstrated that 
humoral and cellular immune responses are important for protection (Dedieu et al., 
2005a; Dyson and Smith, 1975), to understand their involvement during the 
progression of the disease remains a challenge. There is insufficient information in 
this area because the use of cattle for experiment is too costly (Dyson and Smith, 
1975; Dedieu et al., 2005a; Masinga et al., 1975; Gourlay, 1975; March, 2004).  
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1.12 The immune responses 
 
Mycoplasmas cause respiratory diseases in animals and humans and have a huge 
economic and health impact over the world (Blanchard and Browning, 2005). Due to 
the severity of the infection brought by them, it is possible that both innate and 
adaptive immune systems are employed to combat the disease (Blanchard and 
Browning, 2005). Vaccines elicit the immune responses to resist infection and or the 
immune responses to stop the infection from disseminating to other tissues. 
However, in many Mycoplasma diseases, the pathogen persists in the host and 
result in the establishment of the immunopathologic lesions merely because the 
immune responses are unable to resist the infection. Immune responses are 
considered to be important factors in the pathogenesis of disease induced by 
mycoplasma (Blanchard and Browning, 2005). The innate immunity is needed to 
clear the infection as soon as the pathogen enters whereas the adaptive immune 
responses take time to develop and they are pathogen specific (Blanchard and 
Browning, 2005). Both B and T lymphocytes are the uniqueness of adaptive immune 
responses and are accountable for the progression of antibody (humoral) and cell-
mediated immune responses during infection (Blanchard and Browning, 2005).  
Mmm is an extracellular organism (Dedieu et al., 2005b) that elicits both cellular and 
humoral immune response upon entering the host (Rana and Srivastava, 2001). The 
role of cell mediated immunity; whether it is important in protection or actively 
contributes to pathology had remained a mystery for a long time (Gourlay and 
Palmer, 1965; Dyson and Smith, 1975; March, 2004) because most of the earlier 
studies focussed on antibody responses. However, the existence of Mmm-specific 
cellular immunity has been suggested albeit, not characterized. Dedieu et al. (2005a) 
investigated the cell-mediated immune response elicited in cattle by Mmm. The 
authors concentrated on the Mmm immunity in acute and recovered CBPP animals. 
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The study revealed among other factors that Mmm–specific IFNy-CD4 T-cell immune 
response was observed in blood from all recovered cattle. Although a Mmm-specific 
CD4 Th1-like T-cell response persisted in the peripheral blood mononuclear cells 
(PBMC) of acute cattle, it did not produce IFN-γ. A similar study that investigated the 
immune response in lymph nodes revealed similar findings (Dedieu et al., 2006). 
Mmm–specific IFN-γ secreting CD4+ T-cells were observed in lymph nodes of 
recovering animals and this persisted for the duration of the experiment (Dedieu et 
al., 2006). Furthermore, IFN-γ secreting CD4+ T-cells were higher in magnitude in 
completely recovered animals compared to recovered animals with lung sequestra. 
Both studies revealed the importance of IFN-γ in protection against Mmm (Dedieu et 
al., 2005a; 2006). The latter study also revealed that the Mmm recovered animals are 
immune from further infection. Totte et al. (2008) unravelled the importance of 
lymphocyte memory T cells in CBPP chronic animals. In that study, lymphocytes 
were analysed in vivo for proliferation, production of cytokine as well as the 
expression of activation and memory markers in reaction to Mmm. Proliferation of 
CD4+ T and B cells was observed in cultures from CBPP chronic animals when 
stimulated with heat-killed Mmm. This phenomenon was not observed in cultures 
from CBPP acute animals. Therefore, TH1 Memory lymphocytes are thought to be 
essential in the control of CBPP (Totte et al., 2008).  
Other researchers failed to prove the importance of IFN-γ in protection. Jores et al. 
(2008) could not establish a correlation between IFN-γ and the absence or presence 
of pathological lesions in CBPP experimental animals. The immunohistochemistry 
analysis revealed the presence of other cells and no increase of IFN-γ cells were 
seen (Jores et al., 2008). Also, Scacchia et al. (2007) reported suppression in the 
cell- mediated immune response with Cyclosporine A (CsA) to influence the 
pathogenesis of CBPP and did not find a correlation between IFN-γ and clinical 
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lesions or severity of the disease. Therefore, the role of CD4+ secreting IFN-γ in the 
control of CBPP needs further research due to this contradicting information. 
Earlier immunological research was mainly concentrated on serological responses 
which yielded contradictory outcomes (Dedieu et al., 2005a). The literature contains 
conflicting reports on the importance of humoral antibody in the protection of cattle 
against Mmm. Several experiments that investigated the passive antibody transfer 
insinuated that the humoral immunity is important in protection (Smith 1967, 1971; 
Dyson and Smith, 1975), whilst others implied differently, due to the lack of 
correlation observed between antibody response and subsequent immunity (Lloyd 
1967; Gourlay 1975; March, 2004). There may not be a correlation between the 
antibody titers measured by either CFT or ELISA and the severity of the lesions 
found at post mortem in naturally or experimentally infected cattle. Cattle with high 
antibody titers may have no visible lesions and vice versa (Nicholas et al., 1996). The 
disparities might be due to differences in the age, the breed, mode of infection, the 
strain used as a source of infection and the health status of the cattle used for the 
experiment (Nicholas et al., 1996). 
Dedieu et al. (2005a) failed to establish the correlation between the onset of the 
disease, CFT results (antibody response) and the different clinical forms of CBPP. It 
was shown that the onset of the humoral response in acute cases developed later 
whereas it appeared early in recovered animals (Dedieu et al., 2005a). However, a 
correlation between the immune response measured and CBPP lesions was 
observed by Hübschle et al. (2003) during the CBPP outbreak in Northern Namibia.  
An experiment with immunostimulating complexes (ISCOM) vaccine postulated 
further the possibility of Th-1 immune response to be responsible for CBPP lesions 
(Hübshcle et al., 2003). The immuno dominant proteins of humoral immune response 
have been studied and characterized in experimentally infected animals with the 
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African and European strains (Abdo et al., 1998). This study showed that the African 
and the European strains have similar immunogenic proteins (110, 98, 95, 85, 80, 72, 
62, 48 and 39 kDa) except the 98 kDa which is missing in the European strains. 
Samples from bronchial lavage revealed 6 immunogenic proteins (110, 95, 85, 80, 72 
and 48 kDa) of IgA with Afade strain. A strong IgA reaction to lipoprotein P72 was 
observed (Abdo et al., 1998). No correlation between antibody titres, clinical lesions 
and lung lesions could be established when humoral immune responses were 
monitored for one year in animals naturally exposed to CBPP (Niang et al., 2006b). 
However, specific IgA immune response was found at both local and systematic 
levels in acute, sub-acute and chronic animals. Animals in sub-acute to chronic 
lesions had high level of IgA immune response (Niang et al., 2006b). The results of 
the IgM, IgG1 and IgG2 did not seem to be different in all groups and no correlation 
of them with the severity of the disease was established (Niang et al., 2006b). 
Therefore, the locally produced IgA may be important in protection against CBPP. 
Studies that investigated the immunity in other mycoplamas species postulated the 
importance of local immunity in host defense mechanism. A correlation was 
established between IgA antibody in respiratory secretions in man and immunity to 
M. pneumoniae (Krause and Taylor-Robinson, 1992). Furthermore, resistance to M. 
bovis in cattle was related to specific IgG in lung washings (Gourlay and Howard, 
1982). Therefore, poor correlation between serum antibody concentrations and 
resistance to infection for Mmm might be because Mmm is located on the mucous 
membrane of the respiratory tract (Ayling, 2002). In serum, immunoglobulin M (IgM) 
responses are usually detected first after Mmm infection followed by immunoglobulin 
G (IgG) (Barber et al., 1970), however the role of these immunoglobulins in 
immunopathology of CBPP is yet to be investigated.  
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It appears that both antibody and cell mediated immune responses are essential for 
prevention and resolution of CBPP (Nicholas et al., 1995) and further studies are 
needed. 
 
1.13 Aim and objective of the study 
1.13.1 Background 
 
Contagious bovine pleuropneumonia (CBPP) caused by Mmm has been in existence 
since time immemorial. It has been eradicated in many parts of the world during the 
19th century through a combination of control measures.  
The only practical control measure for Africa is through the use of vaccines. Current 
vaccines have limitations as they elicit short lived immunity and repeated coverage of 
all animals is impractical. Hence, development of an improved vaccine providing 
longer immunity and increased protection is vital. An improved understanding of the 
protective immune response is essential to facilitate the development of a new 
vaccine.  
 
1.13.2       Aim 
 
The aim of the study is to investigate the issues associated with CBPP by providing 
information on:  
1. The effectiveness of the current T1/44 vaccine given sub-
cutaneously as recommended by OIE. 
2. The effectiveness of the current T1/44 vaccine given intranasally 
to see if it stimulates a protective mucosal immune response. 
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3. Two novel vaccine formulations using a commercial adjuvant 
designed to help stimulate the Th2 response, which may 
stimulate protection. 
4. The importance of humoral immune response 
5. Differences between infections caused by planktonic and biofilm 
grown isolates. 
6. The comparative performance of old and new diagnostic tests. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
2.1 Experimental cattle 
 
The experimental protocol and justification was reviewed and approved by the Chief 
Veterinary Officer of the Directorate of Veterinary Services of Namibia and his team. 
A total of 45 cattle of Sanga and Afrikaner breeds which derived from a cross breed 
of Bos taurus and Bos indicus reared on a Government research farm in Windhoek 
district, an area free of CBPP for more than 85 years, were randomly selected and 
ear tagged for identification. The age of cattle was between 31 and 132 months old. 
Prior to the experiment all cattle were clinically screened and their sera tested 
negative for antibodies to Mmm by Complement Fixation Test (CFT) and Competitive 
Enzyme-Linked Immunosorbent Assay (cELISA), brucellosis and bovine viral 
diarrhoea (results not included). The cattle were transported to an experimental 
research farm, Omashare that is situated in the Okavango region, which is 
approximately 700 km north of Windhoek. The study had to be carried out in the 
Okavango region which is situated in the CBPP endemic area because of trade 
implications. 
Upon arrival at Omashare experimental research farm, cattle were divided into two 
groups, A and B. The older cattle were used for intubation to cause infection and 
serve as the challenge animals for the other groups that were all of similar ages circa 
3 years. The two groups were kept at two different paddocks about 500 meters far 
from each other for the duration of the experiment.  
Group A consisted of thirty-five cattle: ten intubated, five non-treated in-contact 
control, twenty (5 per group) vaccinated and referred to as vaccine group, whilst 
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group B had 10 cattle of which five were intubated with biofilm cells and 5 served as 
non-treated in-contact control (ratio of 1:1) and is referred to as biofilm group. Table 
2.1 below shows the details of the experimental animals of Afrikaner and Sanga 
breed. 
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         Table 2.1.  Animal number, age in months and the type of treatment. 
Animal number Age Type  Group  
2 132 Intubated    
3 132 Intubated    
4 132 Intubated    
6 131 Intubated    
7 131 Intubated  A  
8 131 Intubated    
9 131 Intubated    
10 131 Intubated    
41 92 Intubated    
66 69 Intubated    
146 34 T1/44 sub-cutaneous    
178 33 T1/44 sub-cutaneous  A  
179 33 T1/44 sub-cutaneous    
181 33 T1/44 sub-cutaneous    
192 32 T1/44 sub-cutaneous    
147 34 T1/44 intranasal    
152 33 T1/44 intranasal    
176 33 T1/44 intranasal  A  
186 32 T1/44 intranasal    
195 30 T1/44 intranasal    
150 33 Purified Protein    
155 33 Purified Protein    
161 33 Purified Protein  A  
162 33 Purified Protein    
189 32 Purified Protein    
139 32 Tween 20 cells    
158 33 Tween 20 cells    
170 33 Tween 20 cells  A  
182 32 Tween 20 cells    
194 31 Tween 20 cells    
145 34 In-contact    
165 33 In-contact    
175 33 In-contact  A  
177 33 In-contact    
188 32 In-contact    
11 127 Biofilm intubated    
20 116 Biofilm intubated    
62 69 Biofilm intubated  B  
67 69 Biofilm intubated    
78 69 Biofilm intubated    
138 34 Biofilm in-contact    
154 33 Biofilm in-contact    
159 33 Biofilm in-contact  B  
180 33 Biofilm in-contact    
183 32 Biofilm in-contact    
All animals were a breed of Afrikaner and Sanga which derived from a cross of Bos inducus 
and Bos taurus. Group A “Vaccine group and Group B “Biofilm group”. 
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2.2 Vaccine studies 
 
Four groups of five cattle (see Table 2.1) were vaccinated on the 22nd of August 2007 
with one of the vaccines T1/44 (2 different routes), Purified Proteins or Tween 20 as 
described in sections 2.2.1 to 2.2.3. 
2.2.1 T1/44 Vaccine  
 
The Panvac modified (PERIBOV) T1/44 freeze dried vaccine, with a minimum colony 
forming unit (cfu) of 107 as manufacturer’s information, was obtained from the 
Botswana Vaccine Institute in Gaborone. It was reconstituted as per manufacturer’s 
instructions immediately prior to use. Five cattle were injected sub-cutaneously 
behind the left shoulder with 1 ml of the vaccine as recommended by the 
manufacturer. A further five cattle were intranassally injected with the same dose of 
this vaccine. 
2.2.2 Recombinant protein vaccine 
 
A novel vaccine consisting of a cocktail of five purified proteins, herein referred to as 
purified protein vaccine, was evaluated. The recombinant putative variable surface 
proteins (MSC_0117, MSC_0364, MSC_0847, MSC_0816 and MSC_1033) were 
prepared as described previously (Hamsten et al., 2008). Briefly, these proteins were 
expressed in E. coli BL21 (DE3) and purified by Immobilized Metal Affinity 
Chromatography (IMAC). The vaccine consisted of equal amounts of each protein to 
a total protein concentration of 1 mg/ml (0.2 mg/ml of each protein) with the same 
adjuvant as 2.2.3 (Hamsten et al., 2010). The vaccine was prepared at Department of 
Proteomics, School of Biotechnology, Royal Institute of Technology, Stockholm, 
Sweden.  
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Five cattle (Table 2.1), age between 32 and 33 months were sub-cutaneously injected 
with 1 ml of the purified protein vaccine behind the left shoulder. 
2.2.3 Tween 20 vaccine  
 
A culture of the Mmm isolate designated “Matapi”, previously isolated in 2004 from 
the Okavango region of Namibia was grown overnight at 37oC in 100ml of Eaton’s 
broth media (Table 2.3) (Nicholas and Baker, 1998). The culture was harvested by 
centrifugation at 10,000 g for 40 minutes at 4oC. The pellet was washed in 0.1M PBS 
pH7.2 by centrifuging three times as above. After the last centrifugation, the sediment 
was suspended at 1 mg/ml in 0.0125M PBS containing 1% Tween 20. The 
concentration of 1 mg/ml (measured by using a Pierce BCA protein assay kit) was 
selected based on the concentration used for M. bovis vaccine (Nicholas et al., 2002). 
The culture was incubated for two hours at 37oC then centrifuged and the sediment 
suspended in 0.1M PBS pH7.2 with Emulsigen® (MVP Laboratories Inc., Omaha, 
USA) and AIOH, Rehydragel-LV® (Reheis Inc. New Jersey, USA) as per 
manufacturer’s instructions. Five cattle (Table 2.1) were injected sub-cutaneously 
behind the left shoulder with 1 ml of the Tween 20 washed cells vaccine. 
 
2.3 Experimental infection of cattle 
 
2.3.1 Mycoplasma strain and growth conditions 
 
A culture of the second passage of Mmm field strain 40F05 from a previous outbreak 
in Okavango which has been frozen at -80 oC was grown in a sterile Erlenmeyer 
flask. A four point five millilitre of Modified Hayflick’s Medium (MHM) (Table 2.2) 
(Freundt, 1993) was inoculated with 0.5 ml of 40F05 Mmm strain and incubated 
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overnight at 37oC under gentle agitation. A 5 ml culture was added to 245 ml of MHM 
and incubated as above. To measure the titer of the culture, a serial dilution was 
prepared into 10 test tubes containing 10 ml of MHM. Briefly, a 1 ml of the broth 
culture was added to the first tube, and then a serial dilution was performed by 
transferring 1 ml to the next tubes until the last tube. Two hundred microliter of the 
culture was placed on MHM and blood agar media in order to observe and count the 
Mmm colonies and to ensure that the culture was not contaminated. A titre of 109 
colony forming units (cfu) per ml at a second passage was used for the experimental 
infection of cattle. The culture was placed into 10 x 20 ml Falcon tubes and stored at 
+4oC until intubation. Meanwhile, MHM agar was prepared and 30 ml was poured into 
each 15 x Falcon tubes. The Falcon tubes were stored at +4oC until the cattle were 
intubated which was within 72 hours. 
 
Table 2.2. Composition of MHM (pH 7.8) 
Components    Concentration 
Heart infusion broth (Difco)  28.5g 
Deionized water    900 ml 
Fresh yeast extract (25%, w/v)  100 ml 
Horse serum     200 ml 
Calf thymus DNA (0, 2%, w/v)     2 ml 
Thallium acetate (1%, w/v)    10 ml 
Penicillin G (200, 000 units/ml)  2.5 ml 
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Table 2.3. Composition of Eaton medium (pH 7.6- 7.8) 
Components    Concentration 
Difco PPLO broth    21g 
Deionized water    700 ml 
Fresh yeast extract     100 ml 
Glucose     10g 
Horse serum     200 ml 
DNA      0.02g 
Phenol red (0.2%)     12.5 ml 
Penicillin (200, 000 IU/ml)              0.5ml 
 
2.3.2 Infection of cattle 
 
Ten cattle, age ranging between 69-132 months old were infected on the 1st of 
October 2007. For each cow intubation was carried out by inserting a horse stomach 
tube (Hübschle et al., 2003) into the trachea of the animal down to the site where the 
lungs split (bifurcation). After it was ascertained that the horse stomach tube was at 
the right place, a 20 ml of the Mmm culture that was prepared as described in section 
2.3.1 was used for the inoculum followed by 30 ml of MHM agar (crushed and mixed 
by using an ultra-turrax machine). Lastly a fifty millilitre of MHM was added to flush 
down all materials to the target site.  
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2.3.3 Growth of biofilm  
 
A one millilitre aliquot of a second passage of the strain 40F05 described in section 
2.3.1 was added to 9 ml of MHM and incubated overnight at 37oC. The overnight 
culture was diluted at 1/40 into fresh pre-warmed MHM. Using sterile forceps, 0.1 µm 
pore size 48 mm diameter cellulose acetate filter membrane (Sartorius) was placed 
on dry MHM agar and 1 ml of the diluted culture was placed on the membrane. The 
plates were left under a laminar flow hood for one hour at room temperature for the 
culture to soak into the filter membrane. Then, the plates were incubated at 37oC with 
5% CO2 for 72 hours. Five millilitre of MHM was placed into 10 x 50 ml Falcon tubes. 
Two biofilm membranes at a time were removed from the plates and placed face 
inwards into the Falcon tube containing 5 ml MHM. The adherent cells were removed 
from the membrane by vortexing for 1 minute. Each Falcon tube had 10 membranes 
re-suspended in it. The 5 ml culture from each Falcon tubes was pooled (50 ml) and 
centrifuged at 10,000 g for 20 minutes at 4oC. The supernatant was removed and the 
sediment re-suspended in 50 ml MHM. It was aliquoted into 5 x 10 ml tubes and 
stored at 4oC, ready for intubation.  
 
2.3.4 Infection of cattle with biofilm culture 
 
Five cattle 69-127 months old were infected on the same day and in the same 
manner as described in section 2.3.2 with a 10 ml of the biofilm culture prepared in 
section 2.3.3 with the cell count of 109 cfu per ml. 
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2.3.5 Exposure of vaccinated and control cattle to intubated cattle 
 
To challenge controls and vaccinated cattle, the intubated cattle were placed in their 
respective groups (group A and B) in two different paddoks , 500 meters away from 
each other on the day the intubation was carried out. At each camp, the cattle had 
access to clean water and were supplied daily with adequate quantities of pellets of 
Lucerne/hay. Subsequently, daily temperature and clinical signs were recorded by a 
trained veterinarian. Also, blood was collected once a week from each animal through 
the jugular vein using sterile 21 gauge needles and 10ml vacutainer tubes that were 
labelled with the animal number and date of collection. The clotted blood was 
centrifuged at 800g for 10 minutes and sera were collected into 15 ml Falcon tubes 
(BD) which had the same label as the vacutainer tubes. The sera were stored at -
20oC prior to overnight shipping to the Central Veterinary Laboratory via a courier. 
The experiment continued for 122 days following the initial intubation of the cattle. 
 
2.4 Serological tests 
 
2.4.1 Complement Fixation Test (CFT) 
 
The CFT is a method for demonstrating the presence or absence of antibody in the 
serum. The test is based on the property of antigen-antibody complexes to fix 
complement that is demonstrated by testing for free complement using a haemolytic 
indicator system. The CFT was carried out as described in the OIE Manual of 
Standards for Diagnostic Tests and Vaccines (Anon, 2004) with minor modification. 
Sera, including positive and negative reference were pre-diluted 1/10 in calcium-
magnesium veronal buffer (VB) (IDVET innovative diagnostics) before inactivation at 
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56oC for 30 minutes. The antigen and reference sera used were obtained from 
Instituto Zooprofillatico Esperimentale, dell Abruzzo, an OIE Reference Laboratory for 
CBPP. An antigen dilution of 1/70 was used at a dose of 2 complement fixing units. 
The complement (Dade Behring) at a dilution required for 2 units in 25 µl was used. A 
haemolysin (Dade Behring Diagnostic) was used at a dilution of 1/700 in VB (14 µl 
into 10 ml VB). An equal volume of sheep red blood cells (SRBC) was collected into a 
graduated bottle containing Alsever’s solution from a research farm and stored at 4oC 
for at least five days prior to use. On the day of the test, the cells were washed by 
centrifugation at 1500g for 10 minutes which was repeated three times in VB. Then 
the SRBC fraction was reconstituted in VB to make a 6% suspension. An equal 
amount of the diluted haemolytic serum was added to the 10 ml of 6% SRBC 
suspension to make a 3% SRBC suspension (haemolytic system). A 25 µl aliquot of 
VB was added to the appropriate wells of a round bottom microtiter plate. A 25 µl 
aliquot of the diluted sera were added to the appropriate wells and serial dilutions of 
25 µl were performed and the last 25 µl was discarded followed by the addition of 25 
µl aliquot of diluted antigen to the appropriate wells. A 25 µl aliquot of the 1/20 
complement was added to all the wells. The mixture was incubated at 37oC for 30 
minutes together with the haemolytic system. After 30 minutes, a 25 µl aliquot of the 
haemolytic system was added to the plate and incubated for 30 minutes. The plate 
was centrifuged at 2000g at 4oC for 5 min. The results were read visually and 
interpreted as described in the OIE Manual for Diagnostic Tests and Vaccine for 
Terrestrial Animal with a positive samples having 100% inhibition of haemolysis at a 
1/10 dilution. 
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2.4.2 Competitive Enzyme Linked Immunosorbent Assay (cELISA) 
 
The cELISA developed by CIRAD and described in the OIE Manual for Diagnostic 
Tests and Vaccine for Terrestrial Animal was used. This ELISA was designed to use 
a specific monoclonal antibody (117/5) which does not cross react with other 
mycoplasmas. The test was performed following the manufacturer’s instructions. 
Briefly, 100 µl aliquot of dilution buffer (DB) was added to all the wells of a pre-test 
plate (dilution plate). Then 11 µl of the test sera and control sera were added to the 
appropriate wells. A 110 µl aliquot of the monoclonal (diluted 1/120 in DB) was added 
to all the wells, leaving wells A1 and A2 as conjugate controls. After that, a 100 µl of 
this mixture was transferred to the corresponding wells of the antigen coated plate 
and incubated for sixty minutes at 37oC under constant gentle shaking. The plate was 
washed three times with washing buffer and a 100 µl aliquot of 1/100 diluted 
conjugate was added and incubated as described previously for 30 min. After a 
further wash, a 100 µl aliquot of 3,3’,5,5’ Tetramethylbenzidine (TMB) substrate was 
added and incubated at 37oC for 20 min. A 100 µl aliquot of stop solution (0.5 M 
sulphuric acid) was added and the plate was read using the microtiter plate reader 
(Multiskan EX, Thermo Electron Corporation) with 450nm filter. The percentage 
inhibition (PI) value for each serum was calculated using the following formula:  
PI = {(ODmab-ODtest serum)/ (ODmab-ODconjugate)} x 100% 
ODmab = optical density for the monoclonal antibody; ODtest serum = optical density for 
the test serum and ODconjugate = optical density for the conjugate. 
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2.4.3 Procedure for LPPQ ELISA 
 
An indirect ELISA based on the antigenic recombinant peptide N’-terminal half of the 
lipoprotein LPPQ of the Mmm developed by CHEKIT (Bommeli Diagnostics, 
Switzerland) (Bruderer et al., 2002) was used to test only some sera because the 
production of the kits was discontinued during the course of the experiment. The sera 
were diluted at 1/10 in dilution buffer. A 100 µl aliquot was added to the appropriate 
wells of the coated plate and incubated for 90 minutes at 23oC. The wells were 
washed three times using the washing buffer. Subsequently, 100 µl aliquot of anti-
ruminant IgG-conjugate horseradish peroxidase was added and incubated for 60 
minutes as previously described. After a further wash, 100 µl aliquot of the 
chromogen solution was added. The optical density was measured with a microtiter 
plate reader at 405 nm and the value for the sample was expressed as below: 
(OD sample-OD mean of negative control/ OD mean of positive control) x 100% 
 
2.4.4 Procedures for the indirect ELISA 
 
2.4.4.1 Preparation of Antigen for the indirect ELISA 
 
A 0.5 ml freeze dried stock culture of Mmm from APHA was reconstituted and sub 
cultured in 4.5 ml Eaton medium. After overnight incubation at 37oC with 5% CO2, the 
culture was poured into 90 ml pre-warmed medium in order to increase the volume of 
the culture and was incubated as previously on the shaker for 48 hours. Then the 
culture was centrifuged at 10,000g for 40 minutes. The supernatant was discarded 
and the sediment re-suspended in 20 ml of 0.1M PBS. A Thermo 2mg/ml 
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concentration of antigen was determined with a bicinchoninic acid (BCA) protein 
Assay (Scientific Pierce).  
 
2.4.4.2 Chequerboard titration for the indirect ELISA 
 
A chequerboard titration was performed to determine the specific dilutions for both 
antigen and immunoglobulins. Different dilutions of antigens (1/100; 1/200; 1/400; 
1/800; 1/1600 and 1/3200) were prepared in carbonate/bicarbonate buffer (one Tablet 
0.05M (Sigma) was dissolved in 100 ml of distilled water). Two columns (row A to H) 
of the flat bottom shape microtiter plates were coated with 100 µl aliquot of the 
appropriate dilution of antigen. The plates were incubated at 37oC for 2 hours. The 
plates were washed 4 times with PBS using the microtiter plate washer and after the 
last wash the plates were tapped on absorbent paper to remove any excess fluid. A 
100 µl aliquot of the positive and negative control sera at a dilution of 1/100 in 
serum/conjugate diluent buffer (0.1M PBS, 0.025% Tween 20 and 1% powdered milk) 
were added to the appropriate wells. The plates were incubated for 30 minutes before 
being washed as previously described.  
The dilutions of conjugate (1/1000; 1/2000; 1/3000 and 1/4000) were performed in 
conjugate diluent buffer and a 100 µl aliquot of 1/1000 conjugate was added to wells 
of rows A and B, a 100 µl aliquot of 1/2000 conjugate to wells of rows C and D, a 100 
µl aliquot of 1/3000 to wells of rows E and F, and a 100 µl aliquot of 1/4000 conjugate 
was added to wells of rows G and H. The plates were incubated at 37oC for 30 
minutes and washed as above. A 100 µl aliquot of freshly prepared enzyme substrate 
(mix substrate buffer 1:1 with substrate chomogen) (Vetequinol Cat no 0701360 & 
0701349) was added to all the wells. When the OD of positive control was between 
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0.28 and 0.32 when measured at 405nm, a 50 µl aliquot of stop solution (1M Citric 
acid) was added and the final reading was measured at 450nm. The optimum dilution 
of the antigen and the conjugate were taken as the highest dilutions that gave an 
OD450 value of approximately 1 for the positive serum and 0.20 for the negative 
serum. The chequerboard titration was carried out for each immunoglobulin (IgG1, 
IgG2, IgM and IgA). 
 
2.4.4.3 Test procedure for indirect ELISA for Mycoplasma mycoides 
subspecies mycoidesantibodies 
 
An indirect ELISA was performed to detect the antibodies to Mmm using different 
immunoglobulins. The antigen was diluted in carbonate/bicarbonate buffer at 1/400, 
1/100, 1/200 and 1/100 for IgG1, IgG2, IgM and IgA respectively as previously 
determined by chequerboard titration described in section 2.4.4.2 and incubated for 2 
hours at 37oC. After two hours of incubation the plates were washed 4 times with PBS 
and a 100 µl aliquot of 1/100 diluted sera (including controls) in dilution 
serum/conjugate diluent buffer were added to appropriate wells. A 100 µl aliquot of 
the serum/conjugate diluent buffer was added to G11 and H to serve as blank control 
wells. After 30 minutes of incubation at 37oC, the plates were washed as above and a 
100 µl aliquot per well of secondary antibody (IgA, IgG1, IgG2 and IgM) anti-cow 
horseradish conjugate (Sigma) was added. The secondary antibodies were diluted in 
the same buffer as for serum at a dilution of 1/10,000; 1/500; 1/10,000 and 1/2000 for 
IgG1, IgG2, IgM and IgA respectively as previously determined in chequerboard 
titration as described under section 2.4.4.2. The plates were incubated for a further 30 
minutes at the same temperature as described previously. After 4 washes, substrate 
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was added, followed by stop solution when the OD of the positive control was 
between 0.30 and 0.40 nm, determined by Multiplate reader at 405nm. The final 
optical density reading was measured with a photometer at a wavelength of 450nm. 
The calculation for each serum was automatically done using the generic Newbovis 
program with this formula. 
OD mean sample-OD mean of blank/ OD mean of positive control- OD mean of blank 
  
2.4.5 Test procedures for Latex Agglutination Test (LAT) to detect the 
antibodies against the Mycoplasma mycoides 
 
The BoviLAT from Animal and Plant Health Agency (APHA), Weybridge, UK, was 
used as per manufacturer’s instructions. The test utilizes a polysaccharide antigen 
extracted from the Mmm capsule that is bound to latex beads. Mmm was prepared as 
described in 2.4.4.1. The supernatant was used as it contains more carbohydrate 
than cells. After the pH of the supernatant was adjusted to 5.0 it was boiled for one 
hour before filtered through a grade 1 Whatman paper, (Sigma-Aldrich). Ethyl alcohol 
was added to the filtrate. After an overnight incubation of the mixture at 4oC, the 
precipitate was collected by centrifugation for 15 minutes at 1000g. The precipitate 
was suspended in distilled water and agitated for 2 hours at room temperature before 
the mixture was centrifuged for 30 minutes at 3000g. The sediment was discarded 
and carbohydrate was extracted by adding an equal volume of aqueous phenol. The 
mixture was incubated at 68oC for one hour and left overnight at 4oC followed by 
another centrifugation for 30 minutes at 3000g. After that the aqueous layer was 
separated through a PD10 column with distilled water. After several steps of 
centrifugation, the precipitate was lyophilized. The lyophilized precipitate was 
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suspended in PBS (pH 7.2) and carbohydrates were separated according to size by 
filtration through a column with BioSep Sec 3000, 60 x 2.1 cm (Phenomerex, UK) 
using an M45 HPLC/low pressure system (Waters, UK). The extracted 
polysaccharide antigen was used to bind the latex beads. Briefly, the latex beads 
were mixed with polysaccharide extract in PBS containing sodium ethylene diamine 
tetra-acetate and sodium azide (Ayling, 2002). After properly shaking the mixture, it 
was incubated at 37oC for one hour.  
For the execution of the test, 10 µl of the sera collected during the course of the 
experiment was added to an equal volume of the latex beads with bound 
polysaccharide antigen on microscope slide. After two minutes of mixing the presence 
or absence of the agglutination was observed against a dark background (Ayling, 
2002).  
 
2.4.6 Test Procedures for the Lateral Flow Device (LFD) to detect the 
antibodies against the Mycoplasma mycoides. 
 
The performance of the newly constructed LFD by Foresite Diagnostics (York, UK) in 
conjunction with APHA, Weybridge (Churchward et al., 2007) was evaluated. 
Essentially, the test uses the same Mmm carbohydrate extract antigen that is used in 
the LAT. However, it includes within one slide, the test and control. Briefly; a 9 µl of 
serum or whole blood was added to the dilution buffer and mixed well and 75 µl of the 
mixture was placed on the LFD and left for 5 minutes to incubate. Although a clear 
single band or double bands is visible when the test is negative or positive 
respectively, a battery operated portable reader was used to obtain a clear-cut result 
of a percentage value relating the colour of the test band to the positive control band. 
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Fig. 2.1. Lateral Flow Device 
 
 
 
 
Fig 2.2. Reading of Test 
 
 
 
 
Fig. 2.3. Portable Lateral Flow Reading Device 
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2.4.7 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) and Western blotting for the determination of antibodies against 
the Mycoplasma mycoides subspecies mycoides in sera collected during 
this experiment 
 
2.4.7.1 Preparation of CBPP antigen for SDS PAGE 
 
The antigen was prepared as described in section 2.4.4.1 and 5.2 µg/ml 
concentration of the protein was used. Seventy-one microliter of antigen was added 
to 29 µl of PBS and 100 µl Laemmli buffer (Laemmli (1970). The mixture was boiled 
for 10 minutes and cooled on ice before it was briefly vortexed.  
 
2.4.7.2 SDS PAGE Gel Preparation  
 
Mini-Protean III gels plates with 1mm spacers were used. The procedure was carried 
out according to Laemmli (1970). Briefly, a 12% resolving gel was prepared using 
30% Acrylamide, HPLC water, 0.5M Tris-HCL (pH 6.8), 10% Sodium dodecyl 
sulphate (SDS), 10% Ammonium Persulphate (APS) and 
Tetramethylethylenediamine (TEMED). A five millilitre of the prepared gel was 
dispensed between the assembled glass plates to about 4 cm below the top and one 
millilitre of isobutyl alcohol was immediately added to the gel to allow the gel to settle 
evenly. After the gel polymerised, the isobutyl was removed and the gel was washed 
with running tap water. The residual water was removed by inserting a thin blotting 
paper. A four percent stacking gel (30% Acrylamide, HPLC water, 1.5M Tris-HCL (pH 
8.8), 10% SDS, 10% APS and TEMED) was prepared and layered over the solidified 
resolving gel. The comb was inserted into the gel before the gel was allowed to set for 
30 minutes. The casting was dissembled, comb removed and the glass plates 
containing the gels were placed into the central core of the electrophoresis tank. A 
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concentrated electrode buffer (75g Tris (hydroxymethyl) aminomethane, 25g Sodium 
Dodecyl Sulphate (10% w/v), 360g Glycine, 5 liters of H2O) was diluted at one to five 
in deionised water and enough volume to cover the lower part of the gel was added to 
the tank. A 195 µl aliquot of the antigen prepared as described in section 2.4.7.1 was 
added to each gel and a 15 µl aliquot of the molecular weight marker (Dual color plus, 
Bio-Rad) was loaded into the well. The tank was connected to the power pack 200 
(Bio-Rad) and electrophoresed for 45 minutes at 200 volts.  
 
2.4.7.3 Transfer of the gel from the electrophoresis apparatus 
 
The electrophoresis apparatus was dismantled and the gels were transferred to a 
container containing Bjerrun and Schafer-Nielsen transfer buffer (Tris NH2C 
(CH2OH)3) 5,82g, Glycine 2,93g, SDS 0,0375g, Methanol 200ml and Water 1L). The 
gels were placed on top of pre-soaked 0.45 µm nitrocellulose membranes that were 
cut to the same size as the size of the thick blotting paper and the gel. The apparatus 
was connected to the power source at 15 volts for 30 minutes. The membranes were 
removed and stained with 0.2% (w/v) Ponceau S (2 g Ponceau S, 30 ml acetic acid 
(3% v/v), to make up 1L in ddH2O) in order to visualize that the protein was 
successfully transferred from the gels to the membranes. The membranes were 
rinsed with deionised water followed by PBS and placed in blocking buffer (1M 
Glycine, 1% Ovalbumin, 5% Skimmed milk in 0.1M PBS) at either room temperature 
for one hour under slow shaking or overnight at 4oC. Subsequently, they were 
washed twice with PBS + 0.1% Tween 20 and rinsed once in PBS.  
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2.4.7.4 Western Blotting for the detection of antibodies against Mycoplasma 
mycoides 
 
The Western blotting was carried as described by Nicholas et al. (2008b). The 
membranes were cut into 4mm wide strips. A single strip was used for each serum 
including negative and positive controls. Each strip was placed on a channel of the 
incubation tray and soaked in 1 ml of serum diluted at 1/50 in serum/conjugate diluent 
(0.1% skimmed milk, 0.1% chicken egg albumin, 0.1M PBS) and incubated at 37oC 
for 2 hours under gentle shaking. The strips were washed thrice in washing buffer 
(0.1M PBS + 0.1% Tween 20) and rinsed once with PBS. One millilitre of the anti-
species conjugate diluted to the correct concentration as previously determined (IgM 
=1/10,000; IgG1 = 1/1000; IgG2 = 1/1000) was added and incubated for 1 hour as 
before. After washing as above, the strips were soaked in 4-chloro-1-naphthol (4CN) 
(Thermo Scientific, Pierce Biotechnology) at room temperature until the band 
developed to a desired intensity and then the reaction was stopped by rinsing the 
strips with deionised water.  
 
2.5 Detection of CBPP antigen in lungs and lymph nodes of experimental 
animals by histological and Immunohistochemistry (IHC) analysis 
 
Pieces of lungs and lymphnodal tissue were cut and fixed in neutral buffered formalin. 
The fixed tissues were passed through baths of concentrated ethanol in order to 
remove the excess water. The alcohol was removed from the tissues with a 
hydrophobic clearing agent (xylene) before they were infiltrated in paraffin wax. The 
infiltrated tissues were then embedded in wax blocks (Scanziani et al., 1997). 
Sections of 5µm were stained with standard haematoxylin and eosin. Sections were 
also used for immuonohistochemical staining to assess the localization of the Mmm 
70 
antigen in the lung and lymph node. The Streptavidin Biotin Complex Peroxides 
(DAKO) method was used. All samples were tested with rabbit hyper-immune serum 
anti-Mmm (IZS A&M) diluted 1:1560 in tris-buffered saline solution, pH 7.6 containing 
5% skimmed milk powder. The rabbit serum was used for negative control. 
 
2.6 Pathology and clinical scores of experimental animals 
 
At the end of the experiment, cattle were euthanized and examined for gross 
pathological changes, including adhesions, the presence of pleural and pericardic 
fluids. The clinical scoring system (Chapter 3, Table 3.1) for CBPP as described by 
Hübschle et al. (2006) was used. The aim was to quantify the serological response, 
clinical signs and post mortem findings weighting the score in favour of the size of 
CBPP lesion. The maximum scoring number is 18. The cattle that were sacrificed 
early due to CBPP during the course of the experiment or that died of CBPP were 
given a maximum clinical score of 18 by a veterinarian. 
 
2.7 Statistical analysis of data of indirect ELISA and CFT  
 
A Proc Mixed statistical tool (SAS, 2003) was used for immunological study on data 
analysed with indirect ELISA because it gives flexibility in covariance structures for 
repeated measurements data and accounts for within animal, time-dependent 
correlations (Littell et al., 1998). The predictor variables considered in the models 
were type of vaccine (A = T1/44 sub-cutaneous; B = T1/44 intranasal; C = Purified 
Protein; D = Tween 20 and E = Control), time (week = to 18) and treatment X time 
interaction. The dependent variables were IgG1, IgG2, IgM and IgA. 
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CHAPTER THREE 
EXPERIMENTAL STUDIES ON THE EFFECT OF T1/44 VACCINE, PURIFIED 
PROTEIN VACCINE, TWEEN 20 VACCINE, IN THE CONTROL OF CBPP AND 
THE INTERACTIONS BETWEEN Mmm BIOFILMS AND THE HOST IN VIVO 
3.1 Introduction 
 
Although vaccines are available to control CBPP, they lack the required efficacy with 
limited duration of immunity, therefore requiring repeated annual vaccinations 
(Thiaucourt et al., 2000). Furthermore, the T1/44 strain maintains a level of 
pathogenicity when administered to cattle through the intra-tracheal route (Hübschle 
et al., 2002). T1/44 is nonetheless used in the absence of a better product (Scacchia 
et al., 2007). To date, the development of a new generation of vaccines has not given 
satisfactory results (Abusugra et al., 1997; Hübschle et al., 2004). Although the use of 
antibiotics is officially discouraged due to the possibility that it may mask the disease 
and create chronic carriers (Provost et al., 1987), they are still widely used.  
In order for an improved vaccine to be formulated, the understanding of the humoral 
immune response, clinical signs and pathological lesions caused by Mmm is needed. 
Formation of biofilms by mycoplasma species was reported by Simmons and Dybvig, 
(2009) and McAuliffe et al. (2006). This phenomenon is alleged to lead to the survival 
of mycoplasmas in harsh environment. It is further alleged to be responsible for 
mycoplasmas resistance to antibiotics as well as persistance in the host. When 
different strains of 11 mycoplasmas species were tested for their abilities to form 
biofilms on 11 mm2 glass coverslips, Mmm did not show biofilm formation (McAuliffe 
et al., 2007). However, Mmm formed biofilm when it was grown on cellulose acetate 
filter membrane (McAuliffe et al., 2008). The role of Mmm biofilm in the establishment 
of the disease, its pathogenicity, evasion of the immune system or possible re-
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emergence has not yet been evaluated. Therefore, the interactions between Mmm 
grown as a biofilm and the host in vivo were evaluated. 
This study was therefore in two folds. First, to assess the clinical signs and 
pathological lesions in experimentally vaccinated, intubated and control animals. 
Secondly, to assess the same parameters as above in animals intubated with a 
biofilm grown mycoplasma. 
 
3.2 Materials and Methods   
 
3.2.1 Experimental cattle 
 
The experimental protocol and justification was reviewed and approved by the Chief 
Veterinary Officer of the Directorate of Veterinary Services of Namibia and his team. 
A total of 45 cattle of Sanga and Afrikaner breeds (age 31 and 132 months old) which 
derived from a cross breed of Bos taurus and Bos indicus reared on a Government 
research farm in Windhoek district, an area free of CBPP for more than 85 years, 
were randomly selected and ear tagged for identification. Prior to the experiment all 
cattle were clinically screened and their sera tested negative for antibodies to Mmm 
by Complement Fixation Test (CFT) and Competitive Enzyme-Linked Immunosorbent 
Assay (cELISA), brucellosis and bovine viral diarrhoea (results not included). Animals 
were examined for the presence of endo- and ecto-parasites and no treatment was 
considered necessary. 
Upon arrival at Omashare experimental research farm (approximately 700 km north of 
Windhoek, in the Okavango region) cattle were divided into two groups, A and B. 
Group A consisted of thirty-five cattle: ten intubated, five non-treated in-contact 
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control, twenty (Four groups of five cattle ) vaccinated and referred to as vaccine 
group, whilst group B had 10 cattle of which five were intubated with biofilm cells and 
5 served as in-contact control (ratio of 1:1) and is referred to as biofilm group. See 
Chapter 2, table 2.1 which shows the details of the experimental animals of Afrikaner 
and Sanga breed. The two groups were kept at two different paddoks which were 
about 500 meters far from each other for 122 days.  
 
3.2.2 Infection of experimental cattle with Mycoplasma mycoides subspecies 
mycoides  
 
3.2.2.1 Infection of experimental cattle through endobronchial intubation 
 
3.2.2.1.1 Intubation of experimental cattle with conventional Mmm culture 
 
The mycoplasma culture was prepared as described in Chapter 2, section 2.3.1. 
Briefly, an endo-tracheal intubation was performed by inserting a horse stomach tube 
into the trachea until bifurcation (the site where the lungs split). Briefly, each of the 10 
cattle in the intubated group (group A) (see Chapter 2, Table 2.1) was infected with 
20 ml of mycoplasma culture with 109 colony forming units (cfu) per ml at a second 
passage as described in Chapter 2, section 2.3.2. 
 
3.2.2.1.2 Intubation of experimental cattle with biofilm Mmm culture 
 
The procedure for the preparation of biofilm mycoplasma culture is described in 
Chapter 2 under section 2.3.3. Briefly, five cattle 69-127 months old were infected on 
the same day and in the same manner with a 10 ml of the biofilm culture with the cell 
count of 109 cfu per ml (see sections 2.3.2 and 2.33  
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3.2.3 Infection of experimental animals by contact with experimentally infected 
animals 
 
In-contact non-treated animals and animals vaccinated with various vaccines (see 
Chapter 2, sections 2.2.1, 2.2.2 and 2.2.3) five weeks prior to infection were placed 
together with the intubated cattle on the day the intubation was performed. The 
biofilm intubated animals were also placed together with the in-contact non-treated 
animals on the day the intubation was carried out. The animals in the vaccine group 
(Group A) and the biofilm group (Group B) were kept at 2 different paddocks which 
were 500 meters apart from each other for 122 days (17 weeks).  
 
3.2.4 Clinical examinations of experimental animals 
 
A Veterinary Officer was stationed at the site of the experiment. All animals were 
observed daily and clinical findings were recordedy for the duration of the experiment. 
These included rectal temperatures, cough, nasal discharge and dyspnea. Animal 
with a temperature exceeding 39.0oC was considered febrile.  
 
3.2.5 Serological examination of experimental animals 
 
Blood samples were collected once a week from each animal via jugular 
venepuncture using sterile 21 gauge needles into 10ml vacutainer tubes that were 
labelled with the animal number and date of collection. The clotted blood was 
centrifuged at 800g for 10 minutes and sera were collected into 15 ml Falcon tubes 
(BD) which had the same label as the vacutainer tubes. The sera were stored at -
20oC prior to overnight shipping to the Central Veterinary Laboratory via a courier. 
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Samples from each animal were tested for the presence of Mmm antibodies using 
CFT. The CFT was carried out as described in the OIE Manual of Standards for 
Diagnostic Tests and Vaccines (Anon, 2004) with minor modification (see Chapter 2 
section 2.4.1). 
3.2.6 Postmortem examination of experimental animals 
At hundred and twenty-two days’ post infection, cattle were euthanized by stunning 
with a captive bolt pistol followed by exsanguination. The nature of lung lesions and 
the percentage of parenchyma involved in the pathological process were recorded. 
The lesions recorded in the lungs of affected animals were characterized as: 
 Acute lesions – hepatisation at different stages, thickening of interlobular 
septa, presence of serous pleural exudates in the thoracic cavity and of 
fibrinous pleuritis 
 Sub-acute lesions – fibrinous adhesions between visceral and parietal pleura, 
necrotic areas in lung parenchyma 
 Chronic lesions – encapsulated sequestra at different stages of organisation or 
liquefaction. 
The clinical scoring system for CBPP (Table 3.1) as described by Hübschle et al. 
(2006) was used. The cattle that were sacrificed early during the course of the 
experiment due to CBPP were given a maximum clinical score of 18. Samples of lung 
tissues, pleural fluids, lung sequestra, lymph nodes and kidneys were collected from 
all animals.  
Lungs and lymphnodal tissue collected at post mortem were fixed in neutral buffered 
formalin and embedded in paraffin (see Chapter 2, section 2.5). 
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Table 3.1.  The pathological scoring system for CBPP of Hudson and Turner (1963) 
was adapted as follows: 
Indicators of infection    Pathological scores 
Serological response (CFT) to challenge 
<10        0 
10        1 
20-80        2 
≥160        3 
Clinical response to challenge 
Pyrexia at least 39.5 
0
C for >3 but <7 days   1     
Pyrexia for >7 days      2 
Animal succumbed/euthanized     3 
PM findings 
Chronic lesions (sequestra)     1 
Acute/sub-acute (marbling etc.)     2 
Mmm isolated or detected     2 
Multiply the sum by a factor depending on lesion size 
<5cm         x 1     
>5cm but <20        x 2 
>20cm         x 3 
 Maximum score is 
 Serology      3 
 Clinical       3 
 PM (2 +2) 3               12 
 Total                18 
Hübschle et al. (2006) 
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3.3 Results 
 
3.3.1 Clinical and serological findings of animals within the vaccine group 
 
3.3.1.1 Clinical and serological findings of conventionally Intubated animals 
 
Elevated body temperatures were first recorded between days 6 and 106 post 
intubation. The average time of elevated temperatures among animals was 11 days.  
Persistence of pyrexia varied from 1 to 16 days. Respiratory distress of variable 
intensity was recorded in 8 animals. Serological response measured by CFT was first 
detected at day 6 post intubation while the last animals sero-converted at day 107 
post intubation. The CF titres varied between 640 and 10240. Nine animals were CFT 
positive at post mortem. One animal remained CFT negative with no apparent clinical 
signs for the duration of the experiment. None of the animals succumbed to CBPP; 
they were only necropsied at the end of the experiment, at week 17 (122 days).  
 
3.3.1.2 Clinical and serological findings of animals vaccinated sub-
cutaneously with T1/44 
 
The elevated body temperature was recorded in one animal at day 100 post infection. 
Three animals did not show any respiratory distress while two presented respiratory 
distress of variable mild intensity. Two animals (#146 and 178) were CFT positive 2 
weeks post vaccination and all five animals became positive in CFT 4 weeks post 
vaccination. However, the CF titres in four animals (#146, 179, 181 and 178) declined 
to zero between days 74 and 114 post infection and remained negative up to the end 
of the experiment. The fifth animal that was febrile for one day was CFT positive at 
post mortem. None of the animals died during the course of the experiment. 
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3.3.1.3 Clinical and serological findings of animals vaccinated intranasally 
with T1/44 
 
Pyrexia was recorded in two animals between days 61 and 86 post infection with an 
average time of two days. Respiratory distress of variable intensity was recorded in 
four animals. The average time for detecting serological response was 7 days’ post 
infection with the earliest reaction recorded on day 44 and the latest on day 93 post 
infection. Peak CF titres varied between 10 and 5120. One animal remained sero-
negative and one became sero-negative 3 weeks prior to post mortem examination. 
All 5 cattle were culled at the end of the experiment.  
 
3.3.1.4 Clinical and serological findings of animals vaccinated with Purified 
Protein  
 
Elevated body temperatures were recorded between days 44 and 84 post infection 
with an average time of 9 days. Two animals presented respiratory distress of 
variable intensity. The average time for detecting serological response in all animals 
was 11 days; the earliest reactions were recorded on day 30 post infection and the 
latest on day 86. One animal (#150) was CFT positive 4 weeks post vaccination and 
the titer increased in intensity at day 72 post infection. All animals were CFT positive 
at post mortem. None of the animal succumbed to the disease during the course of 
the experiment.  
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3.3.1.5 Clinical and serological findings of animals vaccinated with Tween 20 
cells  
 
Pyrexia was first recorded between days 44 and 76 post infection in three out of five 
animals. Persistence of high fever varied between 9 and 12 days. Respiratory 
distress was recorded in all animals. Three animals had vaccine titers prior to 
infection. However, the intensity of the CF titers increased between days 37 and 51 
post infection at which time the animals were febrile. Two animals (#182 and 194) 
succumbed to CBPP during the course of the experiment on week 16 and 12 with CF 
titers of 2560 and 1280 respectively. Two of the three surviving animals had CF titers 
at post mortem while the third animal that had low CF titers varied between 10 and 40 
for 8 weeks was negative for additional 8 weeks prior to post mortem examination.  
 
3.3.1.6 Clinical and serological findings of non-treated in-contact control 
animals 
 
Raised body temperatures were first recorded between days 44 and 93 post infection 
with an average time of 5 days. Respiratory distress of variable intensity was 
recorded in three animals. In three animals (#165, 188 and 177), sero-conversion 
preceded pyrexia whereas in two, the contrary was observed. The first serological 
response was detected at day 23 post infection while the last animal sero-converted 
at day 100. Peak CF titres varied between 40 and 5120. All animals were CFT 
positive at slaughter. 
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3.3.2 Clinical and serological findings of animals within biofilm group 
 
3.3.2.1 Clinical and serological findings of biofilm Intubated animals 
 
Pyrexia was recorded in one animal (#78) on days 112 and 113 post intubation. The 
same animal had low CF titres of 20 for two days. Sero-conversion preceded pyrexia 
in this animal. Respiratory distress was recorded in two animals. Animal #67 was the 
only animal with high CF titres from day 31 post intubation until at post mortem 
examination. Sero-conversion was recorded in the total absence of pyrexia (Table 
3.3). All cattle were sacrificed at the end of the experiment. 
 
3.3.2.2 Clinical and serological findings of non-treated in-contact control 
animals 
 
One animal (#138) was sacrificed on day 79 post infection, due to an acute form of 
CBPP. The body temperatures were recorded in 2 animals (#138 and 159) on days 
37 and 96 post infection with an average time of 3 days. Persistence of pyrexia varied 
from 2 to 3 days. These two animals sero-converted on days 73 and 93 post infection. 
In animal #138, sero-conversion was observed before pyrexia while in animal #159, 
the contrary was observed.  
The clinical findings of the animals within the vaccine and the biofilm groups are 
summarised in Tables 3.2 and 3.3 respectively. 
 
3.3.3 Post mortem findings of animals within both vaccine and biofilm groups 
 
The post mortem findings of animals in vaccine and biofilm groups are summarised in 
Tables 3.2 and 3.3 respectively. Necropsy was carried out on all animals at the end of 
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the experiment. The types of lesions in the thoracic cavity were recorded on a 
specifically designed form (see appendix 1) and classified as: acute lesions: 
hepatisation at different stages, thickening of interlobular septa, presence of pleural 
fluid in the thoracic cavity, fibrinous pleurisy- “omelette”; sub-acute lesions: adhesion 
between visceral and parietal pleura, necrotic area in lung parenchyma; chronic 
lesions: encapsulated sequestra at different stages of liquefaction (Scacchia et al., 
2011). Three cattle out of 45 were necropsied on welfare ground at different times 
during the cause of the experiment. The typical lesions observed at post mortem were 
characterized by straw coloured fluid and the affected portion of the lung was large 
and solid. Increased interlobular septa; red and gray areas of hepatisation; fibrinous 
deposits on parietal surface of lungs; liquefaction necrotic areas and sequestra were 
observed.  
 
3.3.3.1 Post mortem findings of animals intubated with conventional Mmm 
culture 
 
Chronic lesions were observed in seven animals. One animal (#8) had three stages of 
the lesions: acute, sub-acute and chronic while animal #10 had sub-acute and chronic 
lesions. Figure 3.3 shows fibrin in visceral pleura of animal number 8. Animal #9 did 
not have CBPP lesions but the lung was hypertrophic. CBPP was confirmed by Real 
Time PCR (carried out at IZS, Teramo) in all animals excluding #9. The total 
integrated score for the intubated animals was 94. 
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3.3.3.2 Post mortem findings of animals vaccinated sub-cutaneously with 
T1/44 
 
Pathological lesions found during post mortem examinations in these cattle were less 
severe compared to the cattle vaccinated with the same vaccine but intranasally and 
those vaccinated with Tween 20 and Purified Protein. Two animals (#179 and 192) 
had chronic lesions with small sequestra of 1 cm and 5 cm (Table 3.2). No CBPP 
lesions were observed in the other three animals. The cattle in this category had less 
clinical symptoms with a total integrated score of 12. 
 
3.3.3.3 Post mortem findings of animals vaccinated intranasally with T1/44 
 
Chronic lesions were observed in all the animals. However, two animals (#152 and 
176) had small sequestra of 1.2 and 2 cm. The total integrated score was 39. 
3.3.3.4 Post mortem findings of animals vaccinated with Purified Protein  
 
Animals in this group had chronic pathological lesions with large sequestra varied 
between 8 and 25 centimeter in diameter (Table 3.2). The entire lung of one animal 
was sequestrated. Figure 3.1 depicts the encapsulated sequestrum with necrotic core 
from an animal vaccinated with purified protein vaccine. The lesions in the animals of 
this group are comparable to the lesions of the in-contact control animals. The total 
integrated score was recorded at 59. 
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3.3.3.5 Post mortem findings of animals vaccinated with Tween 20 cells  
 
Two animals (#194 and 182) succumbed to CBPP at weeks 12 and 16 post infection. 
Chronic pathological lesions were recorded in four animals including the animals 
which died during the course of the experiment. Animals # 94 and 182 had large 
sequestra that invaded the left epical lobes. The total integrated score among all 
animals was 44. 
 
3.3.3.6 Post mortem findings of none treated in-contact control animals 
 
Chronic lesions with various sizes of sequestra were recorded in all animals at post 
mortem examination. Apart from chronic lesions, animal #145 had sub-acute lesions 
with lung hepatisation and marbling. Figure 3.2 shows lung adhesion of animal 
number 177. The total integrated score was 58. 
 
3.3.3.7 Post mortem findings of animals within Biofilm Intubated and none 
treated in-contact control cattle 
 
Chronic pathological lesions were observed in one animal (#159) of the control group. 
Animal #138 in the control group died of acute form of CBPP. There were no CBPP 
lesions observed in the rest of the animals (Table 3.3). Biofilm mycoplasma seemed 
to have established a mild form of the disease when compared to the counterparts in 
the vaccine group. The total integrated score was 11 for intubated animals and 30 for 
in contact challenged animals.  
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Table 3. 2. Summary of clinical, pathological and serological results for cattle within 
vaccine group 
 
Cattle 
No 
Age in 
Month 
Group 
Type 
No of 
days 
Temp 
≥39 
0
C 
Cough Clinical 
score 
CFT 
at 
    PM 
CFT + 
Duration 
(weeks 
CBPP 
mortality 
Type of 
lesions 
Size 
of 
sequestrum 
2 132 Intubated 9 No 14 1280 6 No S, PF >40 cm 
3 132 Intubated 7 Yes 13 320 10 No S, PF 30 cm 
4 132 Intubated 1 Yes 10 160 6 No S, PF 12 cm 
6 132 Intubated 15 Yes 10 80 16 No S 6 cm 
7 132 Intubated 16 Yes 8 320 17 No S, PF 3.5 cm 
8 132 Intubated 11 Yes 17 2560 3 No S, PF  
9 132 Intubated 0 Yes 2 0 0 No N  
10 132 Intubated 11 No 9 640 3 No S, PF  
41 92 Intubated 15 Yes 7 40 17 No S, PF 2.5 cm 
66 69 Intubated 14 Yes 14 2560 7 No S 
 
40 cm 
146 34 T1/44 s/c 0 Yes 2 0 19 No PF, PF*  
178 33 T1/44 s/c 0 No 2 0 16 No  PF  
179 33 T1/44 s/c 0 No 2 0 16 No S, PF* 1 cm 
181 33 T1/44 s/c 0 Yes 2 0 13 No PF, PF*  
192 32 T1/44 s/c 1 No 4 160 20 No S, PF       4 cm 
 
147 34 T1/44 i/s 4 Yes 12 5120 1 No S, PF 10, 20, 15 
cm  
152 33 T1/44 i/s 0 No 3 0 7 No S, PF* 1.2 cm 
176 33 T1/44 i/s 0 Yes 3 0 0 No S, PF 2 cm, 2 cm 
186 32 T1/44 i/s 0 Yes 12 1280 5 No S >40 cm 
195 30 T1/44 i/s 2 Yes 9 640 14 No S, PF 10 cm 
 
150 33 PP 1 No 9 2560 15 No S, PF 10 cm 
155 33 PP 12 Yes 11 1280 9 No S, PF, 
PF* 
15 cm 
 
 
161 33 PP 13 Yes 14 2560 6 No S, PF >40 cm 
162 33 PP 9 No 11 320 13 No S 8 cm 
189 32 PP 10 No 14 320 12 No A, S, PF 25 cm 
139 32 Tween 20 12 Yes 8 320 12 No S, PF 5 cm 
158 32 Tween 20 0 Yes 2 0 8 No H, PF  
170 32 Tween 20 0 Yes 4 80 18 No  PF  
182 32 Tween 20 13 Yes 15 2560 * Yes S, PF >40 cm 
194 31 Tween 20 12 Yes 15 1280 * Yes S >40 cm  
 
145 34 Contact 2 No 15 640 5 No H, M, S, 
PF 
28 cm 
165 33 Contact 1 Yes 6 160 15 No S, PF, 
PF* 
<2 cm 
175 33 Contact 1 Yes 9 160 9 No S, PF 5 cm; 3 cm 
 
177 33 Contact 8 Yes 14 5120 7 No S, PF >40 cm 
188 32 Contact 11 No 14 1280 10 No S 35 cm 
 
A (Lung adhesion); S (sequestrum); PF (Pleural Fluid); H (Lung hepatisation); PF* (Pericardic fluid); N (Negative); i/s (Intranasal) 
s/c (Sub-cutaneous) 
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Fig.3.1. Encapsulated sequestrum with a necrotic core from an animal vaccinated with a purified protein 
vaccine  
 
 
 
Fig.3.2. Lung adhering to the chest wall of an in-contact control animal from the vaccine group (images from 
this study) 
 
 
 
Encapsulated 
sequestrum 
Lung adhesion 
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Fig.3.3. Fibrin in visceral pleura of an Mmm intubated animal  
 
 
Fig.3.4. Marbled lung with thickened interlobular septa from an Mmm intubated animal (images from this study) 
 
 
 
 
 
 
 
 
 
Fibrin in visceral 
pleura 
Marbling 
Thickened 
interlobular 
septum 
 septa 
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Table 3. 3. Summary of clinical, pathological and serological results for cattle within 
biofilm group 
Cattle 
No 
Age in 
Month 
Group 
Type 
No of 
days 
Temp 
≥39 
0
C 
Cough Clinical 
score 
CFT 
at 
  PM 
CFT + 
Duration 
(weeks 
CBPP 
mortality 
Type 
of 
lesions 
Size 
of 
sequestrum 
11 127 Intubated 0 Yes 2 0 0 No H, PF*  
20 116 Intubated 0 No 2 0 0 No PF*  
62 69 Intubated 0 No 2 0 0 No N  
67 69 Intubated 0 Yes 3 160 14 No PF*  
78 69 Intubated 2 No 2 0 2 No N 
 
 
138 34 Control 3 No 13 5120 * Yes S  
154 33 Control 0 No 2 0 0 No   
159 33 Control 3 No 10 1280 5 No S, PF 15-17 cm 
180 33 Control 3 No 3 0 0 No PF, 
PF* 
 
183 32 Control 1 Yes 2 0 1 No   
A (Lung adhesion); S (sequestrum); PF (Pleural Fluid); H (Lung hepatisation); PF* (Pericardic fluid); N (Negative) 
 
 
3.3.4 Histopathological findings on animals within the vaccine and biofilm 
groups 
 
Histopathological findings were similar in most animals and they were characterized 
as following: 
 The observations on the lung tissues were: catarral fibrinous pneumonia and 
pleuropneumonia; fibrosis of septa with infiltration of inflammatory neutrophils, 
eosinophils and macrophages. Also, edema, emphysema, atelectasis, necrosis 
and congestion were observed on the lungs. 
 The lymph nodes displayed the lymphoid infiltration around the lymphatic 
vessels. The lymphatic vessels were dilated and lymphoid hyperplasia with 
marked enlarged follicle was visible. 
 No major findings were seen in kidney tissues, however interstitial nephritis 
and glomerulonephrosis were observed in one animal.  
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3.3.5 Immunohistochemistry findings of animals within both vaccine and 
biofilm groups 
 
The result of the immunohistochemistry (IHC) is detailed in Table 3.4. A distinctive 
immunostaining of macrophages, alveoli, fibrin, bronchial lumen, epithelium and 
BALT was recorded in lung tissues of most animals. The follicle germinal centers and 
medulla of the lymph nodes stained positive for the presence of Mmm.  
Mmm antigen was detected by IHC in the lungs and/or lymph nodes of most of the 
animals. The biofilm intubated animals did not present detectable stained Mmm 
antigen in their lungs, however, Mmm antigen was detected in the lymph node of cow 
number 154.   
The immunoglobulin A was detected in the majority of the vaccine non-treated in-
contact and Purified Protein vaccinated cattle. The antibody responses in the Purified 
Protein cattle were comparable to the responses of cattle in the vaccine non-treated 
in-contact. The Complement component 3 (C3c) responses were detected in the 
majority of animals with high CF titers at post mortem. 
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Table 3. 4. Immunohistochemistry activities of animals in vaccine and biofilm groups 
An. Type IHC 
CBPP 
  IHC IgA   IHC IgM   IHC IgG1   IHC IgG2   IHC C3c   
No 
  
Lung Lymph 
node 
Lung Lymph 
node 
Lung Lymph 
node 
Lung Lymph 
node 
Lung  Lymph 
node 
Lung Lymph 
node 
2 IN POS POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
3 IN POS POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
4 IN POS POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
6 IN POS POS NEG NEG NEG NEG POS POS NEG NEG NEG POS 
7 IN POS POS NEG NEG NEG NEG POS POS NEG NEG NEG POS 
8 IN POS POS NEG NEG NEG NEG NEG NEG NEG NEG POS NEG 
9 IN POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
10 IN POS POS NEG NEG NEG NEG POS POS NEG NEG POS NEG 
41 IN POS POS NEG NEG NEG NEG POS POS NEG NEG POS POS 
66 IN POS POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
146 T1/44 s/c NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
178 T1/44 s/c NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
179 T1/44 s/c NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
181 T1/44 s/c NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
192 T1/44 s/c POS POS NEG NEG NEG NEG POS POS NEG NEG POS POS 
147 T1/44 i/n POS POS NEG NEG NEG POS NEG NEG NEG NEG POS POS 
152 T1/44 i/n NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
176 T1/44 i/n NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
186 T1/44 i/n POS POS NEG NEG POS NEG NEG NEG NEG NEG POS NEG 
195 T1/44 i/n POS POS NEG NEG NEG POS NEG NEG NEG NEG NEG NEG 
150 PP POS POS POS POS POS POS POS POS POS NEG NEG POS 
155 PP POS POS POS POS NEG POS NEG POS NEG NEG NEG POS 
161 PP POS POS NEG POS NEG NEG NEG NEG NEG NEG NEG NEG 
162 PP NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
189 PP NEG POS NEG POS NEG POS NEG POS NEG NEG NEG POS 
139 T20 POS POS NEG POS NEG POS NEG POS NEG NEG NEG POS 
158 T20 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
170 T20 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
182 T20 POS NEG POS NEG POS NEG NEG NEG NEG NEG NEG NEG 
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194 T20 POS NEG NEG NEG NEG NEG NEG NEG NEG NEG POS NEG 
145 VC POS POS POS NEG POS POS POS POS NEG NEG POS POS 
165 VC NEG POS NEG NEG NEG POS NEG POS NEG NEG NEG POS 
175 VC POS POS POS NEG POS POS POS POS NEG NEG POS POS 
177 VC POS POS POS NEG POS POS POS POS NEG NEG POS POS 
188 VC POS POS POS NEG POS POS POS POS NEG NEG POS POS 
11 BFI NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
20 BFI NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
62 BFI NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
67 BFI NEG POS POS  ND POS POS  ND POS NEG NEG NEG NEG 
78 BFI NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
138 BFC POS POS POS POS NEG NEG NEG NEG NEG NEG POS POS 
154 BFC NEG NEG NEG  ND NEG NEG NEG NEG NEG NEG NEG NEG 
159 BFC POS POS NEG NEG NEG NEG NEG NEG NEG NEG POS NEG 
180 BFC POS POS NEG  ND NEG NEG NEG NEG NEG NEG NEG NEG 
183 BFC POS NEG NEG NEG NEG NEG  ND NEG NEG NEG NEG NEG 
NEG = Negative; POS = Positive and ND = Not done
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3.4 Discussion 
 
Mycoplasma mycoides subsp. mycoides (Mmm) is the causative agent of contagious 
bovine pleuropneumonia (CBPP) (Mulongo et al., 2013). CBPP is still a priority disease 
for FAO-Emergency Prevention System for Transboundary Animal Diseases (FAO-
EMPRES) (Niang et al., 2010). It is a serious respiratory disease of cattle that causes 
major economic losses, specifically in Sub-Saharan Africa (Egwu et al., 1996; Manso-
Silva et al., 2009; Jores et al., 2013). In most countries in Africa, where the disease is 
present, vaccination with live attenuated strain T1/44 is the preferred control measure 
(Amanfu, 2009). However, it elicits short-lived immunity (Niang et al., 2010). Therefore, 
an improved vaccine is urgently needed. An animal experiment was conducted with the 
aim of assessing the capacities of the two novel vaccines (Tween 20 and Purified 
Protein) to protect animals from CBPP. Their protection capacities were compared to the 
current T1/44 vaccine.  
Animals that were vaccinated with Purified Protein, Tween 20 cells and conventional 
T1/44, 5 weeks earlier were placed together with artificially infected animals and in-
contact control animals. The purpose of the artificially infected animals was to transmit 
the infection to other animals (Niang et al., 2006b). Furthermore, the artificially infected 
animals give an approximate evaluation of the quantity of organism and incubation 
period (Gull et al., 2013). Similarly, animals that were endobronchially infected with 
biofilm prepared mycoplasma cultures were placed with in-contact healthy control 
animals, also to simulate natural infection of the disease.   
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At necropsy, the intubated cattle had chronic pathological lesions. This observation was 
in accordance with Scacchia and colleagues (2011). The one animal that did not have 
CBPP lesions was serologically negative for the duration of the experiment. This could 
be that the circulating antibodies bound to soluble antigen and prevented the antibodies 
to be detected by serological tests (Provost et al., 1987). However, no CBPP lesions 
were seen in this animal at post mortem examination, which make this phenomenon 
unlikely.  The same situation, although that animal had acute lesions, was observed by 
others (Nicholas et al., 1996) where one animal was serologically negative. The author 
postulated that the lesions may have been caused by other respiratory pathogens 
(Nicholas et al., 1996). The sequestra observed in the lung of the majority of animals in 
the vaccine group were well formed and the affected lungs had acute and/or sub-acute 
and chronic lesions. The lesions in all animals were unilateral. Nunes Petisca et al. 
(1990), observed unilateral lesions in 95% of the 566 affected lungs (cited by Nicholas et 
al., 2008). The lesions observed in this study are in accordance with lesions described 
by Bygrave et al. (1968). 
Judging from the lesions found at post mortem, the Tween 20 and Purified Protein 
vaccines appeared to have exacerbated the disease. There were no clear differences in 
terms of pathological lesions and clinical signs between the animals vaccinated with 
Purified Protein and the non-vaccinated control animals. Mulongo et al. (2013) observed 
a similar situation between immunized and control animals, although in their experiment 
Freund’s adjuvant formulations were used. The Purified Protein contained the variable 
surface protein (Vmm). Variable surface proteins (Vmm) are alleged to enhance 
colonization of the host tissue (Hamsten et al., 2008; Persson et al., 2002). The rationale 
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for the formulation of the Purified Protein was to elicit the immune responses which avert 
the action of the Vmm (Hamsten et al., 2010). The failure of the Purified Protein to 
mount protection may be due to the protein concentration, the adjuvant used and the 
administration conditions (Hamsten et al., 2010). The vaccines formulated so far have 
failed to elicit protective immune responses in all animals. The ISCOM and Saponin 
vaccines experiment held in Namibia exacerbated the disease as the vaccinated 
animals were as equally affected as the in-contact control animals (Hübschle et al., 
2003; Nicholas et al., 2004). 
The T1/44 vaccine in sub-cutaneously administered animals elicited a better protection. 
Cattle in this sub-group had less clinical score. A strong humoral immune response to 
MSC_1046 (LppQ) in the T1/44 sub-cutaneously vaccinated animals was reported. It is 
assumed that this protein plays an important role in protection provided it induces 
immune response prior to the onset of the disease (Hamsten et al., 2010). However, this 
assumption needs to be determined. In order to evoke local immune response, a 
mucosal route of vaccine administration needs to be explored (Abusugra and Morein, 
1999). Although T1/44 vaccine is not recommended to be administered in mucosal 
tissues, its performance was nonetheless evaluated. The majority of animals in this sub-
group developed chronic lesions. This discrepancy might be attributable to the dose 
given. It is possible that a higher dose might have elicited protection. Mice immunized 
intranasally with a dose three times higher exhibited higher IgA and IgG subclass 
responses (Abusugra and Morein, 1999). 
A second part of the experiment was to evaluate the interaction of the biofilm grown 
Mmm in the establishment of the infection. The term ‘Biofilm’ was discovered and 
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described in 1978 (Costerton et al., 1978). Biofilm is formed by a group of bacteria that 
aggregate together and/or attached to a biotic or abiotic substratum and are protected 
by a polysaccharide matrix (McAuliffe et al., 2008). This formation enables them to 
survive in harsh environmental conditions such as heat (McAuliffe et al., 2007). A biofilm 
is alleged to persist in the host and cause damage to the host tissues as well as to 
exacerbate the infection (McAuliffe et al., 2008). Although the ability of Mmm to form 
biofilm has been evaluated (McAuliffe et al., 2008), the evolution of the disease in the 
host caused by biofilm mycoplasma has not yet been evaluated. The intubated cattle in 
the biofilm group had fewer clinical scores than anticipated. However, judging from 
clinical scores and the pathological lesions found in in-contact control animals, the 
intubation was a success. The differences in the evolution of the disease in the biofilm 
intubated animals and control animals could possibly be that when the planktonic cells 
are released from biofilm in the non-treated cattle, they mutate and become more 
virulent.  
The immunohistochemistry examination revealed the concentration of Mmm/antigen in 
the macrophages cells, bronchial lumen as well as in the germinal centers of the 
lymphoid follicles. Scanziani et al. (1997), observed large concentration of Mmm antigen 
in the germinal centers of the follicles. This could be due to the activation of the B-cell 
that takes place in most chronic microbial diseases (Cotran et al., 1994 cited by 
Scanziani et al., 1997). The majority of the animals were positive for IgG1 and C3c. 
Chronically infected animals in the in-contact non-treated control animals (Group A) and 
animals vaccinated with Purified Protein exhibited strong IgA immune response. It 
seems that IgA is involved in the progression of the disease in this study. This is 
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contrary to the observation made by Niang et al (2006b). The histopathology results 
showed no noteworthy difference on the lesions observed with-in and between groups of 
animals. The microscopic lesions of the lungs included fibrinous pleuropneumonia, 
fibrosis septa and lymphangiectases in most of the animals. The lesions of the 
tracheobronchial lymph nodes were lymphoid hyperplasia with marked enlarged follicle 
germinal centre in all animals but three animals that were vaccinated with T1/44 sub-
cutaneous and two animals in biofilm intubated group did not have lesions. These lymph 
node lesions are in accordance with lesions found in animals that were infected with 
various strains of Mmm (Gull et al., 2013). 
Animal experiments are important in simulating the disease. However, the high cost 
involved in setting up animal experiment results in the use of few cattle that makes it 
difficult to arrive at meaningful conclusions from pilot experiments, however they give a 
good indication of whether novel vaccines or antibiotic treatments are worth pursuing. 
Moreover, the use of different breeds of cattle and different inoculum dose make difficult 
to compare data from different experimental infections. Therefore, as suggested by 
Jores et al. (2013), a uniform challenge model for study of CBPP infection would be 
ideal. Nonetheless, this study concluded that the two novel vaccines did not provide 
protection and the T1/44 sub-cutaneously vaccinated animals were better protected. 
However, it may be that changes in the concentration of the antigens in the vaccines, or 
a different adjuvant may have had different outcomes. Therefore, these vaccine 
formulations should not be totally disregarded in future, but the immunological data 
obtained should be used for future vaccine design. Similarly, the biofilm animals did not 
derive meaningful conclusion but it was interesting to note that intubated animals had 
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fewer lesions, although they were evidently infected and passed the infection to in-
contact control animals. May be some form of biofilm based vaccine could be useful in 
future, therefore, more research is needed. 
In conclusion, the author’s results indicate that induction of humoral immune response to 
Purified Protein and Tween 20 vaccines failed to protect animals against challenge with 
the organisms, with vaccinated animals showing exacerbated pathology. Therefore, in 
the absence of better vaccines, improved diagnostic tests should be one of the options 
for CBPP control in Africa (Ssematimba et al., 2015). Sera collected during this 
experiment were used to evaluate the performance of Lateral Flow Device (LFD) as a 
potential field test (Chapter 4). 
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CHAPTER FOUR 
 
COMPARATIVE EVALUATION OF COMPETITIVE ELISA, LIPOPROTEIN Q ELISA, 
LATEX AGGLUTINATION TEST AND LATERAL FLOW DEVICE FOR THE 
DETECTION OF Mmm ANTIBODIES IN EXPERIMENTAL CATTLE  
 
4.1  Introduction 
 
In the absence of efficient CBPP vaccines, an improved and easy to use diagnostic test 
that is able to identify animals in all stages of diseases will assist in the control of CBPP 
in Africa (Heller et al., 2016; Ssematimba et al., 2016). A quick and reliable diagnosis is 
a prerequisite for any disease treatment and more so for the diseases that have trade 
implications. Conventional Polymerase Chain Reaction (PCR) and real-time PCR are 
available for the quick diagnosis for early response as well as for disease monitoring 
(Schnee et al., 2011; Vilei and Frey, 2010; Bashiruddin et al., 2005). However, these 
tests require sophisticated equipment and skilled technicians (Mair et al., 2013, Ayling et 
al., 2007). Moreover, not all laboratories in developing countries where the disease is 
present have enough resources to carry out these tests. 
At present, the ideal method to detect CBPP is through the detection of antibodies using 
serological diagnostics techniques (Amanfu et al., 2002). Different serological tests such 
as Complement Fixation Test, Tube Aggutination Test, Tube Precipitation Test, Agar 
Plates, Enzyme Linked Immunosorbant Assay and Slide Agglutination Test were used in 
the diagnosis of CBPP. These tests are sensitive but the specificity is questionable 
(Onsa et al., 2018). Therefore, modified and or new tests: Latex agglutination (BoviLAT), 
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Competitive ELISA (CIRAD EMVT, Montpeller) and Immunoblotting were developed for 
the diagnosis of Mmm (Nicholas et al., (1996), Le Goff et al., (1998), Gonclaves et al., 
(1998).   However, these serological tests have some advantages and limitations as 
well. 
The immunoblot is highly sensitive and specific. It was used in Portugal during the 
outbreak. It is a useful technique in case of uncertain results from CFT and/or cELISA 
(Gonçalves et al., 2008). However, some report that the test is not reproducible and 
would not be useful during mass campaign (Schubert et al., 2011). On the other hand, 
the CFT, an OIE recommended test, is the preferred serological diagnostic test 
(Nicholas et al., 1996). It has low sensitivity and specificity and can only detect about 
70% of the chronically infected animals (Ayling, 2002). CFT is good during acute stages 
and alleged not to detect antibodies from asymptomatic animals during the early stage 
of the infection (Provost et al., 1987). The test is difficult to standardize due to different 
antigens and fresh red blood cells used (Le Goff and Thiaucourt, 1998). The cELISA, 
also an OIE recommended test has almost the same sensitivity and specificity as the 
CFT. Its sensitivity was found to be 71% when compared to CFT as a gold standard 
(Enyaru et al., 2003). Although cELISA, CFT, LAT and Immunoblot are available, there 
is still no “gold standard” serological test for this disease (Ayling, 2002) and they are 
expensive (Onsa et al., 2018). 
A diagnostic test that is capable of detecting all infected animals and be able to 
differentiate the vaccinated from infected animals would be the ideal test in controlling 
CBPP. It should be able to fulfil most if not all the criteria for a test. These criteria are: 
Affordable, Sensitive, Specific, User-friendly, Robust and rapid, Equipment free and 
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Deliverable to the user (ASSURED) (Mabey et al., 2004). The Lateral Flow Device (LFD) 
was developed with the aim to meet these criteria as a field test. 
The LFD constructed by Foresite Diagnostics (York, UK) in conjunction with APHA, 
Weybridge uses the same Mmm antigen that was successfully used in Latex 
Agglutination Test. Additionally, an anti-bovine IgG2 conjugate is imbedded in. 
Previously, the performance of LFD was evaluated against the CFT. The LFD detected 
less positive samples than CFT and this might be due to the difference in the type of 
immunoglobulins LFD (IgG) and CFT (IgM) recognized (Tjipura-Zaire et al., 2008). 
Therefore, due to differences in immunoglobulins recognized by CFT and LFD, the aim 
here was to compare the performance of the LFD with Competitive Enzyme Linked 
Immunosorbent Essay (cELISA), Lipoprotein Q Enzyme Linked Immunosorbent Essay 
(LppQ ELISA) and Latex Agglutination Test (LAT).  
4.2  Materials and Methods 
 
4.2.1 Sera from experimental animals 
 
A total of 1,495 sera collected from experimental animals described in Chapter 2 under 
section 2.1 were used. One thousand three hundred and five sera were from animals in 
the vaccine group whilst the remaining 190 were from animals in the biofilm group as 
described in Chapter 2, section 2.1. The collection of blood and centrifugation was done 
as described in Chapter 2 under section 2.3.5. 
The majority of sera were subjected to 3 tests (cELISA, LAT and LFD). It was not 
possible to analyse all the sera using the LppQ ELISA as the production of the ELISA 
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kits ceased during the course of the experiment. The test procedures for cELISA, LppQ 
ELISA, LAT and LFD are described in Chapter 2 Materials and Methods under sections 
2.4.2, 2.4.3, 2.4.5 and 2.4.6 respectively. 
 
4.3  Results of the LppQ ELISA, LAT and LFD 
 
Serological results are summarized in Tables 4.1 to 4.3. 
4.3.1 Measurement of Mycoplasma mycoides subspecies mycoides antibody by 
cELISA 
 
A total of five hundred and nineteen sera were analysed in cELISA and 204 (39%) were 
positive. Most of the positive samples were from Tween 20 vaccinated animals followed 
by sera collected from animals vaccinated sub-cutaneously with T1/44.  
 
4.3.2 Measurement of Mycoplasma mycoides subspecies mycoides antibody by 
LppQ ELISA 
 
Two hundred and sixty-four sera were analysed with LppQ ELISA. Twenty sera reacted 
positive for Mmm. It is worth to note that the LppQ ELISA was used in the analysis of 
sera collected in the early stage of the experiment. This could be the reason why the 
majority of the sera tested negative. The majority of the sera tested positive were from 
animals #146, #181 (both T1/44 sub-cutaneously vaccinated) and #194 (Tween 20).  
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4.3.3 Measurement of Mycoplasma mycoides subspecies mycoides antibody by 
LAT 
 
Not all sera were analysed with LAT, however a total of three hundred and ninety-nine 
sera were tested with LAT and 194 (49%) were positive. The LAT had the most positive 
samples compared to the cELISA and LFD. 
 
4.3.4 Measurement of Mycoplasma mycoides subspecies mycoides antibody by 
LFD 
 
A total of three hundred and ninety-five sera were analysed and 151 (38%) were positive 
at a 30% cut-off. The LFD had the least positive samples in comparison to cELISA and 
LAT. 
 
4.3.5 Comparison of the the results of cELISA, LppQ ELISA, LAT and LFD in 
detecting Mycoplasma mycoides subspecies mycoides antibodies for 
experimental animals 
 
Table 4.1 shows a summary of 770 sera tested with cELISA, LAT and LFD. All the tests 
detected almost equal numbers of positive and negative samples. The agreement was 
38% and 45% between cELISA and LFD in positive and negative sera respectively. For 
cELISA and LAT, the agreement was 37% and 42% for positive and negative sera 
respectively. Table 4.2 shows rhe comparion of the performance of LppQ, LAT and LFD 
with cELISA an OIE recommended test for the diagnosis of CBPP. A total of 353 sera 
were analysed in all four tests. LppQ ELISA had less sensitivity compared to the other 
three tests (table 4.2). Most of the positive sera detected by LppQ ELISA are from 
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animal #194 vaccinated withTween 20 which succumbed to the disease during the 
course of the experiment. The results of the comparisons of cELISA, LFD and LAT for 
intubated animals in the vaccine group for specified weeks are depicted in tables 4.3. 
Out of 40 sera tested in three tests from intubated animals in the vaccine group (group 
A) 20 (50%) were positive in all 3 tests while 15 (37.5%) were negative in all tests (table 
4.3). The results of the comparisons of 4 serological tests (cELISA, LppQ, LFD and LAT) 
are shown in table 4.4 to 4.9 in appendix 2. The cELISA and LppQ ELISA are measured 
in percentage inhibition at a cut-off point of 50. The LFD is measured in percentage 
related to the positive control and the cut-off here was set at 30%. The LAT is measured 
by the degree of clumping as expressed + to +++ depending on the degree of clumping 
to be positive while a negative sample is expressed as -. 
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 Table 4.1. Comparison of tests on 770 sera (381 sera between cELISA and LAT) 
and (389 sera between cELISA and LFD) from experimental animals 
 LAT +VE 
 
LAT –VE 
 
LFD +VE 
 
LFD -VE 
cELISA 
+VE 
 
144 67 *140 43 
cELISA –
VE 
 
35 *135 *44 *162 
*5 samples were tested in cELISA and LFD only while 8 samples were tested in 
cELISA and LAT only 
 
 
Table 4.2. Comparison of tests on 353 sera from experimental animals 
 LppQ 
+VE 
LppQ -VE LAT +VE LAT -VE LFD +VE LFD -VE 
cELISA 
+VE 
11 
 
 
47 20 30 12 38 
cELISA 
-VE 
2 63 4 61 9 56 
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Table 4.3. Comparisons of the results of the three serological tests in sera collected from intubated 
cattle in the vaccine group. 
 
 
Cattle 
No 
8 9 10 41 66 
Date 
in 
weeks  
c
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 %
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8 41 5.8 _ 40 7.9 + 26 11.3 _ 80 68.7 +++ 18 14.5 _ 
9 41 10.0 _ 12 14.0 + 35 10.7 _ 91 43.5 +++ 23 8.9 _ 
10 47 13.9 _ 22 24.0 _ 42 13.7 _ 87 43.3 +++ 8 11.7 _ 
17 70 173.0 + 36 25.5 + 73 104.9 ++ 70 29.3 +++ 68 129.3 +++ 
 
cELISA is measured in percentage inhibition at a cut-off point of 50%. The LFD is measured in percentage and the aim 
here is to determine the cut-off point while the LAT is measured by the degree of clumping as expressed either + to 
+++ depending on the degree of clumping. 
 
 
 
 
 
 
 
 
 
 
Cattle 
No 
2 3 4 6 7 
Date 
in 
weeks 
 c
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8 45 11.0 + 68 34.5 +++ 19 19.1 _ 92 38.7 +++ 96 52.1 +++ 
9 21 17.6 _ 66 103.1 +++ 29 17.7 _ 84 55.5 +++ 89 46.1 ++ 
10 35 19.9 _ 67 101.4 +++ 43 17.1 ++ 79 31.0 ++ 92 42.3 +++ 
17 79 71.9 ++ 77 43.2 +++ 78 46.4 +++ 71 27.1 ++ 73 43.4 +++ 
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4.4  Discussion 
 
The diagnostic accuracy of a Lateral Flow Device that is embedded with Mmm 
carbohydrate extract antigen and anti-bovine IgG2 conjugate as a field test was 
compared to that of cELISA, LppQ ELISA and LAT. Using the combined results of the 
four tests, the possible cut-off point for LFD was determined. 
Many serological diagnostics techniques are available for the diagnosis of CBPP. 
However, their inability to detect antibodies against Mmm at all stages due to disease 
outcomes (acute, subacute, or chronic disease) associated with different or a total 
absence of clinical signs hamper the diagnosis of CBPP requiring more than one 
serological test to be used in an eradication programme (Amanfu et al., 2002, Muuka et 
at., 2011; Schubert et al., 2011; Enyaru et al., 2012), which makes it more difficult in 
some African countries were resources are inadequate (Olabode et al., 2013).  
Diagnostic tests should be highly specific and sensitive as well as easy to execute. 
However, this is difficult to attain, as often an increase in sensitivity results in a decrease 
in specificity, which may lead to false results (Ayling, 2002). The Complement Fixation 
Test (CFT), an OIE recommended test, is cumbersome and requires a well-trained 
analyst to perform. Similarly, the cELISA, also an OIE recommended test requires 
specialized equipment (Ayling, 2002). Both tests have similar sensitivity (Marobela-
Raborokwe et al., 2003). The CFT performs well in detecting antibodies during the acute 
stage while the Immunoglobulin M (IgM) is dominant (Bashiruddin et al., 1994). On the 
other hand, the cELISA detects Immunoglobulin G (IgG). It is, however, not yet known at 
which stage of the disease is the IgG dominant (Muuka et al., 2011). Due to the risk of 
false positive or false negative results in individual animals, CFT and cELISA are 
recommended for diagnosis of CBPP at herd level only (Heller et al., 2016). Since both 
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tests require a fully equipped laboratory the development of improved and easy to use 
diagnostic tests comprising antigens able to identify animals in all stages of disease is 
considered a research priority (Heller et al., 2016). Therefore, pen-side tests, such as 
LAT and the newly tested LFD, would be the ideal diagnostic tests where a quick 
diagnosis is required. 
In China, where 4000 sera were tested, LppQ ELISA had a good agreement with 
cELISA and CFT (Nicholas et al., 2008). The LppQ ELISA performed well in the T1/44 
vaccinated cattle. This could be further substantiated by the fact that LppQ is a marker 
for T1/44 vaccine and the MSC_1046 (LppQ) was the major component of the T1/44 
induced response in the bead-based Mmm recombinant surface protein array (Hamsten 
et al., 2010). 
The LAT, as it was previously reported by Ayling (2002), performed well under this 
study, and hence remained a valid screening test for CBPP. The advantage of the LAT 
is that, it is not expensive, does not require specialized equipment and can be fairly 
performed by any personnel (Ayling, 2002). In general, LAT scored well in sera collected 
at post mortem. Although, LAT uses carbohydrate extract from a European strain, it can 
detect antibody responses elicited by cattle infected by contact or through bronchial 
intubation with African strain. The same observation was obtained when LAT was used 
to test immune response in sera from Uganda (Ayling, 2002). 
The LFD was tested for the first time under an experimental set-up. The test was 
developed by Foresite Diagnostics (York, UK) in conjunction with APHA (Weybridge). It 
uses the same Mmm carbohydrate extract antigen that is used in the Latex Agglutination 
Test for the detection of antibodies against Mmm. The LFD uses an anti-bovine IgG2 
conjugate. Under this study, the LFD displayed a low sensitivity. However, at a cut-off 
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point of 30% it compared well with the cELISA and the LAT. The LFD demonstrated a 
low sensitivity in sera collected from T1/44 sub-cutaneously vaccinated cattle. This could 
be that the LFD is incapable of distinguishing the immune response elicited by T1/44 
vaccine from the CBPP infection. However, this observation will be better tested in a real 
outbreak where vaccination as a control measure is practiced. The LFD as a field test is 
more advantageous than LAT because the result is displayed on a portable reading 
device. This would potentially rule out any ambiguous results usually seen in LAT which 
is a subjective test and low positive result might be interpreted as negative. All 
serological tests currently used have limitations. 
Although the cELISA has a low sensitivity, it compared well with other diagnostics tests 
(Muuka et al, 2011). The cELISA detected more positive cattle in chronic stage of 
infection in Zambia (Muuka et al, 2011). Cattle in the conventionally intubated group 
were positive 9 days after infection. Provost et al. (1987), reported that antibodies can 
be detected from about 10 days after the onset of the clinical signs and remain 
detectable for a few months. This finding is in agreement with the observations made in 
this study. The cELISA is an established test with a defined cut-off point of 50%. The 
LAT gives either a positive or a negative result based on agglutination. Based on the 
correlation of the results of LFD with those of cELISA and LAT in 770 sera (105 positive 
and 141 negative) a cut-off value for LFD was set at 30%. At a cut-off point of 20%, LFD 
would have detected 235 samples positive out of 395. Work done earlier using positive 
and negative reference sera showed that LFD compared well with other serological tests 
(Ayling et al., 2007).  
It was noted that none of the three tests (cELISA, LAT and LFD) have the sensitivity to 
detect all infected cattle at all stages of the disease. Similar findings were reported 
(Enyaru et al., 2012, Gonçalves et al., 2008). Consequently, more than one test should 
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be used in order to have a better understanding of the extent of the infection. The data 
presented in this chapter suggested that the LFD could be a good alternative field test 
as it is not subjective. However, it needs to be refined using different conjugates. 
Therefore, continued research for a test that is capable of detecting CBPP during all 
stages of the disease is important. Furthermore, it is important during the infection of 
CBPP to establish which immunoglobulins (Ig) play role in the protection or progression 
of the disease. The next chapter (Chapter 5) assessed the role of humoral immune 
responses in experimental animals. 
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CHAPTER FIVE 
HUMORAL IMMUNE RESPONSE IN EXPERIMENTAL CATTLE TO 
MYCOPLASMA MYCOIDES SUBSPECIES MYCOIDES (Mmm) 
 
5.1  Introduction 
 
There is little information available regarding the role of Mmm in regulating the host’s 
immune response. Although previous studies have shown that cattle recovered from 
CBPP are normally immune to re-infection or have some resistance (Gourlay, 1975; 
Windsor and Masinga, 1977), it is still not known whether cell-mediated or humoral 
immune response is essential for protection. While both the humoral and cellular 
immune responses are important for protection, their involvement during the progression 
of the disease remains a challenge because the research in the immunopathology is 
hampered by the numbers of cattle used for experiment (Dyson and Smith, 1975; 
Dedieu et al., 2005a; Masinga et al., 1975; Gourlay, 1975; March, 2004).  
Dedieu et al. (2005a) revealed the importance of Mmm–specific IFNγ -CD4 T-cell. The 
study postulated the importance of IFN-γ in protection against Mmm. However, studies 
from Jores et al. (2008) and Scacchia et al. (2007) revealed contradictory information. 
Neither study found correlation between IFN-γ and the absence or presence of 
pathological lesions in CBPP experimental animals (Jores et al., 2008; and Scacchia et 
al., 2007). The immunohistochemistry examination revealed the presence of other cells 
and no increase of IFN-γ cells was observed (Jores et al., 2008). The role of CD4+ 
secreting IFN-γ in the control of CBPP needs to be further investigated. The 
immunostimulating complexes (ISCOM) vaccines experiment postulated the possibility 
of Th-1 immune response in the development of CBPP lesions (Hübshcle et al., 2003). 
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Therefore, it is possible that antibodies against any non-protective antigens will not be 
neutral and might enhance pathological lesions (Nkando et al., 2016). 
Earlier immunological research on serological responses yielded contradictory outcomes 
(Dedieu et al., 2005a; March, 2004; Nicholas et al., 1996; Smith, 1967, 1971; Dyson and 
Smith, 1975; Lloyd, 1967; Gourlay, 1975). Schieck et al. (2014) considered that if 
antibody response played a critical role in controlling the outcome of the disease, the 
animals with less or no pathological lesions would have higher antibody response than 
animals that have more pathological lesions. The severely affected animals had higher 
antibody response which suggested that antigens are being released from sequestra 
which results in the high antibody response (Schieck et al., 2014). However, in the study 
done by Nkando et al. (2016) animals with high titres had lower pathology indexes, 
suggesting that protection was dependant on titres. 
Although there are serological diagnostics techniques such as CFT and cELISA for 
CBPP diagnosis, they lack sensitivity (Ayling, 2002). A more sensitive and specific 
western immunoblot test is available. The immunoblotting test confirms the positive and 
negative samples. However, the analysis of the protein bands requires experience and 
the test is cumbersome, therefore not possible for mass screening (Nicholas et al., 
2008a). The immune dominant proteins of humoral immune response were studied and 
characterized in experimentally infected animals with the African and European strains 
of Mmm (Abdo et al., 1998). They are 110, 98, 95, 85, 80, 72, 62, 48 and 39 kDa but the 
European strains do not have a 98 kDa protein. Samples from bronchial lavage revealed 
6 immunogenic proteins (110, 95, 85, 80, 72 and 48 kDa) of IgA with Afade strain (Abdo 
et al., 1998). 
The role of humoral immune responses has so far not been determined in animals 
experimentally intubated with biofilm Mmm culture. Biofilms are bacteria that stick 
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together and are surrounded by a polysaccharide matrix and are believed to remain in 
the host through the formation of an adherent biofilm (McAuliffe et al., 2006). 
Furthermore, biofilm is believed to enable bacteria to survive in harsh environmental 
conditions (McAuliffe et al., 2007). It is further believed that biofilm is an important stage 
for bacteria in disease initiation (McAuliffe et al., 2006). Studies of Mmm culture from 
biofilm cells were not yet undertaken in vivo. In this study, the role of humoral immune 
response elicited by biofilm cells in cattle was evaluated. 
The main part of this study was to determine the role of humoral immunity in: 
vaccinated, non-treated control and intubated animals. Furthermore, antibody response 
as a result of biofilm culture was also investigated. This information is important in 
understanding the immunopathology and the role of the antibody response in protection 
or in the progression of the disease. The information derived from this study might be 
useful in the development of improved vaccines. 
 
5.2 Materials and Methods 
5.2.1 Experimental animals 
 
A total of forty-five animals were divided into two groups: vaccine and biofilm as 
described in Chapter 2 under section 2.1. The animals were treated and kept as 
described in Chapter 2 sections 2. 2 and 2. 3.   
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5.2.2 Serological tests 
 
The sera were collected weekly for 18 weeks and analysed using indirect ELISA, CFT 
and Western (immuno) blotting.  
The CFT was executed as described in section 2.4.1 of Chapter 2. The indirect ELISA is 
an in-house developed diagnostic technique whereby the plate was coated overnight 
with antigen described in Chapter 2, section 2.4.4.1. After an overnight incubation, the 
plate was washed and blocked with PBS that contained 0.5% skim milk. The test was 
performed as described in Chapter 2, section 2.4.4.2.  
The Western immunoblot has been used to test for antibody responses in M. bovis 
(Poumarat et al., 1994), Mmm (Gonçalves et al., 1994; Nicholas et al., 1996) and M. 
capricolum subsp. capripneumoniae (March et al., 2002). In this study, specific immune 
responses to Mmm proteins were determined using IgG1, IgG2 and IgM anti-cow 
horseradish peroxidase conjugated secondary antibodies. The procedures are detailed 
in Chapter 2, section 2.4.7.  
 
5.2.3 Statistical analysis of Indirect ELISA and CFT data 
 
The observations on humoral immune responses of cattle under different treatments 
were made sequentially over an 18-week period and constitute repeated measures, 
hence the correlation amongst observations on the same animal needs to be taken into 
account. Proc Mixed (SAS, 2003) was used for the data analysis because it gives 
flexibility in covariance structures for repeated measurements data and accounts for 
within animal, time-dependent correlations (Littell et al., 1998). The predictor variables 
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considered in the models were type of vaccine (A = T1/44 sub-cutaneous; B = T1/44 
intranasal; C = Purified Protein; D = Tween 20) and E = Control), time (week = 1-18) and 
treatment X time interaction. The dependent variables were IgG1, IgG2, IgM and IgA. 
The first step in using Proc Mixed is to select an appropriate covariance structure based 
on information criteria such as REML log likelihood (REML logL) and Bayesian 
Information Criterion (BIC); the covariance structure that gave the value of information 
criterion closest to zero indicated a model fit to the data for each immunoglobulin. The 
next step is to select an appropriate model. 
Three types of comparisons employing estimate statements made: (i) differences among 
treatments averaged over weeks; (ii) differences among means for treatments at each 
week; and differences between means for each week and the average of means for 
subsequent weeks for each treatment.  
 
5.3  Results of the indirect ELISA and CFT 
 
The Mmm-specific antibody response was assessed for each animal using the indirect 
ELISA with different immunoglobulins as well as the CFT. However, for easier 
comparisons the averages OD per week for animals under the same treatment were 
used for Indirect ELISA whilst averaged titers per week for animals under the same 
treatment were used for CFT. All animals except one animal in conventional intubation 
seroconverted. Animal seroconverted at different periods post infection. Animals in the 
T1/44 vaccine (sub-cutaneous) group were used as a gold standard since this is the OIE 
recommended vaccine. They are compared to the animals in the other groups. Table 5.1 
shows the selected covariance structures for the different immunoglobulins and the 
effects included in the models. 
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Table 5.1 Selected covariance structures for the different humoral responses and their fit criteria. 
 
 
 
Covariance 
structure 
BIC REML Logl Dependent 
Variables 
IgG1 Simple 75.8 72.6 Treatment, week, 
treatment*week 
IgG2 AR(1) 193.1 186.6 Treatment, week, 
treatment*week 
IgM Simple -68.9 -72.1 Treatment, week, 
treatment*week 
IgA ANTE (1) 509.7 397.0 Treatment, week 
*AR(1) = Autoregressive order 1; ANTE(1) = Ante-dependence order 1 
 
5.3.1 Measurement of Mmm-specific serological isotypes and antibody 
responses  
5.3.1.1 Measurement of Mmm-specific Immunoglobulin G1 (IgG1) response 
 
IgG1 response was affected (P < .05) by treatment, week and treatment x week 
interactions (Figure 5.1). Treatment mean for each week was compared separately due 
to the significant interaction in the IgG1 response. A significantly higher ELISA OD 
response was observed in animals vaccinated with Tween 20 compared with all other 
treatments; OD increased from week 1 to 9 before OD declined. The animals vaccinated 
with purified protein displayed similar kinetic distribution pattern as those in Tween 20 
group although their average OD per week were low. The T1/44 sub-cutaneous group 
maintained a fairly steady antibody OD from week 1 to 8 where it reached a plateau, 
before declining from week 12 to 18. Although the T1/44 intranasal and the non-treated 
in-contact control groups had low serological response at the onset; the responses 
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increased steadily with time; there was no significant difference observed between 
T1/44 intranasal and the non-treated in-contact control over the 18-week test period. 
Both treatments with T1/44 sub-cutaneous and T1/44 intranasal steadily increased the 
IgG1 response, attaining a plateau at week 9.  
 
 
Fig.5.1 shows the average OD data for IgG1 as measured by indirect ELISA for animals in vaccine group. N= number 
of animals (5 animals per group). 
 
5.3.1.2 Measurement of Mmm-specific Immunoglobulin G2 (IgG2) response 
 
IgG2 response was significantly (P < .05) affected by treatment, week and treatment 
times week interactions. Although the interaction was marginally significantly (P =.0483) 
affected, the least square means for IgG2 are plotted in Figure 5.2. IgG2 responses for 
T1/44 sub-cutaneous were significantly (P <.05) higher than the animals in the non-
treated in-contact control group from week 1 to 12. Tween 20 response was significantly 
(P < .05) higher than T1/44 sub-cutaneous from weeks 1 to 18. In other groups except 
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the T20, the IgG2 responses were lower than T1/44 sub-cutaneous and increased from 
week 8 for Purified Protein group and from week 13 onwards for non-treated in-contact 
control group as well as the animals in the T1/44 intranasally vaccinated group. The 
immune response for T1/44 sub-cutaneous was steadily maintained although it was 
slightly above 0.2 OD for the first four weeks and started declining towards the end of 
the experiment. Treatment with Tween 20 evoked a significantly (P < .0001) higher IgG2 
response than Purified Protein.  
T1/44 sub-cutaneous and Tween 20 attained a plateau in IgG2 production at week 10; 
other treatments failed to attain a plateau. 
 
Fig.5.2. shows the average OD data for IgG2 as measured by indirect ELISA for animals in vaccine group. N= number 
of animals (5 animals per group). 
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5.3.1.3 Measurement of Mmm-specific Immunoglobulin M (IgM) response 
 
IgM response was significantly (P < .05) affected by treatment, week and treatment 
times week interactions. Figure 5.3 shows the least square means for serological Mmm-
specific IgM response. The figure shows that the Mmm infection elicited a strong but 
maintained response in all groups. The first high peak was observed at around week 8 
in four groups except the T1/44 sub-cutaneous. As with IgG1 & IgG2, Tween 20 group 
maintained the highest optical density values. The response in T1/44 group was more 
sustained but with intermittence for the duration of the experiment. 
Throughout the 18-week period, there was no significant difference in mean response 
on IgM between treatments T1/44 sub-cutaneous and Tween 20. From around week 6 
onwards, Tween 20 generally evoked a significantly (P < .05) greater response than 
Purified Protein. Furthermore, Tween 20 evoked a significantly (P < .05) higher 
response of IgM than the non-treated in-contact control group between week 8-13. 
Similar to what was observed for IgG1 and IgG2, treatment with T1/44 sub-cutaneous 
reached a plateau at week 9 possibly reflecting the onset of the pathological lesions. 
Treatments with T1/44 intranasal and Tween 20 all gave rise to a plateau in IgM 
production at about weeks 8-9. Purified Protein gave no plateau in IgM production, 
similar to what was observed for IgG1 and IgG2. For the non-treated in-contact control, 
a plateau in IgM production was surprisingly observed much later at week 12. 
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Fig.5.3. shows the average OD data for IgM as measured by indirect ELISA for animals in vaccine group. N= number 
of animals (5 animals per group). 
 
5.3.1.4  Measurement of Mmm-specific Immunoglobulin A (IgA) response 
 
IgA response was significantly (P < .05) affected by treatment and week. Figure 5.4 
shows the least square means of IgA response. Since there was no significant 
difference in treatment X weeks, treatment means were averaged and compared over 
the 18-week trial period and these are given in Table 5. 2. The immune response of 
animals in the Purified Protein was significantly (P < .05) higher than the non-treated in-
contact control. The difference in immune response between T1/44 sub-cutaneously 
vaccinated and the non-treated in-contact control animals neared significance (P =. 
075). Interestingly, the Tween 20 presented lower but sustained IgA response than 
Purified Protein. The second and strong peaks were observed at week 14, 15 and 16 for 
non-treated in-contact control; T1/44 intranasal and Purified Protein respectively.   
T1/44 sub-cutaneous brought about a peak in IgA production at week 7 and again at 
week 11 and 12 before declining (Table 5. 3). 
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Fig.5.4. shows the average OD data for IgA as measured by indirect ELISA for animals in vaccine group. N= number 
of animals (5 animals per group). 
 
Table 5.2 Estimates of treatment differences in IgA averaged over weeks, with standard errors* 
Label Estimate Standard Error Pr >  |t| 
trt A-B avg. over week 1 - 18  0.128 0.069 0.0823 
trt A-C avg. over week 1 - 18 -0.075 0.069 0.2962 
trt A-D avg. over week 1 - 18 -0.097 0.070 0.1775 
trt A-E avg. over week 1 - 18 0.131 0.069 0.0751 
trt B-C avg. over week 1 - 18 -0.203 0.069 0.0088 
trt B-D avg. over week 1 - 18 -0.225 0.070 0.0043 
trt B-E avg. over week 1 - 18 0.003 0.069 0.9618 
trt C-D avg. over week 1 - 18 -0.022 0.070 0.7474 
trt C-E avg. over week 1 - 18 0.206 0.069 0.0079 
trt D-E avg. over week 1 - 18 0.229 0.070 0.0038 
*A = T1/44 sub-cutaneous; B = T1/44 intranasal; C = Purified Protein; D = Tween 20; E = Control 
Table 5.3 Differences between means for each week and subsequent weeks for treatment T1/44 sub-
cutaneous, with standard errors* 
Label Estimate Standard Error Pr >  |t| 
week 1-weeks 2-18 in trt A 0.542  0.113 <0.0001 
week 2-weeks 3-18 in trt A 0.546 0.120 <0.0001 
week 3-weeks 4-18 in trt A 0.585 0.126 <0.0001 
week 4-weeks 5-18 in trt A 0.597 0.138 <0.0001 
week 5-weeks 6-18 in trt A 0.543 0.154 0.0004 
week 6-weeks 7-18 in trt A 0.551 0.177 0.0021 
week 7-weeks 8-18 in trt A 0.256 0.256 0.3183 
week 8-weeks 9-18 in trt A 0.224 0.197 0.2569 
week 9-weeks 10-18 in trt A 0.246 0.178 0.1680 
week 10-weeks 11-18 in trt A 0.264 0.204 0.1981 
week 11-weeks 12-18 in trt A 0.272 0.177 0.1272 
week 12-weeks 13-18 in trt A 0.300 0.197 0.1286 
Week.18 in trt A -0.096 0.082 0.2416 
*Treatment A = T1/44 sub-cutaneous 
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5.3.1.5 Measurement of CFT-specific antibody response 
 
The systemic antibody response as measured by CFT (Fig. 5.5) revealed a first increase 
at week 10 p.i for T1/44 sub-cutaneous, T1/44 intranasal, PP and at week 9 p.i for 
Tween 20. The second increase appeared between week 12 and 14 post infection in all 
sub-groups in the vaccine group except T1/44 sub-cutaneous which appeared to be 
decreasing during that time. The humoral response in non-treated in-contact control 
animals increased steadily from week 9 and reached the first highest peak at week 15 
with the second at week 17. 
 
 
Fig. 5.5. Shows the results of the CFT during the course of the infection for all animals in the vaccine group. Cf titers 
of animals in the same group per week are averaged. N= number of animals (5 animals per group). 
 
5.3.1.6 Measurement of Mmm-specific serological isotypes and antibody 
responses for artificially infected animals 
 
The results of the indirect ELISA and the CFT are shown in figures 5.6 and 5.7 
respectively. The immunoglobulin (M) appeared between weeks 2 and 4 post intubation. 
Intubated animals had high IgA response followed by IgM, then IgG2 responses. The 
CFT responses occurred from week 1 post intubation in animal #41 and animals #7 and 
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#41 sero-converted 2 weeks post intubation. The rest of the animals except #9 became 
positive in CFT by week 15. Animal #9 remained negative in CFT, IgG1 and IgG2; 
however, it had a low positive response in IgM and IgA at week 3 and 4 post intubation.  
 
Fig.5.6. shows the average OD data for immunoglobulins as measured by indirect ELISA for artificially  
intubated animals. N= number of animals. 
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Fig. 5.7. shows the results of the CFT per animal during the course of the infection for artificially intubated animals. N= 
number of animals.  
 
5.3.1.7 Measurements of Mmm-specific IgG1, IgG2, IgM, IgA and CFT-specific 
antibody responses for animals in Biofilm group 
 
The comparison of intubated and control animals gave a significant effect (P < .05) for 
intubated group in IgG1. The best covariance structure for IgG1 based on the Bayesian 
Information Criterion (BIC) of -54.4 was Toeplitz (TOEP). Figure 5.8 shows the least 
square means of IgG1 in ELISA. The highest peak for non-treated in-contact control 
group was observed at week 11. The intubated group had slightly higher IgG2 and IgM 
responses than the control group. The optical density values of intubated animals were 
higher than the control group from day 1 to 6 (results not shown). Animal # 67 in the 
intubation group was the only one which seroconverted from week 7 onwards with a 
highest cf titer of 2560. In the non-treated in-contact control group, animal # 159 
seroconverted for the last 5 weeks of the experiment with a highest cf titer of 1280 whilst 
animal # 139 seroconverted at weeks 11 and 12 before it succumbed to the disease 
(results not shown).  
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Fig.5.8. shows the average OD of IgG1 for animals (intubated and control) in the biofilm group as measured by 
indirect ELISA.  
 
 
5.3.2 Determination of the immunogenic antigens by western immunoblot 
 
5.3.2.1 Determination of the immune responses in experimental animals in the 
vaccine group 
 
The sera collected during the course of the experiment were used to determine the 
humoral immune response. There was no significant difference in the western-blot 
profiles from the sera of animals either within the same group or between groups. 
Furthermore, the responses from different immunoglobulins were almost the same 
except that IgM immunoblot had more insignificant protein bands (appendix 3). None of 
the animals in this study revealed all the 7 Mmm specific protein bands. The responses 
for the three immunoglobulins appeared at different time periods for all animals. 
However, where it was apparent it intensified from week 14 onwards. Antibody 
response to a 60 kDa protein seemed to be dominant and was present in 5 animals in 
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the vaccine group for IgG1 and in 3 animals for IgG2. The antibody responses typical 
for CBPP produced bands: 110 kDa; 98 kDa; 95 kDa; 74 kDa; 48 kDa and 30 kDa 
proteins in IgG1 and IgG2. Since the Immunoblot appeared almost the same, only the 
most significant ones are shown here below in figures 5.9, 5.10 and 5.11 whilst others 
are in appendix 3 
 
 
 
Fig.5.9. Humoral immune response to a local strain “Matapi”. Western-blot based on gradient SDS-PAGE illustrates 
the response of IgG1. The reactions of the sera taken sequential every week from the control untreated animal (#165) 
and infected by contact are shown. The major bands shown on the right appeared prominently between weeks 9 and 
(except week 15) 19 post infection. 
 
 
 
 
Standards 
15 kDa 
 
20 kDa 
 
25 kDa 
 
37 kDa 
 
50 kDa 
 
150 kDa 
 
100 kDa 
 
75 kDa 
 
250 kDa 
 
32 kDa 
 
49 kDa 
 
56 kDa 
 
68 kDa 
 
82 kDa 
 
95 kDa 
Time in weeks 
125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.10. Humoral immune response to a local strain “Matapi”. Western-blot based on gradient SDS-PAGE illustrates 
the response of IgG2. The reactions of the sera taken sequentially every week from the control untreated animal 
(#165) and infected by contact are shown. The prominent bands shown on the right appeared between weeks 13 and 
19 post infections; however, band 100 kDa did not appear at weeks 18 and 19.  
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Fig.5.11. Humoral immune response to a local strain “Matapi”. Western-blot based on gradient SDS-PAGE illustrates 
the response of IgG2.  The reactions of the sera taken sequential every week from the animal vaccinated with Tween 
20 cells (#194) and infected by contact are shown. Days post contact infection is given on top of each stripe. The 
major bands shown on the right reveal the appearance of 98 kDa which is not common to all M. mycoides subsp. 
mycoides SC strains and 115 kDa three weeks before death. 
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5.3.2.2 Determination of the immune response for animals in Biofilm group 
 
Immunoblot analysis showed a strong IgM antibody response to 110 kDa protein. This 
antibody response appeared from week 5 post intubation for cow #78. There were no 
significant bands for the other animals. The control animals produced IgG1 antibody 
response to 141 kDa, 132 kDa and 87 kDa proteins for cow #183 while cow #159 
produced antibodies to 138 kDa, 135 kDa, 87 kDa, 71 kDa and 56 kDa proteins. The 
antibody responses in both cattle appeared from week 10 post infections. Cow #138 
was the only cow in this group which produced antibody responses for both IgG1 and 
IgG2 to 112 kDa, 74 kDa, 52 kDa, 44 kDa, 41 kDa proteins (IgG1) and 107 kDa, 87 kDa, 
87 kDa, 68 kDa, 56 kDa, 46 kDa proteins for IgG2 (not shown). 
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5.4  Discussion 
 
There is currently a lack of information on the nature of protective immunity in CBPP 
(Mulongo et al., 2013). However, the little available information is associated with Mmm-
specific IFN-γ secreting CD4+ T cells and specific serum IgA responses (Dedieu et al., 
2005a; Tote et al., 2008). Therefore, the aim of this research was to evaluate the role of 
the protective immune responses by characterizing the humoral immune responses in 
sera collected during the course of the experiment. The understanding of the protective 
immune responses would be ideal for the development of improved CBPP vaccines.  
The disparity in the humoral immune response exhibited by the animals of this study 
illustrated the complex interaction between the host and the pathogen. This interaction 
led to acute, sub-acute to chronic or symptomless stage of the disease. This chapter 
reports on the humoral immune responses observed on experimental animals. The sera 
used to define the immune responses were collected from vaccinated, non-treated in-
contact control, intubated and biofilm animals. The humoral immune responses were 
evaluated by indirect ELISA, Complement Fixation Test and immunoblot analysis. 
The statistical analysis of the immunoglobulins G1, G2 and M showed that the immune 
responses were affected (p < .05) by treatment (vaccine), week and treatment x week 
interactions. The IgA Mmm-specific response was affected (p < .05) only by treatment 
and week interactions. In general, the Tween 20 vaccine displayed a higher OD 
response for IgG1, IgG2 and IgM than the other groups. However, in IgA the PP vaccine 
maintained a higher response. On average, the immune response reached the first peak 
at around week 8 post infection possibly reflecting the onset of the pathological lesions. 
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The role of antibodies in protection against Mmm is controversial because of the lack of 
correlation between antibody responses, clinical signs and lung lesions (Dedieu et al., 
2005a; Nicholas et al., 1996). The results of the indirect ELISA showed that the T1/44 
sub-cutaneously vaccinated animals maintained steady immune responses in all four 
immunoglobulins. It seemed to be that the antibody elicited by the vaccine in the animals 
under this group mounted a protective immune response. Furthermore, animals in this 
group were less affected. Two animals had chronic pathological lesions with small 
lesions whilst three did not have any lesions. The vaccine elicited a protective immune 
response although it did not prevent the formation of the lung lesions in some animals. 
The T1/44 intranasally vaccinated group exhibited low antibody responses and had 
chronic pathological lesions. 
Animals vaccinated with Purified Protein (recombinant vaccine candidate) did not have 
CF antibody titers at day 1 post infection. Most of the immunoglobulins appeared 
between weeks 6 and 12 post infection possibly reflecting severe disease. However, a 
persistent high IgA response was maintained. The vaccine-induced response was short 
lived and failed to produce a protective immune response. Conversely, the Tween 20 
immunized animals had persisting high immune response in IgG1, IgG2 and IgM. 
Animals in the Purified Protein and Tween 20 groups had high IgA response with 
chronic pathological lesions. The immune response for control animals reached a first 
increased peak between week 8 and 9. Chronic pathological lesions were observed at 
post mortem. These lesions were not different from the ones observed in Purified 
Protein and Tween 20 groups. 
130 
Most of the animals under this study had high IgA response. The IgA appears to be an 
indicator of disease with a high response in animals with high clinical score. However, 
the study of Mmm specific antibody isotypes responses in Zebu cattle experimentally 
infected with Mmm revealed a high IgA response at both local and systemic in animals 
with sub-acute to chronic infections. The author postulated that IgA response is 
associated with protection (Niang et al., 2006b). Studies dealt with other respiratory 
mycoplasmas highlighted the importance of IgA in host defence mechanism (Howard et 
al., 1987; Gourlay and Howard, 1982).  
The antibody response of IgM, IgG1 and IgG2 in indirect ELISA did not show any 
significant difference in terms of intensity and clinical signs among animals. The results 
suggested that these immunoglobulins are not correlated to protection. This finding is in 
accordance with a study done by Niang et al. (2006b). However, the role of IgG has 
been linked to protection in M. bovis (Gourlay and Howard, 1982). The presence of IgG1 
and IgG2 in lung washings of mice infected with M. pulmonis correlated with protection 
(Gourlay and Howard, 1982). 
Serological tools are important in the control of CBPP (Frey et al., 1998). Currently, CFT 
is the official and most commonly used test. Although CFT is specific and sensitive in 
the acute phase of the infection, it detects about 70% of the chronically infected animals 
and nothing of the asymptomatic animals (Nicholas et al., 1996). Additionally, CFT 
presented false positive results during sero monitoring of cattle in CBPP free area (Stärk 
et al., 1995). CFT and cELISA are both recommended to be used as herd tests because 
of either false positive or false negative results associated with them in individual 
animals (Heller et al., 2016). 
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The immunoblotting test (IB) is an OIE recommended test to ideally confirm CFT 
suspected false results (Anon, 2012). IB has higher sensitivity and specificity when 
compared to CFT (Anon, 2012). In this study, the Immunoblot was used to determine at 
which stage of the infection the key proteins appeared. Furthermore, the use of different 
immunoglobulins was to determine which immune response is worth stimulating in order 
to evoke protection. The information derived from IB may lead to the identification of the 
best protein(s) to be used in either for the development of a diagnostic test or for the 
formulation of a vaccine. Usually the sample is considered positive if it simultaneously 
shows a common immunological pattern that has immuno dominant antigens with 
molecular weight of 110, 98, 95, 62/60 and 48 kDa. However, as mentioned earlier, the 
aim of this study was to try to determine which protein appeared at what time during the 
course of the infection. An early and distinct reaction to 110 kDa was present for IgG1 
and IgG2 in animals vaccinated sub-cutaneously and intranasally with T1/44. The 
reaction was persistent in two animals while in one animal it only lasted for the first 5 
weeks post infection. A protein of molecular mass of 98 kDa was observed for IgG1, 
IgG2 and IgM Immunoblot in animals (T1/44 intranasally, control, Tween 20 and PP). 
The reaction occurred between week 4 and 18 post infection. Proteins of molecular 
mass of 95 kDa and 93 kDa were mainly present between weeks 8 and 18 post infection 
except in animals in T1/44 sub-cutaneous group where it was persistent from week 1 
post infection. Immune bands of molecular mass of 85 and 87 as well as 80 kDa were 
observed in sera collected between weeks 5 and 18 post infection in animals in the non-
treated in-contact control group (group A)  and animals in the T1/44 intranasally group. 
A distinct reaction to the protein of molecular mass of 60/62 appeared in both IgG1 and 
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IgG2 in animals in the vaccine control, purified protein, Tween 20 and T1/44 intranasal 
groups. The reaction appeared for the last 12 weeks of the experiment.  
A protein band at 45 kDa which is a glycerophosphate oxidase (GlpO) and associated 
with the induction of H2O2 toxicity and alleged to play a role in CBPP infected cattle (Pilo 
et al., 2005) was present in IgM in two animals in the Purified Protein group from week 8 
post infection. Possibly being the reason why animals in this group had severe 
pathological lesions.  
The lipoprotein Q (LppQ) with a molecular mass of 48 kDa was identified to be 
associated with CBPP (Abdo et al., 2000). The study done by Hamsten et al. (2010), 
indicated that protein MSC_1046 (LppQ) could be an important part of the immune 
response elicited by T1/44. Proteins with molecular mass between 47 and 49 kDa 
appeared at week 1 post infection in T1/44 subcutaneously vaccinated animals and from 
5 to 18 post infection in non-treated in-contact control animals for IgG1 and IgG2. The 
LppQ is alleged to be specific to Mmm and was found in all strains (African, European, 
and Australian) (Abdo et al., 2000). Furthermore, in the same groups of animals, a band 
of molecular mass between 69-71 kDa appeared between week 5 and 18 post infection 
whilst bands of molecular mass of 72 and 74 kDa appeared from week 13 to 18 post 
infections also in T1/44 vaccine and in in-contact vaccine control groups. The LppB 
protein that has a mass of 70 kDa is present in all strains including vaccine strains 
except in the European strains. Like any other membrane lipoproteins, it might play an 
indirect role in the virulence of the Mmm (Vilei et al., 2000). 
Besides the common immune bands of 110, 98, 95 and 74 kDa which appeared in some 
animals in this study, there were bands of lower molecular mass between 37 and 39 
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kDa which were present in either IgG1, IgG2 or IgM in some animals of the T1/44 
intranasal group, vaccine non-treated in-contact control group and the Purified Protein 
group between week 6 and 18. Proteins of low molecular mass of between 36 and 20 
appeared mostly for five weeks towards the end of the experiment in IgG1 for animals in 
the T1/44 intranasal group and the vaccine non-treated in-contact control group.  
In the biofilm experiment, the in-contact control animals were severely affected 
compared to the intubated animals. Two in-contact control animals had high IgA 
response which started at the same period as CFT between weeks 11 and 14 post 
infection. All the animals had persistent IgM response. Bands of molecular weight of 110 
and 74 kDa were prominent in sera collected toward the end of the experiment.  
This study concurs with previous reviews (Lloyd, 1967; Gourlay, 1975; March, 2004) that 
it is difficult to correlate antibody response with clinical signs and lung lesions. However, 
it was found that most of the animals with high IgA response had high clinical scores 
and lung lesions at post mortem. Therefore, the presence of IgA response could be 
responsible for disease development and needs further investigation. 
The immunoblot which was successfully used in the campaign to eliminate CBPP in 
Portugal whilst other control measures presented problems (Nicholas et al., 2008) is an 
OIE recommended test. Although Immunoblot gives high level of sensitivity and 
specificity (Schubert et al., 2011), it is not suitable for mass screening.  
In summary, this study has shown that both IgG1 and IgG2 seemed to be the most 
immunoglobulins to be stimulated during the Mmm infection. It might be useful to 
formulate a vaccine that will stimulate these immunoglobulins. Additionally, proteins with 
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molecular mass of 110, 95 and 48 kDa might be important part of immune response 
since these proteins were present in T1/44 sub-cutaneously vaccinated animals and 
animals in this group were better protected compared to others.  
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CHAPTER SIX 
 
GENERAL DISCUSSION AND FUTURE WORK 
 
Contagious Bovine Pleuropneumonia (CBPP) caused by Mycoplasma mycoides subsp. 
mycoides (Mmm) is a pulmonary disease of cattle and Water buffalo (Provost et al., 
1987). The disease has great economic effects on the cattle industry in Africa (Windsor, 
2000). The decrease in Government subsidised vaccination programmes in some 
African countries, resulted in the spread of the disease. Countries which successfully 
eradicated the disease experienced reappearance of CBPP in the last two decades 
(Marobela-Raborokgwe, 2011; Windsor, 2000). CBPP was eradicated in U.S and 
Australia through strict control of cattle movement, culling and compensation. These 
methods are not feasible in many African countries due to lack of governmental and civil 
resources to forcefully restrict movement of cattle and the financial resources needed to 
compensate cattle owners (Gull et al., 2013). Since there is no official treatment for 
CBPP, vaccination with live attenuated strain T1/44 that induces short-lived immunity 
and causes severe post-vaccine lesions is the only feasible control method currently 
available (Pilo et al., 2007; Mbulu et al., 2004; Tulasne et al., 1996) amongst other 
limitations mentioned in section 1.9.1. Although mycoplasma species are sensitive to 
some antibiotics (Yaya et al., 2003; Ayling et al., 2000), chemotherapy is not officially 
allowed in the control of CBPP for possible development of a carrier state and the 
spread of residues that might results into bacterial resistant in the environment (Yaya et 
al., 2003). However, contrasting opinions exist on the role of antibiotic therapy in the 
control of CBPP. Researches on the use of antibiotics have proved that antibiotic 
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treatment minimizes the numbers of mycoplasma that are shed by infected animals and 
therefore minimizes the chances of infection transmission (Hübschle et al., 2006; 
Nicholas et al., 2012).  
The diagnosis of CBPP is hampered by diagnostic tests which are not sensitive enough 
whilst requiring sophisticated equipment. Therefore, there is a critical need to develop a 
better vaccine and an easy to use robust diagnostic test. The development of a better 
vaccine requires an understanding of the immune response. Thus, the aim of this study 
was to experimentally evaluate the performances of two novel vaccines whilst 
comparing them to T1/44 vaccine and to evaluate the performance of T1/44 as mucosal 
vaccine. Furthermore, the role of Mmm biofilm in vivo was assessed. The sera collected 
during the duration of the experiment were used for the evaluation of the performance of 
the newly developed penside tests (LFD) in comparison to the already existing 
serological tests and to assess the Mmm-specific humoral immune response. 
 
6.1 Experimental study of the vaccines 
 
As no therapeutic treatment for CBPP is available, vaccination is currently the preferred 
control method (Gull et al., 2013). Animal vaccination against CBPP has been in 
practice since the time of Willems (Provost et al., 1987), when parental CBPP infective 
lymph was used as an inoculum and placed into an area of thick connective tissue 
(Provost et al., 1987). This method of vaccination was discouraged due to side effects 
such as loss of tail (Bygrave et al., 1968). Multiple vaccine formulations have been 
developed, however they have drawbacks such as the induction of undesirable side 
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effects and lack of consistent protective or long-lived immunity (Thiaucourt et al., 2003). 
Although sub-cutaneous method of vaccination with T1/44 is practiced, side effects such 
as gross lesions at the site of the inoculation due to improper vaccine administration and 
death in some instances are still present (Nicholas et al., 2008). Despite these side 
effects, attempts to control CBPP in Africa are with T1/44 vaccine strain that has been 
isolated from Tanzania and passaged 44 times in eggs in order to reduce the virulence 
factors (Nicholas et al., 2008). The limitation of this vaccine is well documented 
(Nicholas et al., 2008; Thiaucourt et al., 2000). Previous attempts to develop new 
vaccines have been reported by Nicholas et al. (2005). These were the use of a whole 
cell mycoplasma which was inactivated with saponin and the use of recombinant subunit 
vaccine prepared from lipoprotein Q (LppQ). These two vaccines failed to elicit 
protective immunity and rather exacerbated the pathology in the vaccinated animals 
compared to the in-contact unvaccinated animals (Nicholas et al., 2005).  
Other control measures such as strict animal movement and test and slaughter are 
difficult to implement due to transhumance pastoralism, fragmented veterinary services 
and lack of or insufficient resources for compensation as well as for activities related to 
the control of CBPP (Amanfu, 2009). However, Aligaz and Munganga (2019) suggested 
three possibilities of controlling the disease by (1) treating 85.7% of infectious cattle with 
antibiotics, without vaccinating healthy cattle, (2) vaccinating 80% of susceptible cattle 
within a period of 49 days, without treating the infectious cattle and (3) assuming that 
50% of susceptible cattle are vaccinated within 73 days and 50% of infectious are 
treated with antibiotics. The option of using the combination of vaccination with 
antibiotics is the one likely to be successful (Aligaz and Munganga, 2019). However, for 
138 
this option to be a success, vaccines and antibiotics should be readily available to 
farmers of which cattle are at risk of exposure to infection.  
It is therefore urgent to develop a vaccine that ideally elicits protection for more than two 
years with a single dose of injection and with minimal adverse reactions without 
requiring cold storage (Ayling, 2013).  
It was against the issue of the ineffectiveness of the currently used vaccines that this 
study was conducted. The vaccinated and non-treated in-contact control animals were 
placed together with the intubated cattle. Inoculation of cattle by endobronchial 
intubation gives accurate determination of quantity of organism and incubation period; 
however, it is not natural and could overload the cattle with large and unnatural infection, 
thereby unfairly challenging the vaccines. Despite that, it is the only way of emulating 
the transmission of the infection in the absence of naturally existing sick animals. Nine 
out of ten intubated cattle became infected (Table 3.2). The effectiveness of this route of 
challenge was evident in the unvaccinated control animals whereby all five animals were 
serologically positive with typical CBPP lesions at post mortem (Table 3.2). The chronic 
pathological lesions ranged from lung hepatisation, sequestra of various sizes, pleural 
fluids and pericardiac fluids. It can therefore be assumed that the vaccinated animals 
received sufficient challenge to possibly assess the effectiveness of the vaccines used.  
Of the three vaccine preparations used in the experiment described here, the T1/44 
performed better, with a good protection as evidenced by a low total integrated score 
particularly in the sub-cutaneously vaccinated animals (Table 3.2). However, the 
presence of pleural and pericardiac fluid as well as small sequestra in some animals of 
this group would suggest that these vaccinated animals were theoretically capable of 
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infecting susceptible cattle, although the duration of their infectivity is unknown. Jores et 
al. (2013) reported that the live attenuated vaccines currently in use; do not prevent the 
progression of pathomorphological lesions after challenge. Although T1/44 is not 
recommended to be administered through the nostril it was nonetheless tried. The 
intranasal route of administration was less effective with three vaccinated cattle showing 
significant CBPP lesions (Table 3.2) suggesting that the mucosal immunity was not 
sufficiently stimulated. It might be that either mucosal immunity plays a less important 
role in protection to CBPP than was hoped or that a higher dose might have stimulated a 
better response as the efficacy of the vaccine is dose depended (Thiaucourt et al., 
2004). 
The results of the two novel vaccines (Purified Protein and Tween 20) showed that the 
Purified Protein vaccine provided no protection as the total integrated score was slightly 
higher than the unvaccinated control animals (Table 3.2). It appeared that at least one of 
the proteins in the recombinant protein vaccine exacerbated the disease (Table 3.2 and 
figure 3.1). All of the five animals in this group had chronic pathological lesions with 
large sequestra which varied between 8 and 25cm in diameter (Table 3.2). Figure 3.1 
depicts a typical chronic pathological lesion of encapsulated necrotic core in an animal 
vaccinated with purified protein. Enhanced pathology has been reported in animals 
vaccinated with a recombinant form of the LppQ protein formulated with ISCOM as 
adjuvant and challenged by contact (Nicholas et al., 2004). Due to severe pathological 
lesions of the LppQ vaccine, it was thought that a cocktail of purified proteins might 
cover a wider range of potentially protective proteins and the LppQ would be at a lower 
concentration than that previously tried. However, it was not the case in this study. 
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The effects of the Tween 20 vaccine were more ambiguous. Three of the five vaccinated 
animals had low integrated scores (Table 3.2) which could be that they may have not 
been infected. However, judging by the success of the challenge in the unvaccinated 
and purified protein groups, it appears that this was unlikely and that Tween 20 vaccine 
elicited some protection although it failed to prevent the formation of chronic pathological 
lesions. The total integrated score was lower than the in-contact and the animals 
vaccinated with purified protein. It may be rewarding to further refine this vaccine 
preparation in an effort to improve its efficacy. 
The work undertaken in this study confirmed earlier findings that subunit or inactivated 
vaccines may actually exacerbate the effects of CBPP (Nicholas et al., 2004). The T1/44 
vaccine is probably effective because cattle are exposed to a live semi-virulent 
preparation given in a site where the mycoplasma is generally incapable of initiating 
infection in the lungs (Mbulu et al., 2004). However, the occasional outbreaks of CBPP 
in closed vaccinated herds may be the result of the live vaccine reaching the lung via the 
blood stream (Mbulu et al., 2004).  
  
6.2 The role of Mycoplasma mycoides subspecies mycoides biofilm in vivo 
 
Although mycoplasmas have small genome size, they cause wide range of diseases in 
animals and humans but little is known about their virulence factors and their ability to 
persist in the hosts. When a wide range of mycoplasmas (Mycoplasma putrefaciens, M. 
cottewii, M. yeatsii, M. agalactiae, M. bovis and Mmm) were examined for their abilities 
to form biofilms, all other mycoplasmas except the highly pathogenic Mmm produced 
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prolific biofilms (McAuliffe et al., 2006). However, Mmm was able to produce a biofilm in 
vitro using other substrates (McAuliffe et al., 2007, 2008).  
Even though the ability of Mmm to form biofilm in vitro has been evaluated (McAuliffe et 
al., 2008), the evolution of the disease in the host caused by biofilm mycoplasma has 
not yet been assessed. Therefore, this necessitated the in vivo experiment of biofilm 
mycoplasma. 
Although fewer cattle were used in the biofilm group compared to vaccine group, the 
ratio (1:1) of intubated to in-contact control cattle was higher which made the opportunity 
for Mmm to spread from intubated to in-contact cattle more effective. An unexpected 
lower integrated score was observed in the biofilm intubated cattle (Table 3.2). Apart 
from pericardiac fluid and lung hepatisation, no other typical CBPP pathological lesions 
were observed in the intubated animals (Table 3.2). Interestingly, one animal in the in-
contact control group died due to an acute form of CBPP infection whilst a second 
animal within the same group had a large sequestrum of 15 to 17 cm in diameter with a 
high serological positive response (Table 3.2). This suggested that the intubation was 
effective in initiating the infection. The difference observed in the intubated group may 
be either due to slightly different infection dose, a different response to intubation or 
reasons that are not yet explained. Although the in-contact control animals were 
severely affected compared to intubated cattle in the biofilm group, they had less 
secondary exposure than their counterparts in the vaccine group. It is possible that, 
when the infection in the vaccine trial had taken hold, all animals were potentially 
spreading infection amongst the group, giving a higher rate of infection. The death of 
one animal and the presence of the sequestrum in another animal at post mortem may 
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indicate that passage of the isolate to in-contact cattle changes the pathogenic status of 
the isolate from its biofilm state.  
The finding of the biofilm study is inconclusive and further study with more animals and 
a higher dose of inoculum is needed in order to arrive at meaningful results. However, 
the preliminary finding shows that animals intubated with biofilm grown Mmm present 
less clinical disease than the in-contact control animals.  
 
6.3 Comparison of LFD to cELISA, LAT and LPPQ ELISA 
 
The cELISA and CFT are the OIE recommended tests. Both tests have low sensitivity 
but are good at detecting antibodies at herd level (Marobela-Raborokwe et al., 2003). 
The latex agglutination test is easy to perform but has the same sensitivity as CFT 
(Ayling et al., 2005) which is really promising for a rapid field test compared with a 
laborious expensive laboratory test. The lack of more sensitive and easy to use field 
tests necessitated research into the development of a robust field test. The performance 
of the newly developed LFD as a possible field test for CBPP was evaluated and 
compared to LAT, cELISA and LPPQ ELISA. As mentioned earlier (section 4.2.1), it was 
not possible to analyse all of the samples using LPPQ ELISA.  
In this study, the LFD displayed a low detection level of positive samples at a 50% cut-
off when comparing positive results in all three tests. However, at a 30% cut-off point it 
compared well with the cELISA and the LAT. The majority of the negative sera picked 
up by LFD were of sera collected from T1/44 sub-cutaneously vaccinated animals. This 
might suggest that the LFD is able to distinguish the antibody response elicited by T1/44 
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vaccine from natural CBPP infection. However, it needs to be tested in a real outbreak 
situation where vaccination as a control measure is practiced. Comparing the LFD to the 
current field test, LAT, the LFD has the advantage of using a portable reading device 
which would rule out the possibility of ambiguous interpretation of results.  
The cELISA had more positive results in animals during the chronic stage of infection 
(Muuka et al, 2011). Cattle in the conventionally intubated group were positive 9 days 
after infection. Provost et al. (1987), reported that antibodies can be detected from about 
10 days after the onset of the clinical signs and remain detectable for few months. This 
finding is in agreement with the observations in this study. The cELISA is an established 
test with a defined cut-off point of 50% (as per manufacturer instructions). The LAT 
gives either a positive or negative results based on agglutination. The cut-off value for 
the LFD needed to be established and for this study it was set at 30%. Based on the 
results of the sera tested in the cELISA, LAT and LFD, the agreement between the three 
tests in detecting positive samples was low. Work done earlier (Ayling et al., 2007) using 
positive and negative reference sera showed that LFD compared well with other 
serological tests.  
It was noted that none of the three tests have the sensitivity to detect all infected cattle 
at all stages of the disease. Similar findings were reported (Enyaru et al., 2012, 
Goncalves et al., 2008). Therefore, continued research for a test that is capable of 
detecting CBPP during all stages of the disease is important. The recently developed 
LFD appeared to be a good alternative field test as it is not subjective. However, it 
needs to be refined using different conjugates and re-evaluated.  
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6.4 Assessment of Mmm-specific humoral immune  
 
The work presented here shows that in experimental challenge and field studies, 
humoral immune response against Mmm has been variable. It is important to 
understand the characteristics of the protective immune responses for the development 
of vaccines (Niang et al., 2006b). Although in CBPP, vaccines elicit short term immunity 
and recovered animals developed long term immunity, the protection mechanism is still 
not known (Tulasne et al., 1996; Provost et al., 1987). Knowing that cattle recovering 
from CBPP infection in the field mount long term immunity, Dedieu-Engelman (2008) 
studied the immune response of acute and convalescent animals and revealed that the 
latter had stronger and persisting IgA response as well as higher Mmm-specific CD4+ T-
cell response with the production of gamma interferon detected in the blood and 
respiratory lymph nodes. This might suggest the involvement of both cell-mediated and 
antibody-mediated immune responses in the protection against CBPP.   
Despite the fact that the antibody-mediated immune response plays a role in protection 
against Mmm, it is still not clear at what stage during the infection the antibody is 
effective because of the lack of correlation between antibody response, clinical signs 
and lung lesions (Dedieu et al., 2005a; Nicholas et al., 1996). Animals with high antibody 
titers may have no visible lesions and lesions might be present in animals with negative 
serological responses (Nicholas et al., 1996) making it difficult to establish the role of 
humoral in immune response in CBPP infected animals. 
The statistical analysis of the immunoglobulins G1, G2 and M showed that the immune 
responses were affected (p < .05) by treatment (vaccine), by week and by treatment 
145 
times week interactions. The IgA Mmm-specific response was affected (p < .05) only by 
treatment and by week interactions. In general, the Tween 20 vaccine displayed a 
higher OD response for IgG1, IgG2 and IgM than the other groups. However, in IgA the 
PP vaccine maintained a higher response. On average, the immune response reached 
the first peak at around week 8 post infection possibly reflecting the onset of the 
pathological lesions however; it would be good to do a time course study. 
Animals vaccinated with Purified Protein (recombinant vaccine candidate) did not have 
CF antibody titers at day 1 post infection. Most of the immunoglobulins appeared 
between week 6 and 12 post infection possibly reflecting severe disease. However, a 
persistent high IgA response was maintained. The vaccine-induced response was short 
lived and failed to produce a protective immunity. Conversely, the Tween 20 immunized 
animals had persistent high immune response in IgG1, IgG2 and IgM. Animals in the 
Purified Protein and Tween 20 groups had high IgA response with chronic pathological 
lesions. The immune response for control animals reached a first increased peak 
between week 8 and 9.  
The majority of the animals in this study exhibited chronic pathological lesions such as 
lung adhesions, sequestra and either pleural fluid. Furthermore, a high IgA response 
was observed in the chronically affected animals. This finding is in agreement with the 
study done in Zebu cattle where a high IgA response at both local and at systemic level 
was observed in animals with sub-acute to chronic infections (Niang et al., 2006b). This 
finding led the author to postulate that IgA response is associated with protection (Niang 
et al., 2006b).  
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There was no significant difference observed in humoral immune responses of IgM, 
IgG1 and IgG2. Similar results were observed by Niang et al. (2006b). These findings 
here indicate that these immunoglobulins are not correlated to protection. However, in 
M. bovis IgG is stated to have a role in protection (Gourlay and Howard, 1982). In 
addition, the presence of IgG1 and IgG2 in lung washings of mice infected with M. 
pulmonis correlated with protection (Gourlay and Howard, 1982).  
In the current study, it was observed that animals with smaller pathological lesions had 
early but low serological response, possibly indicating a protective response. However, 
in some cases the production of pleural fluid and pericardiac fluid appeared in the 
absence of sequestra. Conversely, the high CFT antibody responses observed in 
severely affected animals might be an indication that the host response is damaging. 
Whether the presence of pleural fluid or pericardiac fluid prevents the formation of 
sequestra or result in less stress to the host is unknown. In addition, when antibody 
responses were monitored for almost a year following Mmm infection a correlation 
between the response of different immunoglobulins and clinical signs as well as lung 
lesions could not be established (Niang et al., 2006b).   
6.5 Assessment of antibody response with Immunoblotting 
 
Humoral immune responses of different immunoglobulins (Ig) were evaluated with IBT 
and dominant immunogenic proteins with molecular masses of 110, 98, 95, 85, 80, 72, 
62, 48 and 39 kDa were identified (Abdo et al., 1998).  
The analysis of Mmm strains by immunoblotting was successfully carried out from 
European isolates (Gonҫalves et al., 1998). An EU FAIR funded research that involved 
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several European countries has led to the use of immunoblotting for CBPP as a 
diagnostic tool and IBT was successfully used in the eradication of CBPP in Portugal in 
1990 (Nicholas et al., 2008). 
A protein band at 45 kDa which is a glycerophosphate oxidase (GlpO) and associated 
with the induction of H2O2 toxicity and alleged to play a role in CBPP infected cattle 
(Pilo, et al., 2005) was present in some animals. Furthermore, lipoprotein Q (LppQ) with 
a molecular mass of 48 kDa was identified to be associated with CBPP (Abdo et al., 
2000). The study of Hamsten et al, (2010), indicated that protein MSC_1046 (LppQ) 
might be important part of the immune response elicited by T1/44 vaccine. Animals 
vaccinated sub-cutaneously with T1/44 and the in-contact control animals in the vaccine 
group revealed bands with molecular mass between 47 and 49 kDa from week 4 to 
week 7 post infections for IgG1 and IgG2. The LppQ is alleged to be specific to Mmm 
and was found in all strains (African, European, and Australian) (Abdo et al., 2000). 
Bands with molecular mass between 69-71 kDa were as well present. The LppB protein 
that has a mass of 70 kDa is present in all CBPP strains including vaccine strains but 
not in the European strains. Like any other membrane lipoproteins, this might play an 
indirect role in the virulence of the Mmm (Vilei et al., 2000). 
Besides the common proteins of 110, 98, 95 and 74 kDa which appeared in several 
animals under this study, there were bands of lower molecular mass between 39 and 20 
kDa which appeared mostly for five weeks towards the end of the experiment.  
The biofilm in-contact control animals were severely affected compared to the intubated 
animals. Two in-contact control animals had high IgA response which started at the 
same period as CFT between weeks 10 and 13 post infection. All the animals had a 
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persistent IgM response. Bands of molecular weight of 110 and 74 kDa among others 
were seen in sera collected toward the end of the experiment in the biofilm in-contact 
control animals. 
The immunoblot which was successfully used to eliminate CBPP in Portugal while other 
control measures presented problems (Nicholas et al., 2008) is an OIE recommended 
test and is highly sensitive and specific (Schubert et al., 2011), however it lacks 
reproducibility and robustness. Furthermore, the inter-laboratory proficiency test carried 
out in 2009 showed that the test is not reproducible as the results were varied among 
the participating laboratories (Gaurivaud and Poumarat, 2012) because there is no 
standardized protocol; the French protocol is different from the Portuguese Gonçalves 
method. To ensure reproducibility of the immunoblotting results, standardisation of the 
protocol for the production of antigen will be essential. 
 
6.6  FURTHER WORK 
 
As a result of the pathological lesions observed during post mortem examination, no 
vaccine conferred appreciable protection. The Purified Protein that consisted of a 
cocktail of five proteins and was assumed to work against the Vmm exacerbated the 
disease. The AIOH emulsified adjuvant was used for both novel vaccines. It is possible 
that further research in the adjuvant and vaccine area is still needed. Improved 
understanding of the ISCOM might help improvements in the formulation of a subunit 
vaccine. Since Mmm enters the host through mucosal route, it might be necessary to 
look into the possibility of constructing a mucosal vaccine for CBPP or better yet to 
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evaluate the current T1/44 with a higher dose. Vaccination with BEN-1 eradicated CBPP 
in China (Xin et al., 2012). It could be useful to try the efficacy of this vaccine in Africa as 
suggested by Jores et al. (2013). 
The development of an effective vaccine for CBPP has been hampered by a lack of 
understanding of host-pathogen interactions during the infection (Schieck et al., 2015). 
The results of transposon mutagenesis (transfer of genes to a host organisms’ 
chromosome) techniques were inconclusive (Schieck et al., 2016). However, with the 
studies on genome synthesis of M. mycoides subsp. capri (Mmc) that is closer to Mmm 
(Gibson et al., 2010) and other molecular techniques (Noskov et al., 2010; Lartigue et 
al., 2007; Lartigue et al., 2009) have made it easier to understand the biology and the 
pathogenesis of these bacteria (Schieck et al., 2016).  
In addition to evaluating the two novel vaccines, the effect of the biofilm-associated 
Mmm to induce the disease when it is endo-bronchially administered was evaluated. 
The abilities of mycoplasma species to form biofilm as well as their survival and 
environmental persistence were established (McAuliffe et al., 2006; 2008). The severity 
of the disease manifestation was higher in non-treated control animals and less in the 
intubated animals. Clearly, there is a need to determine why biofilm-associated Mmm 
was more virulent in the control animals rather than in the intubated animals. 
Furthermore, there is a need to analyse protein profiles in samples from endo-
bronchially intubated and in-contact control animals in order to determine the changes 
that might be responsible for the virulence factors in none intubated animals.  
In this thesis the performance of the newly developed penside test, LFD in detecting 
positives and negatives animals in experimental animals was evaluated against cELISA 
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and LAT. The LFD was found to be an easy field test that does not require sophisticated 
equipment except a handheld battery operated device. The use of the device would 
make it easier for even untrained community health workers to handle it as it displays 
the value. Furthermore, it will ease the problem of ambiguous results associated with 
LAT. The LFD needs further refining using a different conjugate. 
Specific protective antibody responses to Mmm proteins have not been identified 
(Schieck et al., 2016). Furthermore, the non-production of antibodies that neutralize l-α-
glyserol-3-phosphate oxidase during the chronic stage of CBPP infection that is 
associated with presence of viable mycoplasma suggests that mycoplasma evade the 
host immune system (Schieck et al., 2014; Mulongo et al., 2013). To gain a better 
understanding on the role of antibody immune response, the author investigated the 
humoral immune response in experimental cattle using Indirect ELISA, IBT and CFT. 
Although IBT is reported to be the most sensitive and specific serological tests available 
for CBPP (Schubert et al., 2011), the test is cumbersome and it lacks reproducibility. 
The dominant immunogenic antigens revealed in the study of Abdo et al. (1998) and in 
the study reported here differ. Therefore, a comparison of the studies is difficult. One 
possible noteworthy finding is that bands of lower molecular masses between 39 and 20 
kDa appeared mostly for five weeks towards the end of the experiment. Hence, research 
into an easy to perform IBT with short steps and standardised reagents is needed. 
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APPENDIX 1: CBPP Lung form 
 
Trial n. _____________ Animal Id.N°________  Date ________ Central Veterinary Laboratory, Namibia-IZSAM, Italy 
 
 
 
 
 
 
 
 
 
 Engorg. Red 
Hepat 
Marble 
Policr 
Necrosis Sequestra Gray 
Hepat 
Resolut Pseudomembr Fibr. 
adhesion 
Sinechie Pleura 
fluid 
L. apical            
R. apical            
L. 
cardiac 
           
R. 
Cardiac 
           
Acc 
Lobe 
           
L. 
diaphr 
           
R. 
diaphr 
           
Pleura            
 
Right Lung           Left Lung 
 
172 
 
APPENDIX 2: Comparisons of the results of the three serological tests 
 
Table 4.4.  Comparisons of the results of the three serological tests in sera collected from in-contact control cattle in the 
vaccine group 
Cattle 
No 
188 175 177 145 165 
Date 
in 
Weeks  
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2 44 5 nd nd 51 0 nd nd 51 0 nd nd 38 0 nd nd 40 10 nd nd 
3 45 6 21.0 - 59 0 14.0 - 46 0 9.5 - 44 1 18.4 - 38 5 13.5 - 
4 48 2 21.7 - 51 1 16.5 - 47 2 6.6 - 38 0 18.9 - 41 6 4.9 - 
5 42 4 11.6 - 56 1 15.6 - 44 1 10.5 - 37 1 14.9 - 37 6 9.1 - 
6 52 4 9.7 - 60 2 10.3 - 41 0 9.3 - 43 0 18.8 - 64 64 121.6 ++ 
7 33 nd 21.7 - 54 nd 38.9 - 47 nd 17.7 - 34 nd 29.4 - 67 nd 194.2 +++ 
8 36 nd 38.5 - 60 nd 25.2 - 38 nd 21.6 - 0 nd 12.0 - 74 nd 78.3 +++ 
9 45 nd 30.6 - 42 nd 14.3 - 29 nd 19.2 - 5 nd 23.1 - 73 nd 113.8 +++ 
10 43 nd 15.5 - 54 nd 13.9 - 46 nd 22.0 - 8 nd 23.7 - 82 nd 56.5 +++ 
11 38 nd 53.0 +++ 72 nd 50.4 - 19 nd 13.0 - 25 nd 16.4 - 79 nd 42.1 + 
14 73 nd 115.9 ++ 79 nd 84.5 +++ 72 nd 115.0 +++ 35 nd 29.9 + 77 nd 27.4 + 
17 72 nd 72.0 +++ 72 nd 30.0 +++ 73 nd 64.0 +++ 85 nd 36.6 ++ 76 nd 23.5 + 
cELISA is measured in percentage inhibition (%) at a cut-off point of 50%. The LFD is measured in percentage and the aim here is to determine 
the cut-off point while the LAT is measured by the degree of clumping as expressed either + to +++ depending on the degree of clumping. 
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Table 4.5. Comparisons of the results of the three serological tests in sera collected from cattle vaccinated with Purified 
Protein  
Cattle 
No 
155 150 189 161 162 
Date 
in 
weeks 
 c
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0 27 1 nd nd 45 0 nd nd 26 0 nd nd 25 2 nd nd 46 -1 nd nd 
1 24 1 nd nd 38 2 nd nd 43 6 nd nd 29 5 nd nd 41 1 nd nd 
2 35 4 nd nd 53 0 nd nd 47 4 nd nd 44 2 nd nd 41 0 nd nd 
3 45 0 30.6 - 47 0 43.9 - 47 1 10.8 - 41 2 14.7 - 38 1 14.0 - 
4 40 1 17.6 - 53 0 11.0 - 55 0 31.8 - 43 2 25.8 - 44 -1 30.1 - 
5 40 1 18.9 - 49 0 17.0 - 48 1 16.3 - 47 2 15.8 - 43 0 23.8 - 
6 42 1 21.5 - 46 1 27.2 - 65 3 33.7 ++ 48 2 6.6 - 42 0 15.8 - 
7 21 nd 16.3 - 36 nd 14.8 - 61 nd 112.7 +++ 22 nd 10.8 - 37 nd 7.8 + 
8 45 nd 22.6 - 46 nd 25.2 - 84 nd 147.6 +++ 39 nd 16.2 - 50 nd 157.8 +++ 
9 68 nd 139.9 +++ 34 nd 32.2 - 75 nd 144.7 +++ 39 nd 14.0 + 52 nd 196.7 +++ 
10 85 nd 281.7 +++ 58 nd 43.7 + 84 nd 154.4 +++ 33 nd 11.3 - 77 nd 206.9 +++ 
11 86 nd 176.6 +++ 72 nd 36.2 ++ 81 nd 132.1 ++ 55 nd 16.4 - 77 nd 89.9 +++ 
14 86 nd 69.0 +++ 77 nd 41.8 +++ 83 nd 73.7 ++ 67 nd 118.9 ++ 76 nd 55.4 +++ 
15 93 nd 69.2 +++ 87 nd 51.5 +++ 88 nd 73.3 ++ 75 nd 104.0 ++ 84 nd 46.6 +++ 
17 85 nd 82.1 +++ 89 nd 34.4 +++ 84 nd 93.5 ++ 77 nd 93.2 ++ 83 nd 57.4 +++ 
cELISA is measured in percentage inhibition (%) at a cut-off point of 50%. The LFD is measured in percentage and the aim here is to determine 
the cut-off point while the LAT is measured by the degree of clumping as expressed either + to +++ depending on the degree of clumping. 
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Table 4.6.  Comparisons of the results of the three serological tests in sera collected from cattle vaccinated with Tween 
20 cells  
Cattle 
No 
139 158 194 170 182 
Date 
in 
weeks  
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0 42 -1 nd nd 65 0 nd nd 52 93 nd nd 37 -2 nd nd 46 15 nd nd 
1 53 0 nd nd 61 0 nd nd 44 130 nd nd 29 0 nd nd 48 24 nd nd 
2 52 2 nd nd 63 1 nd nd 55 67 nd nd 37 0 nd nd 41 11 nd nd 
3 53 2 30.2 - 63 1 25.8 - 46 74 26.8 - 37 2 49.9 - 45 13 37.5 - 
4 45 1 22.0 - 62 1 29.1 - 47 80 25.0 - 31 1 29.6 - 43 10 35.8 - 
5 50 2 35.8 - 64 0 27.8 - 76 134 58.4 - 39 -1 29.9 - 45 8 36.4 - 
6 72 72 22.4 - 64 0 17.5 - 93 173 108.4 +++ 43 3 19.9 - 51 3 34.7 - 
7 91 nd 125.4 +++ 42 nd 23.0 - 87 nd 199.0 +++ 40 nd 47.2 +++ 0 nd 35.9 - 
8 90 nd 165.9 +++ 43 nd 18.9 - 91 nd 128.2 + 30 nd 168.0 +++ 0 nd 48.3 - 
9 92 nd 142.9 +++ 40 nd 13.1 - 92 nd 145.5 ++ 51 nd 147.8 +++ 0 nd 34.1 - 
10 74 nd 108.3 +++ 46 nd 18.2 +++ 89 nd 120.7 + 59 nd 104.8 +++ 0 nd 50.0 - 
11 92 nd 64.8 ++ 53 nd 15.8 - nd nd nd nd 72 nd 77.4 +++ 82 nd 16.8 - 
12 93 nd 92.6 ++ 39 nd 10.0 - nd nd nd nd 71 nd 54.8 ++ 82 nd 94.8 + 
13 90 nd 57.4 ++ 33 nd 17.0 - nd nd nd nd 0 nd 56.5 ++ 83 nd 81.2 + 
14 90 nd 70.5 ++ 35 nd 19.6 - nd nd nd nd 39 nd 64.6 +++ 91 nd 73.1 + 
15 96 nd 68.5 ++ 47 nd 23.4 - nd nd nd nd 76 nd 33.6 ++ 93 nd 104.5 + 
16 92 nd 52.9 ++ 32 nd 33.4 - nd nd nd nd 73 nd 44.5 + nd nd nd nd 
17 92 nd 74.7 ++ 41 nd 14.9 - nd nd nd nd 68 nd 64.1 + nd nd nd nd 
cELISA is measured in percentage inhibition (%) at a cut-off point of 50%. The LFD is measured in percentage and the aim here is to determine 
the cut-off point while the LAT is measured by the degree of clumping as expressed either + to +++ depending on the degree of clumping. 
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Table 4.7. Comparisons of the results of the three serological tests in sera collected from cattle vaccinated with T1/44 sub-
cutaneously  
Cattle 
No 
146 192 179 181 178 
Date 
in 
weeks  
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0 61 88 nd nd 28 1 nd nd 39 41 nd nd 57 78 nd nd 50 30 nd nd 
1 68 88 nd nd 42 0 nd nd 45 37 nd nd 71 70 nd nd 68 13 nd nd 
2 57 39 nd nd 32 0 nd nd 42 19 nd nd 60 54 nd nd 55 14 nd nd 
3 67 30 25.4 +++ 34 0 22.0 - 63 11 11.2 - 78 33 13.3 + 20 20 24.1 +++ 
4 58 47 24.2 +++ 43 0 21.8 - 53 14 19.5 - 67 30 11.5 ++ 60 7 13.0 ++ 
5 57 25 17.0 +++ 47 0 35.5 - 59 9 16.1 - 66 57 18.7 ++ 60 13 18.7 ++ 
6 54 53 20.1 +++ 63 39 145.6 + 53 14 10.0 - 62 51 12.7 +++ 57 10 6.5 ++ 
7 45 nd 34.7 +++ 0 nd 273.1 ++ 27 nd 23.7 ++ 53 nd 18.3 ++ 46 nd 31.6 ++ 
8 46 nd 14.5 ++ 33 nd 203.2 ++ 42 nd 17.9 + 68 nd 20.3 + 65 nd 8.5 ++ 
9 32 nd 33.7 +++ 30 nd 91.9 +++ 32 nd 15.6 + 59 nd 15.2 + 40 nd 12.1 - 
10 38 nd 16.8 ++ 21 nd 159.9 ++ 34 nd 23.8 - 60 nd 17.4 - 48 nd 18.5 + 
11 59 nd 19.4 + 18 nd 122.1 + 32 nd 23.4 - 50 nd 14.5 + 46 nd 14.6 + 
14 65 nd 35.4 ++ 23 nd 57.1 - 27 nd 19.6 + 59 nd 19.5 ++ 45 nd 25.7 - 
17 51 nd 26.9 ++ 43 nd 45.5 - 60 nd 25.6 - 61 nd 8.6 ++ 48 nd 15.3 ++ 
cELISA is measured in percentage inhibition (%) at a cut-off point of 50%. The LFD is measured in percentage and the aim here is to determine 
the cut-off point while the LAT is measured by the degree of clumping as expressed either + to +++ depending on the degree of clumping. 
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Table 4.8. Comparisons of the results of the four serological tests in sera collected from cattle vaccinated with T1/44 
intranasal 
Cattle 
No 
186 176 147 195 152 
Date 
in 
weeks  
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0 26 2 nd nd 18 2 nd nd 39 4 nd nd 12 3 nd nd 12 2 nd nd 
1 24 19 nd nd 28 0 nd nd 47 3 nd nd 26 6 nd nd 18 3 nd nd 
2 29 0 nd nd 37 2 nd nd 46 0 nd nd 30 10 nd nd 32 1 nd nd 
3 31 0 6.5 - 44 0 18.9 - 54 0 24.4 ++ 33 -1 11.5 - 36 0 21.8 - 
4 31 1 12.0 - 42 0 22.4 - 49 1 18.4 ++ 40 0 19.3 - 34 1 16.6 - 
5 31 1 14.9 - 36 -4 3.4 - 43 0 16.7 +++ 38 4 19.8 - 31 0 8.7 - 
6 37 0 10.4 - 42 2 19.5 + 55 1 20.1 + 47 15 27.9 - 32 -1 41.2 - 
7 33 nd 27.4 - 20 nd 17.2 + 49 nd 17.6 ++ 59 nd 26.6 +++ 23 nd 17.4 - 
8 45 nd 16.2 - 23 nd 20.4 + 48 nd 16.0 + 63 nd 225.3 +++ 45 nd 16.4 - 
9 23 nd 13.3 - 11 nd 16.6 + 40 nd 29.3 + 66 nd 172.2 +++ 28 nd 11.5 - 
10 47 nd 32.3 - 29 nd 47.7 - 57 nd 19.8 + 74 nd 137.0 +++ 19 nd 16.6 - 
11 45 nd 14.6 - 22 nd 16.8 - 53 nd 14.7 + 81 nd 99.2 ++ 26 nd 12.1 - 
17 78 nd 60.5 ++ 50 nd 13.8 ++ 86 nd 56.9 +++ 59 nd 40.2 ++ 23 nd 6.1 ++ 
cELISA is measured in percentage inhibition (%) at a cut-off point of 50%. The LFD is measured in percentage and the aim here is to determine 
the cut-off point while the LAT is measured by the degree of clumping as expressed either + to +++ depending on the degree of clumping. 
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Table 4.9. Comparisons of the results of the four serological tests in sera collected from cattle intubated with biofilm grown 
cells 
Cattle 
No 
11 20 62 67 78 
Date 
in 
weeks 
 c
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4 59 0 14.4 _ 50 1 7.7 _ 51 0 12.2 _ 90 137 237.8 ++ 56 1 20.5 _ 
5 58 0 25.5 _ 45 1 19.8 _ 46 0 22.1 _ 92 126 219.8 ++ 61 0 13.2 _ 
6 58 -11 18.9 _ 52 1 35.3 _ 53 0 20.0 _ 91 120 174.4 +++ 51 0 36.9 _ 
7 39 nd 24.4 _ 33 nd 19.0 + 42 nd 21.1 _ 93 nd 129.6 +++ 42 nd 28.3 + 
8 33 nd 8.3 _ 22 nd 11.3 + 18 nd 4.3 _ 84 nd 70.1 +++ 8 nd 16.0 + 
9 34 nd 10.4 _ 35 nd 32.3 _ 40 nd 22.2 _ 88 nd 82.4 +++ 37 nd 14.3 + 
10 44 nd 19.0 _ 33 nd 28.2 _ 52 nd 18.2 _ 92 nd 79.8 +++ 27 nd 19.1 _ 
11 50 nd 18.0 _ 43 nd 12.8  41 nd 14.4 _ 90 nd 79.9 +++ 43 nd 16.3 _ 
17 50 nd 9.5 + 37 nd 3.8 + 18 nd 3.1 - 80 nd 25.1 ++ 54 nd 18.5 ++ 
cELISA is measured in percentage inhibition (%) at a cut-off point of 50%. The LFD is measured in percentage and the aim here is to determine 
the cut-off point while the LAT is mswasured by the degree of clumping as expressed either + to +++ depending on the degree of clumping. 
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Table 4.10. Comparisons of the results of the four serological tests in sera collected from in-contact control cattle in the biofilm group 
Cattle 
No 
180 183 138 154 159 
Date 
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weeks 
 c
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4 43 1 nd nd 46 5 nd nd 51 0 nd nd 38 23 nd nd 33 5 nd nd 
5 41 1 nd nd 33 2 nd nd 41 12 nd nd 35 30 nd nd 45 6 nd nd 
6  2 nd nd 29 2 nd nd 51 1 nd nd 37 27 nd nd 37 6 nd nd 
8 38 nd 11.6 - 28 nd 7.2 - 16 nd 4.2 - 12 nd 10.7 + 43 nd 5.8 + 
9 24 nd 13.3 nd 28 nd 14.2 nd 33 nd 8.8 nd 5 nd 19.6 nd 17 nd 13.0 nd 
10 25 nd 28.7 - 28 nd 15.8 - 50 nd 146.5 - 0 nd 15.0 + 19 nd 22.2 + 
11 30 nd nd - 17 nd nd nd 73 nd nd +++ 5 nd nd - 14 nd nd - 
17 41 nd nd - 39 nd nd - nd nd nd nd 25 nd nd ++ 80 nd nd ++ 
cELISA is measured in percentage inhibition (%) at a cut-off point of 50%. The LFD is measured in percentage and the aim here is to determine the cut-off point 
while the LAT is mswasured by the degree of clumping as expressed either + to +++ depending
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APPENDIX 3: Immunoblot and Immunoblot Profile 
 
 
Animal # 175 (Vaccine in-contact) 
 IgG1    IgG2     IgM 
 
 
Animal # 195 (T1/44 intranasal) 
 IgG1    IgG2     IgM 
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Immunoblot profile 
 
 IgG1 Immunoblot (kDa) profile from animals in vaccine group  
Control T1/44 i/s T1/44 s/c Tween 20 Purified Protein 
188 175 177 145 165 186 176 147 146 192 178 194 170 182 155 150 161 
126 81 110 87 95 189 120 87 102 49 110 126 91 120 117 126 120 
100 58 91 60 85  98 74 93  93 115 89 78 115   
74 48 74 51 69  56 60 71  55 79 69 65    
60  60  68  46 54     60 54    
50  35  56  37 32     55     
36  20  49   30     50     
    30   21          
                 
 
 
IgG2 and IgM Immunoblot (kDa) profile from animals in vaccine group 
Control T1/44 i/s T1/44 
s/c 
Tween 20 Purified 
Protein 
Tween 20 
IgM 
Purified Protein 
IgM 
188 175 177 145 165 186 147 178 194 170 182 161 162 182 189 161 162 
57 93 110 129 100 174 112 155 115 55 115 120 123 123 100 91 120 
 91 91 72 65 132 95 126 98  98 97 85 110 79 58 87 
 72 74 66 58 100 74 91   76 95  93 59 50  
 59 60 60 48 76 60 48   62   89 50 45  
 54 55   39 55    50   79 47 39  
 39 35    36        37   
 
 
